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ABSTRACT  
 
LEI ZHANG: Development and Preclinical Evaluation of a Compact  
Image-guided Microbeam Radiation Therapy System 
(Under the direction of Otto Zhou) 
 
Microbeam radiation therapy (MRT) is a novel and experimental cancer treatment 
modality. It has received increasing emphasis worldwide in recent years due to the 
demonstrated high therapeutic ratio in preclinical studies. MRT uses arrays of quasi-parallel 
radiation beams that are up to a few hundred microns wide and separated by several times of 
its beamwidth. Extensive preclinical experiments conducted at European Synchrotron 
Radiation Facility and several other national synchrotron facilities have shown that 
microbeams with doses of several hundreds of grays are well tolerated by healthy brain 
tissues while causing preferential damage in tumors. As the effort now moves towards large 
animal and clinical trials, there are eminent needs to develop compact and economically-
viable microbeam irradiators for MRT radiobiology research and clinical installation 
eventually.  
Our research group has invented the carbon nanotube (CNT) field emission based X-
ray source technology and has been dedicated to CNT-based medical device research over 
the past decade. A laboratory-scale microbeam irradiator has been recently developed with 
iv 
the CNT source array technology. The unique nature of CNT X-ray cathode allows for 
optimization of the anode focal spot shape and size, and therefore overcomes the obstacles of 
producing high flux microbeam radiation with conventional X-ray tubes. Preliminary studies 
have shown that the CNT-based MRT prototype is capable of generating orthovoltage 
radiation with all essential dosimetric characteristics of microbeam radiation therapy. The 
goals of this dissertation are to characterize and to optimize the system performance, to 
implement image guidance for dose delivery, and to evaluate the treatment efficacy in 
preclinical studies.  
Characterization of radiation source and dosimetric parameters was performed and 
described in detail. An on-board imaging system was constructed and integrated with the 
microbeam irradiating system. Dedicated image-guidance protocols were developed for high 
accuracy microbeam delivery in small animal models. Therapeutic assessment of brain tumor 
bearing mice was conducted with the CNT-MRT prototype. Preliminary results included 
encouraging treatment effects in terms of tumor local control and mean survival time 
extension. MRT radiobiological evaluations were carried out, for the first time, using a non-
synchrotron-based compact radiation source. Additionally, feasibility of delivering multi-
arrays of microbeams cross-firing geometry at the brain tumor target was successfully 
demonstrated facilitated by multi-modality 3D image guidance.  
The results in this work demonstrate the advantages of CNT-based MRT system as an 
attractive alternative for microbeam generation and delivery. With continued effort in system 
development and optimization, this nanotechnology-based compact MRT system could 
v 
become a powerful research tool that can be installed in a laboratory environment for 
elucidating the still poorly understood therapeutic mechanism of MRT without the need of 
synchrotron light sources. The feasibility studies also showed that the CNT-based MRT 
technology offers a promising pathway for clinical implementation in the near future.  
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 INTRODUCTION CHAPTER 1:
 
 Radiotherapy for Cancer Management   1.1
The human body is a complicated ecosystem whose individual members are cells that are 
organized into collaborative assemblies of tissues. Its integrity and stability are synergetic effects 
of “regulatory systems” composed of hierarchical components, from the chromosome in an 
individual cell to the whole body immune regulations. Only certain types of cells have the 
capability of dividing and proliferating, and errors occur during these processes due to internal 
instability or environmental influences. Some of the errors are fatal to the cells, and some can be 
reinstituted by the gene repair mechanisms. The failure of proper repair of deoxyribonucleic acid 
(DNA) damage often results in cell death in most cases and mutagenesis that could lead to 
innocuous cell survival. Very rarely malignancies occur if mutated cells escape the restraints of 
replicative senescence and the guard of the human immune system, and persist to divide, invade 
and colonize territories normally reserved for other cells (Figure 1.1). About 90% of human 
cancers are carcinomas, perhaps because most of the cell proliferation in the body occurs in 
epithelia, or because epithelial tissues are most frequently exposed to the external damages that 
stimulated the form of cancer [1].  
Cancer is one of the most significant terminal diseases in the western world, exceeded 
only by heart diseases as the second leading cause of death. In the United States, almost one in 
every three people develops certain type of cancer in their lifetime, and one out of four people 
will die of cancer eventually [2]. The development of cancer is a microevolutionary process that 
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usually takes years. Clinical data have shown clearly that for most cancers the treatment outcome 
is significantly better when the cancers are diagnosed at earlier than late stages. The limited 
capability of available technologies today to detect early stage, small, in situ tumors is the main 
challenge in cancer management, and the main cause of the high mortality.    
 
 
Figure 1.1 The radiation biology flow chart (Lecture handout for Radiation biology at UNC Chapel Hill. Reprinted with 
permission from Dr. Elaine Zeman, UNC Department of Radiation Oncology) 
 
Radiation therapy (RT), or radiotherapy, is one of the most effective treatment modalities 
for cancer management together with surgical resection and chemotherapy. It uses ionizing 
radiation that damages the DNA in the cells through direct and indirect effects that may lead to 
cell death. RT demonstrates advantages in treating cancers located at eloquent sites that are 
physically not feasible for surgical removal, as well as in sterilizing remaining cancer cells after 
surgery. The sensitivity to radiation damage varies in different types of cells. To certain extend, 
normal tissue responds to radiation in a slightly different way compared to tumors. One of the 
main reasons is that tumors usually contain immature and less intact vasculature with a large 
amount of structural and functional abnormalities, and are therefore more sensitive to radiation 
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damage compared to those in the normal tissue. This opens up the therapeutic window in 
radiation therapy. However, the amount of the radiation dose and the treatment volume required 
for complete tumor cell sterilization often unavoidably lead to radiation dose to nearby normal 
structure that exceeds their tolerance, and hence increases the risk of severe normal tissue 
complications. Radiation-induced normal tissue complications remain as the major concern and a 
great challenge in RT. The risk of serious damage in normal tissue increases with radiation dose, 
as does the probability of local tumor control. The rapid rate of tumor regeneration and 
metastasis further complicates the treatment strategy. Improving the therapeutic ratio, i.e. 
maximizing the local or locoregional tumor control by permanently inactivating all cancer cells 
while minimizing the normal tissue damage, is the goal in radiotherapy [3]. In the last decade, 
new technologies in image guidance, treatment planning, as well as dose delivery have 
developed greatly and contributed substantially to the optimization in the clinical practice and 
treatment outcome of radiation therapy. One main way to improve the therapeutic efficacy is to 
achieve physical dose conformality in the clinical target volume (CTV) discerned by image 
guidance and decrease the volume of normal tissue irradiated and therefore the probability of 
normal tissue complications. In terms of external beam radiation therapy for instance, 3D 
conformal and intensity-modulated radiation therapy (IMRT) with the aid of computer-controlled 
dynamic multileaf collimators and treatment planning software has demonstrated significant 
advantage in delivering a high dose to the target volume and acceptably low dose to the 
surrounding normal structures. The advent of stereotactic radiosurgery (SRS) using X-rays or 
gamma rays, or stereotactic radiotherapy (SRT), is another advance for treating intracranial 
lesions. SRS is a single fraction radiotherapy procedure using a combination of a stereotactic 
apparatus and narrow multiple beams delivered through noncoplanar isocentric arcs. The same 
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procedure is called SRT if multiple dose fractions are delivered. A high degree of dose 
conformity is a hallmark of SRS, which is generally achieved by using appropriate circular 
beams to fit the lesion, optimizing arc angles and weights and using multiple isocenters or 
dynamically shaping the field during arc rotation with mini (or micro) multileaf collimators [4].  
The effectiveness of tumor control using radiation therapy, as well as with other types of 
cancer treatments is not completely known yet. The treatment outcome is often largely dependent 
on various factors including the type of the cancer, the stage and progression, and the sites of the 
malignancies etc. Malignant brain cancer is one of the most aggressive cancers nowadays with 
minimum breakthrough made in terms of extending the patients lifespan using modern treatment 
technologies. The risk of losing major neurological functions often limits the extent and effect of 
surgical resection. Chemotherapy alone is often not effective for brain cancer management due to 
the blood-brain barrier which prevents a high dose uptake in the brain tumor. Radiation therapy 
plays an important role in the curative and palliative treatment of patients with primary and 
metastatic brain tumors. Existing SRS techniques including CyberKnife and Gamma Knife are 
able to achieve effective tumor control with minimum treatment toxicity for small lesions (<3 cm 
in diameter) at non-eloquent areas. The field size of gamma knife is limited to a maximum of 18 
mm in diameter [4]. However, glioblastoma multiforme (GBM), the most common and 
malignant brain tumor, is highly aggressive and infiltrative in nature. These tumor cells are fast 
proliferating and tend to invade into the surrounding normal tissue, rendering a large and not 
well-defined lesion site surrounded by critical brain structures. The clinical target volume needs 
to be typically large in order to completely sterilize the primary tumor mass as well as the cancer 
cells that interdigitate with the surrounding normal brain tissue. For these reasons, severe 
radiation-induced side effects are difficult to avoid in GBM patients treated with existing RT 
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technologies, and tumor recurrence at the primary site happens in 90% of the cases [5]. The acute 
and late effects of RT on the brain are common and represent a significant source of morbidity. 
Primary brain cancer is also the second most prevalent cancer type in children, accounting for 22% 
of tumors in those < 18 years of age [6]. Radiation toxicity is even more of an issue for pediatric 
brain tumor patients as their developing central nervous system tissues can be more sensitive to 
chronic radiation damage. Over the last 50 years the survival extension has improved minimally 
for brain cancer patients. The median survival time in those with GBM is merely 15 months after 
diagnosis even when aggressive multi-modality treatments are applied [5, 7, 8].  
 Microbeam Radiation Therapy – Roots, Status, and Prospects 1.2
 History and inspiration 1.2.1
Incidence of severe normal tissue complications is the major prohibitive factor from 
delivering sufficient radiation doses for effective tumor local control. The search for solutions to 
reduce RT-induced side effects and to achieve high dose in the CTV has been the ongoing task in 
the history of development and implementation of effective RT in cancer management. The first 
successful attempt was made by Dr. Alban Köhler in 1909 in Germany, by applying an iron grid 
with 1 mm thick wires and spaced 3.0 – 3.5 mm apart at the patient’s skin when treating a large 
and deep-seated tumor using orthovoltage X-ray, the available radiation therapy technology at 
that time [9, 10]. This method allowed him to deliver a dose that was 10 – 20 times higher than 
typically tolerable with a seamless open field without inducing an incurable X-ray ulcer. Similar 
concept was employed by Dr. Liberson in the US later in 1933 by using a perforated lead sheet 
to prevent skin damage during the treatment of deep-seated lesions [11]. The grid was made of 
lead and rubber with equally spaced, 1cm circles cut into it presenting the entire treatment region 
with 50:50 open versus shielded areas. Both methods revealed the critical roles of the protected 
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normal cells that acted as the healing centers around the irradiated areas. This method was later 
recognized as spatially fractionated radiation therapy, or more commonly known as GRID 
therapy, and was routinely performed in orthovoltage beam RT in the 1950s to avoid prohibitive 
skin and subcutaneous tissue toxicity when treating deep-seated tumors [12, 13]. Nowadays, the 
advantage of GRID therapy has been largely overshadowed by the widely employed 
megavoltage beams RT with linear accelerators which achieve natural dose buildup underneath 
the skin entrance and deep penetration to reach internal tumors. GRID is mainly utilized as a 
palliative treatment for advanced bulky tumors using LINAC with new development in the grid 
design in recent years [14-16]. GRID therapy represents the very first successful clinical 
adaptation of the later formulated radiation dose-volume effect in the form of spatial-
fractionation. The dose-volume effect describes the inverse relationship between the threshold of 
tolerable radiation dose in normal tissue and the irradiated macroscopic tissue volume [17].  As a 
common radiotherapeutic perception today, the radiation dose-volume effect is established based 
on accumulating preclinical and clinical experience, and has guided the development of modern 
radiotherapy in many ways [18, 19]. 
Microbeam radiation therapy [20] is also a spatially-fractionated radiotherapy modality 
that exploits the dose-volume effect at a microscopic scale. The concept was initially inspired by 
the studies led by Drs. Wolfgang Zeman and Howard. J. Curtis at the Brookhaven National 
Laboratory (BNL) in the early 1960s to investigate the biological effect of heavy cosmic rays on 
astronauts in space primarily on brain tissue [21-24]. These pioneer experiments demonstrated 
the increased tolerance of mouse brain tissue to extremely high doses of microscopic radiation 
beams (Figure 1.2). Deuteron beams of 25 µm with dose of up to 4,000 Gy caused complete 
destruction of nerve cell bodies. However, the irradiated nerve fibers and interstitial glia cells 
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were largely preserved; neither was there permanent damage to the vessels. It was assumed then 
that the microscopic radiation beams only caused localized and predominantly direct injuries 
without much additional indirect effect such as interference with blood supply as seen in the 
broader beam irradiations. These encouraging findings correlated well with the macroscopic 
radiation dose-volume effect [17], but also led to the further exploration of using microbeam 
radiation for brain cancer treatment starting in the 1990s at both BNL National Synchrotron 
Light Source (NSLS) in Upton, New York and the European Synchrotron Radiation Facility 
(ESRF) in Grenoble, France [25-29].  
 
 
Figure 1.2 Histopathologic evidence of different radiobiological effects caused by microscopic versus millimeter-sized deuteron 
beam on the visual cortex of the mouse brain, which is a direct proof of the dose-volume effect. Adapted from Zeman W. et al., 
Radiation Research 15, 4 (1961) 
 
As originally proposed, MRT refers to an experimental treatment technique which 
employs arrays of quasi-parallel, microscopically thin planar X-ray beams that are separated by a 
distance several times the beamwidth. Several features stand out in MRT compared to 
conventional external beam radiation therapy (or sometimes referred to as “broad beam” RT in 
this context). It uses orthovoltage radiation with the beamwidth ranging from 25 µm – 75 µm as 
in classic synchrotron MRT studies [25, 26, 28], to a few hundred microns as reported effective 
in recent experiments [30-34]. The microbeams create unique dose depositing profiles of 
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alternating peaks (high dose) regions and valleys (low dose) regions with a signature index 
named the peak-to-valley-dose-ratios, or PVDR [25, 29]. The total prescribed dose is usually 
delivered in a single fraction, either from one direction, or multiple ports around the target. The 
synchrotron generated microbeams are also featured by their ultra-high flux and minimal 
divergence. As shown in numerous preclinical studies using duck embryos, mice, rats and 
weanling piglets,  MRT allows for administration of a single radiation dose that is two orders of 
magnitude higher than the total dose delivered in temporal fractionated RT from LINAC in the 
CTV without causing severe functional damage in normal tissue [26, 28, 35-47]. While existing 
RT technologies strive to achieve physically localized dose deposition for an optimal therapeutic 
ratio, MRT provides an alternative with the intrinsic differential radiobiological effects on tumor 
versus on normal brain tissue.  
 Synchrotron-based microbeam radiation therapy 1.2.2
 Experimental characteristics 1.2.2.1
The original pilot experiments, as well as the majority of MRT preclinical studies in the 
last two decades were carried out at the NSLS and ESRF. Particularly, the ESRF Biomedical 
Beamline ID17 is currently the major beamline for MRT biological studies, veterinary trials and 
the clinical trials that are under preparation [48]. In recent years, increasing efforts have also 
been made in instrumentation upgrades and development to incorporate MRT studies at several 
other beamlines worldwide, including the Canadian Light Source (CLS) [49-52], the SPring-8 
synchrotron radiation facility in Japan [53, 54], and the Australian Synchrotron facility [55]. As a 
powerful and valuable tool for a wide variety of research, synchrotron radiation differs 
dramatically in the beam generating mechanism. Inside a synchrotron facility, a group of charged 
particles (typically electrons) are circulating and accelerated into the relativistic regime in a 
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storage ring. The high-energy beam is then directed through strong magnetic fields generated by 
bending magnets or insertion devices (undulators or wigglers). The applied magnetic fields are 
perpendicular to the beam to deflect the beam trajectory and the synchrotron radiation is thus 
emitted at the bending points of the beam paths.   
Compared to radiation generated through other mechanisms, synchrotron radiation 
demonstrates following properties [56]:  
1. High intensity: the flux of synchrotron radiation is several orders of magnitude higher 
than that produced using conventional sources. Besides, the extremely high photon 
intensity is concentrated over a very small spatial and angular distribution,  rendering 
an extreme beam brightness (photon·s
-1
·mrad
-2
·mm
-2
·(0.1% bandwidth)
-1
); 
2. Broad and continuous spectral range from far infrared (<1 meV) to hard X-ray region 
(~ hundreds of keV) with flexible energy modulation; 
3. Natural narrow angular collimation: the emitted radiation beam is highly directional 
with minimal angular divergence; 
4. High degree of polarization; 
5. High beam stability. 
The unique properties of SR present SR-based MRT with several characteristics. Firstly, 
the X-ray energy spectrum used in SR-based MRT is within the orthovoltage range. The 
treatment beam used at ESRF MRT is a filtered “white beam” (continuous spectrum from 50 – 
350 keV) with a maximum intensity at 83 keV and a mean energy around 100 keV [25, 57]. 
Using orthovoltage radiation can largely preserve the sharp dose falloff and reduce the amount of 
scattered photons that would otherwise increase the energy deposition in the valley regions. The 
beam energy can also be tailored for imaging purposes [58]. Secondly, SR’s naturally low 
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divergence allows for generation of quasi-parallel ultra-thin microplanar beams using over a 
large range without redundant collimation. The radiation beam used for MRT experiments at 
ESRF Biomedical Beamline ID17, has a divergence of 1 mrad horizontally and 0.1 mrad 
vertically with a maximum dose rate of 16,000 Gy/s [59]. The typical microbeam width is 25 – 
100 µm generated by the multislit collimator with little variation resulted from the beam 
divergence within the treatment volume. Kilovoltage photon energy with minimal beam 
divergence ensures a highly localized dose deposition in the microscopic scale, yielding a high 
PVDR and a small beam penumbra which are considered critical for achieving the biological 
advantages in MRT. The influence of beam divergence as well as polarization on the dose 
distribution in MRT has also been investigated and reported in detail by Dr. Heidi Nettelbeck et 
al., and Dr. Stefan Bartzsch et al. separately [60-62]. Besides, the large photon fluence and the 
resultant high dose rate essentially enable the delivery of high dose radiation within the shortest 
treatment time window. It could largely reduce the patient motion induced beam blurring and 
misfiring during the treatment, as well as discomforts of patients caused by long time treatment 
and immobilization.  
 
Figure 1.3 A photo of the sample positioning stage in the MRT experiment room at ESRF Biomedical Beamline ID17 
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In the implementation of synchrotron-based MRT preclinical studies as well as future 
clinical trials, substantial effort has been made in the past two decades through international 
collaboration of multiple research institutions and facilities. This includes, but not limited to, the 
design of multi-slit collimators [27, 63, 64], the development of positioning and patient safety 
system (PASS)[48, 65], developing new dosimeters, dosimetry and dosimeter calibration 
protocols [66], beam energy related simulations and optimizations [57, 67], image guidance 
protocols [58, 68], as well as the development of a dedicated treatment planning system [60, 69-
71]. In May 2013, an European Union supported consortium of laboratories from 16 countries 
has launched within the European Cooperation in Science and Technology (COST) action 
TD1205 (SYRA3), which is dedicated to the Innovative Methods in Radiotherapy and 
Radiosurgery using Synchrotron Radiation to treat brain tumors and other diseases of the central 
nervous system [65]. The COST workgroup coordinates a multidisciplinary group of pioneers to 
address the challenges and solutions towards the clinical implementation of MRT. Veterinary 
trials were initiated in late 2013 and are ongoing at ESRF, with the aim to confirm the 
therapeutic efficacy and tissue responses in larger animals and further optimize the irradiation 
geometries and parameters prior to MRT human clinical trials [20, 72].  
 Biological features 1.2.2.2
Overview 
Microbeam radiation therapy has the potential to outperform current external beam RT 
technologies with two main advantages identified in preclinical studies: 1) normal brain tissue 
and spinal cord have shown to tolerate peak MRT doses that are 100 times greater than those 
used in the conventional RT; 2) the entire tumor may be destroyed under MRT even though only 
a small portion of the entire volume is irradiated at peak doses. These extraordinary effects have 
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been confirmed in various synchrotron-based MRT studies using small animal models, including 
duck embryos [35], mice [36-38, 40], rats [26, 28, 41-45], and weanling piglets [46, 47] for 
histopathological response in normal tissue and tumors, tumor local control and survival 
investigations. Tumor types that have been investigated include 9L gliosarcoma (9LGS), C6 
glioma and F98 glioma in rats, EMT-6 mammary carcinoma [36] and squamous cell carcinoma 
(SCCVII) [37] in mice. Various parameters that are considered directly related to the overall 
treatment outcome in MRT have been experimentally examined.  These include beamwidth and 
center-to-center (c-t-c-) distance [37, 45, 73], peak and valley doses, and the PVDR, geometry of 
irradiation [31, 36, 74-77], spectrum and mean beam energy [25, 67, 78], effects of 
radiosensitizers [79-83].  
Although there is accumulating preclinical evidence of high normal tissue tolerance and 
tumor ablation in MRT, the underlying biological mechanisms are yet to be revealed. It is 
believed that the additional biological mechanisms come into play when the spatial fractionation 
reaches microscopic scale other than the general dose-volume effect. MRT differs from 
conventional seamless beam RT in the way of spatial dose modulation with significantly 
increased areas of interface between irradiated and non-irradiated tissues. These specific surfaces 
(SS) are believed to play a key role in the mediation and repair of the heavily damaged tissue 
induced by the high dose irradiation [84]. Several effects related to the specific surfaces, 
including the bystander effect, the manifestations of microvasculature alteration and regeneration, 
have been hypothesized possibly responsible for parts of the biological responses induced by 
MRT. The systemic effects from the immune or endocrine systems have also been speculated to 
contribute to the preferential damage in tumor cells [85, 86]. However, none of these alone can 
be attributed to the overall biological responses. Substantial amount of systemic studies remain 
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to be carried out to elucidate the governing theory behind the therapeutic efficacy in MRT, which 
in turn would benefit the optimization of parameterized treatment planning and the eventual 
clinical use. 
Bystander effects 
The bystander effect is a widely discussed phenomenon in the field of gene therapy, 
toxicology and radiotherapy. It reflects the complex cell-to-cell communications through various 
pathways in order to govern their behavior for the benefit of the organism as a whole. Within the 
scope of radiation therapy, bystander effects refer to the presence of signal mediated effects 
induced by radiation in cells that are in the vicinity of the target volume and are exposed to only 
very low levels of scatter radiation, if any [87, 88]. These radiation induced signaling effects 
have been shown to be mediated through direct physical cell contact via gap junction 
intercellular communication (GJIC) [89, 90] or through the secretion of diffusible signaling 
molecules into the surrounding medium [91, 92]. Radiation-induced bystander effects (RIBEs) 
have been observed in vitro in a variety of cell lines and in vivo in rodent models exposed to both 
densely ionizing and sparsely ionizing radiations [93-95]. Dilmanian, et al. used a single 
microbeam that is 270 µm wide to irradiate the rats’ spinal cords [96]. They hypothesized the 
involvement of a “beneficial” bystander effect in the repair process that led to the tissue 
restoration likely through the release of growth factors such as cytokines and the initiation of 
cell-signaling cascades. These cascades have possibly promoted angiogenesis to replace 
damaged capillary blood vessels, and proliferation, migration and differentiation of the 
progenitor glial cells to produce new, mature, and functional glial cells. The fact that certain 
types of signaling can coordinate decisions by groups of identical cells and different cells 
respond differently to the same type of extracellular signal molecules could explain part of the 
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different bystander responses observed in the normal tissue versus tumor cells that irradiated by 
high dose microbeams [1].  
On the other hand, with the highly localized dose deposition as well as the ability of 
precise delivery of radiation microbeam radiation has also been a valuable tool in identification 
and analysis of the signaling factors that mediate the bystander effect [93, 97]. In the studies by 
Mothersill, et al., an inter-mammal bystander effect has been observed in the cage mates of rats 
irradiated by high doses of MRT [95]. Our evolving understanding towards the radiobiological 
responses in RIBE will certainly benefit the elucidation of the therapeutic mechanisms in MRT.   
Vasculature responses 
Blood vessels extend into the tissues to replenish nutrients, protein growth factors and 
oxygen and meanwhile carrying off waste products, in support of the normal functions and 
sometimes proliferations of the local organs. Besides, the immune responses as well as certain 
types of cell communication through secreted signaling molecules rely largely on the 
transportation via bloodstream. Fast proliferation in tumors induces angiogenesis with wide 
spread network of capillaries in response to the high demand of nutrients which thereafter 
promote further expansion and invasion of tumors into surrounding regions. Evidence however 
has pointed out the immaturity of tumor vasculatures with profound structural and functional 
abnormalities compared to the more intact and radioresistant vessels in normal tissue. This gives 
the chance of cancer cure by attacking the more vulnerable vessels to achieve tumor eradication. 
Indeed, the different microvasculatures and angiogenesis behaviors have been assumed largely 
responsible to the tissue specified responses to microbeam irradiation, as supported by 
accumulating numbers of small animal studies. The experiments by Bouchet, et al. showed for 
the first time that preferential damage of MRT to tumor vessels versus preservation of 
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radioresistant normal brain vessels contributes to the efficient palliation of 9L gliosarcomas in 
rats [98]. Sabatasso, et al. used chick chorioallantoic membrane model of an almost pure 
vascular system with immature vessels to study the microbeam effects and found out that MRT-
induced vascular toxicity and physiological effects depend on the stage of capillary maturation 
[99].  
Severe complications such as cerebral edema, hemorrhage, or necrosis that are typically 
associated with blood vessel damage were not observed in high dose microbeam irradiated 
normal tissues, indicating the high radioresistance of large mature vessels or the existence of 
rapid repair effects in damaged microvasculature [39, 43, 100]. Repopulation and migration of 
unirradiated cells from the valleys into the peak regions through the large area of interfaces (i.e. 
specific surface) were suggested to have facilitated the replacement of dead cells and the repair 
the highly damaged microvasculature [26]. A high level of vascular endothelial growth factor 
(VEGF) expression was also observed in the irradiated normal tissue, which could have 
contributed to the rapid repair of the destroyed microvessels and stimulated vascularization [98]. 
Therefore an adequate blood supply was maintained in microbeam irradiated normal tissue, 
whereas MRT induced tumor hypoxia in 9L gliosarcoma bearing rats [101-103].  
Studies by van der Sanden, et al. have shown that microbeam peak doses under a certain 
range is able to reduce the clinical risks of long-delayed disruption or occlusion of non-targeted 
arteries from MRT compared to the corresponding risks from broad-beam radiosurgery [104].  
Tumor vascular damage induced by high dose microbeams may provoke vascular 
normalization and may be exploited to improve tumor control using agents targeting 
angiogenesis [105].  
16 
 
 Compact microbeam delivery systems – challenges and efforts 1.2.3
In the last half century, synchrotron light source has played a pioneering role in 
developing and advancing MRT research. The extremely high beam brilliance and low 
divergence provide unsurpassed dosimetric characteristics that are customizable for optimizing 
treatment parameters and probing into the radiobiologies. However, widely accessible, compact 
radiation sources are desired not only to promote the worldwide research to address the 
remaining technical and biological issues associated with the current state-of-the-art MRT, but 
also to expedite the ultimate clinical applications.  
Spatial modulation in the microscopic range with high photon flux and steep dose 
gradient is the key to achieve therapeutic effect in MRT. Such dosimetric characteristics, 
however, are challenging to produce with conventional X-ray sources. Flux and collimation are 
the main problems with thermionic orthovoltage cathodes. Substantial collimation (small 
opening and high aspect ratio) has to be applied to the naturally divergent photon beam from the 
large and isotropic focal spot, in order to keep a small beam penumbra and a low valley dose. 
Therefore the overall efficiency in microbeam production is extremely low as the majority of x-
ray photons are wasted as heat.  Although micro-focused orthovoltage X-ray tubes are 
commercially available, they operate at much lower power and therefore cannot meet the 
required photon flux that is needed for treatment. Clinically employed LINAC uses megavoltage 
radiation that produces a large number of scattered, secondary charged particles. These high-
energy charged particles leave a long-range of dose deposition outside the beam path and 
therefore smear out the microbeam patterns [106].  
Currently, two types of new radiation sources are considered potential candidates for 
microbeam generation and delivery. The first one employs inverse Compton scattering (ICS) and 
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is currently being exploited by several groups around the world, including the French ThomX 
project [107-109], and the California based Lyncean Technologies Inc (Palo Alto, CA). The first 
generation ICS based irradiator developed by Lyncean has been installed at the Technische 
Universität München Institute for Medical Engineering (IMETUM) in Germany. Several 
limitations with the current ICS technologies exist, including relatively low photon flux and 
beam energy. The other radiation source being explored for compact MRT is the carbon 
nanotube (CNT) distributed source array technology [110, 111], which is the enabling X-ray 
technology for the work presented in this thesis. CNT distributed source array technology 
demonstrates numerous advantages over conventional X-ray tubes, and provides an attractive 
alternative and practical solution for generating the specific dosimetric characteristics in MRT in 
a laboratory-scale device.  
 The Scope of This Work 1.3
The development of a CNT-based compact MRT system is a continuing long-term effort 
that requires iterations of system optimization, large amount of systemic preclinical validations 
from various perspectives, and extensive multi-disciplinary collaborations. It has brought 
together the expertise of several research groups and pioneers since the beginning, and also 
inspired related new endeavors both at the University of North Carolina at Chapel Hill, and Duke 
University. As part the effort in developing a compact microbeam radiation therapy system using 
carbon nanotube distributed source array technology, my work conducted at the Applied 
Nanotechnology Lab that constitutes the bulk of this thesis mainly focused on the following two 
aspects: 
1) To bridge the system design and biological studies by implementing image guidance 
for microbeam delivery.  
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2) To initiate the preclinical studies using the first-generation system with the aim to 
validate the system’s therapeutic performance as a microbeam irradiator, as well as to 
investigate the radiobiological mechanisms in MRT using small animal models.  
The first part includes hardware design, construction and conditioning, as well as 
establishing and validating methodologies and protocols regarding the detailed procedures to 
demonstrate targeted microbeam delivery in small animal models.  These efforts are detailed in 
chapters 4 and 5. 
Demonstrating the treatment efficacy with the specific dosimetric characteristics 
produced by the new system is the main topic of the second part. The work completed in this part 
has involved extensive collaborations with the UNC Biomedical Research Imaging Center 
(BRIC) and the kind support from the Translational Pathology Lab (TPL) at UNC Lineberger 
Comprehensive Cancer Center.  Tumor local control, survival time and hispathological analysis 
have been performed with the aid of several techniques and facilities. This is detailed in chapter 
6. 
Feasibility of multi-array microbeam delivery to enhance dose deposition in tumor with 
the CNT-based MRT system has also been explored. Chapters 5 and 6 covered the methodology 
development, dedicated hardware upgrade, image guidance protocols as well as comparative 
studies of treatment outcome tested in U87MG bearing mice.  
A brief introduction of MRT from the historical, experimental and biological perspectives 
is presented in Chapter 1. Carbon nanotube distributed source array technology and applications 
in medical imaging and therapy are reviewed in Chapter 2.  Chapter 3 discusses the current status 
of the system development, system characterization, and several issues and corresponding 
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remedies identified during the course of my thesis project over the past 5 years using the first-
generation prototype.  
Finally, the concluding chapter presents the summaries of this work, and some 
prospective discussion.  
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 CARBON NANOTUBE FIELD EMISSION SOURCE ARRAYS CHAPTER 2:
 
 Overview 2.1
Carbon nanotube is a relatively new member of the large family of carbon allotropes. It is 
generally believed to be experimentally observed and structurally characterized in 1991 for the 
first time, not long after the discovery of fullerenes, by Dr. Iijima [1] although the true identity of 
the discoverers of CNTs remains somewhat controversial.  Since this pioneering work, the 
worldwide study of carbon nanotubes in terms of their synthesis, properties, and applications in 
various fields has progressed rapidly.  
This chapter reviews the fundamentals of carbon nanotubes from material science 
perspectives, the CNT field emission source array technology, and its recent applications and 
advancement in medical devices including diagnostic imaging and radiotherapy systems.  
 Structures and Physical Properties of Carbon Nanotubes 2.2
Structurally, a carbon nanotube can be described as a honeycomb lattice (one or multiple 
sheets of graphene) seamlessly rolled into a cylindrical shape, with one or both ends capped with 
a fullerene hemisphere. On each graphene layer along the cylindrical section, carbon atoms are 
arranged in repeating hexagonal units. Each cap, on the other hand, contains six pentagons and 
an appropriate number and location of hexagons that are selected to fit perfectly to the long 
cylindrical tube body [2]. Depending on the number of graphene sheets they consist of, CNTs are 
often named as single-walled carbon nanotube (SWNT), or multi-walled carbon nanotube 
(MWNT) with an average inlayer spacing of 0.344 nm [3]. The diameter of a carbon nanotube is 
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of nanometer size, ranging from less than 1.0 nm to 50.0 nm, depending on the number of walls 
composing the nanotubes. For example, a SWNT usually has a diameter of 0.7 – 10.0 nm, 
although most of the observed SWNTs have diameters < 2 nm [2]. The length of the tube can be 
more than 10 µm or even longer [3], resulting in a large length-to-diameter aspect ratio in the 
order of 10
4
 -10
5
 or more. Single-walled CNTs are the sharpest inorganic structures found in 
nature so far [4]. 
The structure of a carbon nanotube is specified by the chiral vector, which describes the 
orientation of the repeating hexagonal unit on each layer relative to the axis of the nanotube as 
well as the diameter of the nanotube. The chiral vector thus classifies the symmetry of a carbon 
nanotube being either achiral (symmorphic) or chiral (non-symmorphic). An achiral carbon 
nanotube is the one whose mirror image has an identical structure to the original one, whereas a 
chiral nanotube exhibits a spiral symmetry whose mirror image cannot be superimposed on to the 
original one. There are only two cases of achiral nanotubes, namely armchair and zigzag 
nanotubes. The names of armchair and zigzag characterize the shape of the cross-section of the 
edge of the cut nanotubes.  
 Therefore, the full geometry of a carbon nanotube can be described mainly by its 
diameter, chirality, cap structures, and number of layers. Carbon nanotubes demonstrate a variety 
of unique physical properties (thermally, electrically, mechanically, etc.) due to the uniqueness in 
their structures. Notably, a CNT can be either metallic or semiconducting, depending on its 
chirality, which changes subtly their electronic structures, and therefore the electrical 
conductivity, as shown in Figure 2.1. Furthermore, the energy gap of semiconducting carbon 
nanotubes can be varied continuously from 1 eV to 0 eV, by varying the diameter [2].  Some of 
the main physical properties of carbon nanotubes are summarized in Table 2.1. 
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Figure 2.1 Electronic density of states for two zigzag carbon nanotubes, a metallic (9, 0) one on the left, and a semiconducting 
(10, 0) one on the right. Reprinted from Saito et al. Applied Physics Letters 60(18), 1992 [5] 
 
Table 2.1 Selected physical properties of carbon nanotubes [3, 6] 
 
 
 Field Emission from Carbon Nanotubes 2.3
 Fundamentals of field emission theory 2.3.1
Electron field emission (FE) is a well-known quantum-mechanical effect [7]. Briefly, it 
describes the phenomenon of extraction of electrons from the surface of condensed matter (solid 
or liquid) into vacuum under an intense static electric field. As illustrated in Figure 2.2, the 
combined effect of image force potential and the strong external electric field narrows the 
effective potential barrier of electrons at the surface of the condensed matter (e.g. metal) into a 
rounded triangle shape, so that electrons around the Fermi level would have a significant 
probability to escape from the surface to the vacuum level through the quantum tunneling effect. 
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The stronger the external electric field, the narrower the energy barrier is. The emission 
coefficient and current are mainly determined by the strength of the electric field and the type of 
material, and have been quantified by Fowler – Nordheim theory [8-10].   
 
 
Figure 2.2 A schematic illustration of the potential energy of electron U(x) (in eV) as a function of the distance x from the metal 
surface in an external static electric field. The effective energy barrier is sufficiently narrowed that the electrons could tunnel 
through. Horizontal dotted line illustrates the energy barrier width for electrons at Fermi level to tunnel through. 
 
 
The Fowler-Nordheim equation [11-13] is as follows : 
𝐼 = 𝑎𝑉2 exp (−
b∅
3
2⁄
𝛽𝑉
) 
where a and b are constants, I is the emission current, V is the applied voltage,  is the work 
function of the material, and  is the field emission enhancement factor. The work function 
ranges from 2-5 eV for metals, and depends strongly on the surface crystallographic structures 
[14]. Detectable field emission starts at extremely high local electric field about 10
7
 - 10
8
 V/cm.  
In order to achieve such high local fields at the metal surface using attainable potential, a 
geometrically sharp emitting tip/protrusion with the apex radius of curvature ranging from tens 
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of angstroms to several microns is practically favorable, producing a largely intensified local 
electrical field at the tip end that is much higher than the macroscopic applied field [15]. This 
geometrical effect at the surface is characterized by the factor  in the equation namely the field 
enhancement factor, i.e. the ratio between the local and applied electric fields.  The larger the β is, 
the higher the field strength enhanced at the surface, and therefore the lower the effective 
threshold voltage requires to apply for emission [16]. For an isolated tip shaped as a hemisphere-
on-orthogonal cone, β is well approximated by 1/(5r) where r is the radius of curvature of the tip 
[17]. 
 Commonly used field emitters include sharp metals tips (mainly tungsten and 
molybdenum), silicon, diamond, graphite, and more recently nanostructures especially carbon 
nanotubes which will be discussed in section 3.3.2. [15].  
 Field emission is an alternative to classical thermionic emission for electron generation, 
with numerous advantages including (but not limited to) [15, 18]: 
a) No heating required in the FE process, i.e. “cold cathode” (although FE are combined 
with thermionic emission in some circumstances); 
b) High steady-state FE current density (approaching 105 - 106 A/cm2); 
c) Small electron energy spread; 
d) A high beam coherence due to the narrow energy spread and the use of small (atomic 
dimension) emission areas; 
e) Sub-millisecond response to electric field variation; 
f) Resistance to temperature fluctuations; 
g) Small source dimensions (compared to thermionic cathodes); 
h) Longer service life (compared to thermionic cathodes); 
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 Field emission sources do generally require relatively higher vacuum level compared to 
thermionic electron sources (10
-9
 -10
-10
 torr for FE versus as low as 10
-5
 torr for thermionic 
filament) [15]. Field emission electron sources have found widespread applications in vacuum 
microelectronic devices such as in high-resolution electron microscopy, electron lithography, 
holography, frequency amplifiers, field emission displays (FEDs), X-ray generators etc. [3, 11, 
14, 15, 19] 
 Carbon nanotubes as field emitters 2.3.2
Field emission from individual carbon nanotubes 
As mentioned in section 2.1, carbon nanotubes are among the sharpest inorganic 
structures found in nature. The small radius of curvature at the tips, high aspect ratio, exceptional 
thermal and chemical stability, high mechanical strength, as well as high electrical conductivity 
make CNTs ideal field emitters [3, 17]. Particularly, the tip geometry (i.e. the tube chirality and 
diameter as well as the presence of defects) is the main factor that determines the field emission 
properties of the nanotubes [20, 21]. Electron field emission from both single-walled and multi-
walled CNTs was first demonstrated in 1995 [22-24] and has since been studied extensively.  
Carbon nanotubes as field emitters exhibit superior features compared to field emitters made of 
sharp metal tips [3, 13, 17, 25-29]:  
a) high brightness: the reduced brightness can be an order of magnitude larger than the 
values of metal field emitters such as tungsten; 
b) highly stable electron emission: much more stable at high currents compared to other 
field emitters; 
c) low threshold field for emission (i.e. the electric field to produce a current density of 
10 mA/cm
2
) due to small radius of curvature and high aspect ratio, the emission 
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threshold field of CNTs is 2-5 V/µm which is significantly lower than the values 
reported for other field emitters; 
d) relatively low vacuum level required: CNT can stably operate at 10-8 torr, whereas 
ultra-high vacuum (UHV) of 10
-10
 torr is generally required for metal field emitters 
such as tungsten; 
narrow energy spread: ~ 0.2 – 0.3 eV, which is half that of metallic emitters (typically 
around 0.45 eV); 
e) environmentally and economically friendly: no hazardous or precious elements used; 
f) long lifetime: CNTs are resistant to sputtering and oxidation, and degrade gently 
under non-UHV, high-current, high-temperature, and high-electric-field conditions; 
g) relatively low-cost mass production; 
h) energy savings. 
The exceptional characteristics of CNT field emitters have found them applications in a 
large variety of electronic devices with either single- or multiple-electron-beam, such as light 
sources [17, 30-33], microwave amplifiers [3, 13, 34, 35], discharge tubes for over-voltage 
protection [36], high-resolution electron beam instruments such as electron beam lithography 
(EBL) and electron microscopes [4, 35, 37], field emission displays [19, 35, 38-41], X-ray 
generators [26, 42, 43], etc. Some of the applications have already hit the market such as CNT 
based X-ray tubes (Oxford Instruments X-ray technology Inc., Xintek Inc., etc.), while others are 
still under active investigation or at prototyping stage.  
Macroscopic FE cathodes with CNTs 
Most applications of CNT field emission sources require the utilization of macroscopic 
cathodes with continuous or patterned films consisting ensembles of highly aligned and 
35 
 
uniformly distributed CNT emitters, as well as stable electron emission with high current 
densities. It is indeed technically challenging to achieve optimal emission performance from an 
array or a group of nanotubes since not only the microscopic structures of individual CNTs but 
also the higher-level architecture of the cathode have to be considered and optimized 
systemically. The key materials parameters that affect the macroscopic performance of the 
cathode include: the type of CNTs (i.e. SWNT versus MWNT, with closed or open caps), the 
presence of defects in the crystalline structure, additions of dopants, the purity of the CNTs in the 
film (e.g. presence of amorphous carbon or other residues), the orientation of the CNTs, the 
height and diameter of CNTs, the density of the CNTs, the uniformity in the distribution of CNT 
emitters, and the interaction of the CNTs with the supporting substrates [16, 28]. The CNT 
cathodes fabrication techniques have been explored and the performances of CNT cathodes for 
different applications have been evaluated extensively [3, 26, 33]. In particular, the technology 
of fabricating high current and high current density CNT field emission source array for x-ray 
production, and related applications developed previously and currently at the University of 
North Carolina at Chapel Hill are briefly reviewed in the following sections of this chapter. 
 Carbon nanotube field emission X-ray technology 2.3.3
The methods of fabricating carbon nanotube field emission cathodes have been studied 
and optimized over the past decade in our lab at the University of North Carolina at Chapel Hill 
[16, 27, 44-47]. The technology of developing CNT-based X-ray systems has been successfully 
developed and its potential for medical applications has been investigated [43, 46, 48, 49]. As 
illustrated in Figure 2.3, the main components of a CNT-based X-ray tube include (i) CNT field 
emission cathode, (ii) anode, (iii) gate electrode, and (iv) focusing electrodes. Instead of heating 
the cathode filament to an ultrahigh temperature as in conventional thermionic X-ray tubes, an 
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electric field is applied between the cathode and the gate electrode to extract the electrons from 
the CNT emitters. Under the high voltage (~kV) electrons are accelerated to bombard the anode 
surface for X-ray production. Two focusing lenses are usually arranged next to the gate mesh to 
define the shape and size of the electron beam and the resultant focal spot on the anode. All 
components are sealed inside a stainless steel vacuum chamber with a window made of less 
attenuating materials such as aluminum, beryllium, or stainless steel as X-ray exit port.  
 
Figure 2.3 The configuration of an X-ray tube with the CNT field emission cathode. G represents the gate mesh where the 
electrostatic potential is applied for electron extraction. F1 and F2 are focusing electrodes for customizing the shape of the 
electron beam as well as the resultant focal spot on the anode. High voltages (kV) are applied between the cathode and anode for 
electron acceleration and X-ray generation. All parts are sealed inside an evacuated housing with a thin layer of window material 
as X-ray exit port. Electronic control circuit is now shown here for simplicity purpose.  
 
The cathode is fabricated by depositing multi-walled CNTs onto the conducting substrate 
using a liquid-phase room temperature electrophoretic deposition (EPD) method developed 
previous in our lab [48, 50-52]. The CNT cathodes fabricated in such manner have demonstrated 
long-term stability under high current and high voltage conditions [48]. This method has enabled 
fabrication of CNT cathodes with variable geometries and dimensions including multi-pixel 
cathode arrays. The variation among individual cathodes has shown to be generally small [48].   
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CNT field emission based X-ray tubes have intrinsic advantages over conventional 
thermionic X-ray tubes. They are compact in size, with the flexibility of constructing X-ray tubes 
with multiple sources, and/or in different geometries and configurations (Figure 2.4). Because of 
the nature of field emission mechanism, the source can be electronically controlled with near-
instantaneous response in either continuous or pulsed mode [43]. This allows for programmable 
control of each individual source when an array of multiple emitting pixels is used, as shown in 
on the left in Figure 2.4, meaning a more flexible utilization of the X-ray and more efficient heat 
management of the anode heat load.  
 
 
Figure 2.4 A schematic illustration (left) of a multi-beam x-ray source with five individually controlled CNT emitting pixels [53];  
and examples of CNT-based X-ray tubes with multiple sources and in linear (middle) or square (right) geometries, photos 
courtesy of XinRay Systems Inc.  
 
 Carbon nanotube source array based medical devices 2.3.4
Carbon nanotube field emission source array technology brings a wide range of 
possibilities for practical applications with numerous advantages over the state-of-the-art X-ray 
technologies as discussed previously. In particular, the potential of translating this technology 
into clinical uses in both diagnostic imaging and radiotherapy devices has been extensively 
explored and demonstrated in our lab at the University of North Carolina at Chapel Hill.  
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 Diagnostic imaging devices 2.3.4.1
A dynamic micro-computed tomography (micro-CT) scanner 
Small animal imaging is challenging especially for organs such as lung and heart due to 
the extremely fine anatomical structures and the motion blurs induced by the rapid respiratory 
and cardiac rates. Therefore imaging techniques with both high spatial and temporal resolutions 
are generally required for detailed anatomical and physiological characterization in preclinical 
studies using small animal models. Micro-CT is widely used as a non-invasive imaging modality 
with resolution in the micrometer scales. The high spatial resolution is achieved by utilizing a 
microfocus tube with small focal spot sizes, and a high resolution detector. However the 
performance of most micro-CT scanners with conventional thermionic sources is still poor in 
resolving the fine internal structures in the organs such as heart and lung with high-frequency 
motion.  
Gated imaging can largely reduce the physiological motion (both respiratory and cardiac) 
induced blurring artifacts and therefore improve the overall image quality, without having to 
intubate the patients, which compromises the physiological parameters of interests. There are 
typically two methods to perform physiologically gated CT imaging, namely retrospective gating 
and prospective gating [54]. Retrospective gated imaging requires taking multiple complete sets 
of CT projections meanwhile acquiring the physiological (respiratory or cardiac) traces. 
Projections are sorted into bins based on the phases they are captured and reconstructed 
afterwards. This method is relatively time efficient but results in a higher level of radiation dose. 
The other approach, prospective gated imaging, is to “freeze” the organ motion by exposing the 
object of interest to X-rays only at certain phase of the respiratory and/or electrocardiogram 
(ECG) cycles. The CNT field emission source array technology with swift switching and precise 
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pulse control of individual sources is an ideal suit for achieving gated X-ray imaging, and has 
therefore enabled the successful development of preclinical micro-CT scanners with the 
capability of both respiratory and cardiac gating for in-vivo pulmonary and cardiac imaging [54-
57]. Two different setups have been investigated over the course of development. The first 
prototype contained a stationary pair of X-ray source and a flat panel detector with a rotating 
sample stage. The later modified model introduced a rotating gantry where the microfocus tube 
and detector are mounted to rotate in synchrony on opposite sides of the imaged object which 
stays still during image acquisition. The sample holder is mounted on a stage with freedom of 
linear translation along three axes. 3D volume information is acquired by rotating the source-
detector pair around the sample for a full coverage of region of interest.  
Figure 2.5 shows photos of the CNT-based microfocus tube and the latest model of CNT-
based micro-CT scanner named Charybdis with a rotating gantry built in our lab. The microfocus 
X-ray tube has a focal spot size of about 50 µm and can operate at up to 50 kVp. The flat panel 
detector (Hamamatsu Photonics K.K., Japan) has a pixel size of 50 µm with a 50 x 50 mm active 
area. The scanner is equipped with physiological monitoring sensors and user control interface 
for monitoring the respiratory and cardiac signals which are used to gate the X-ray exposures and 
image acquisition. A commercial software Cobra (Exxim Computing Corp., CA) is installed for 
image reconstruction. Studies have demonstrated that using this CNT-based micro-CT scanner 
high-resolution CT images of beating mouse hearts can be obtained at 15 ms temporal resolution 
and 6.2 lp/mm spatial resolution at 10% system modulation transfer function (MTF) [57]. 
Prospectively gated pulmonary imaging with high resolution has also been demonstrated using 
this scanner [54]. So far the CNT-based micro-CT scanners have been installed at several 
facilities, including the Biomedical Research Imaging Center at UNC Chapel Hill, the 
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comprehensive lung imaging center at the University of Iowa, and the department of Physics and 
Astronomy at UNC for image-guided microbeam radiation therapy research.   
 
  
  
Figure 2.5 Top: a photo of the CNT field emission based microfocus X-ray tube built in the CNT-based micro-CT scanner. 
Reprinted from Cao et al. Medical Physics 37 (10), 2010 [57]. Bottom left: a photo showing the main components of the CNT 
micro-CT scanner including a rotating gantry, a CNT-based microfocus X-ray tube, a high-resolution flat panel detector, a high 
voltage power unit, and a sample stage. The gantry and sample stage are mounted on an optical table. Bottom right: a photo of the 
external appearance of the CNT micro-CT scanner Charybdis enclosed inside a painted shielding housing .  
 
Stationary digital tomosynthesis systems 
Digital X-ray tomosynthesis is a type of new imaging technique developed based upon 
principles of computed tomography [58] initially designed for breast cancer screening. The main 
idea is to produce arbitrary number of slice images over a limited angular coverage (i.e. smaller 
angular span than that is used in CT) and create a pseudo-3D reconstruction of the imaged object. 
It improves the depth information of overlapping anatomical structures that are obscured in 
conventional 2D radiography, with the benefit of reduced radiation dose compared to a full CT 
scan. Digital tomosynthesis bears great potential as a clinical imaging modality with the recent 
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advances in the source development, digital detector speed and efficiency, reconstruction 
algorithms, computer calculation power, and methods for noise reduction. The applications of 
digital tomosynthesis have been investigated in breast imaging, chest imaging, joint imaging, 
angiography and dental imaging [59].  
Previously two acquisition modes are used in digital tomosynthesis systems, step-and-
shoot, and continuous motion. Both modes employ a single X-ray source rotating around the 
object of interest and a stationary detector over the angular span [60]. Motion-induced image 
blurring is one of the major artifacts in digital tomosynthesis, which degrades the image 
resolution and therefore compromises its detection capability for objects with fine anatomical 
structures, or in extremely small scales such as microcalcifications in breast imaging. Continuous 
motion tomosynthesis systems suffer from the image blurring induced by the continuous travel 
of the X-ray source during image acquisition. The step-and-shoot tomosynthesis systems, on the 
other hand, have sources of motion from the patients due to the extended scan time, as well as 
mechanical vibration due to the incomplete stop of the gantry at each angular location for 
exposure. 
The innovation of introducing CNT-based field emission source arrays into 
tomosynthesis creates a new mode of system operation namely the stationary digital 
tomosynthesis. This is an example of utilizing the unique characteristics of CNT cathodes, e.g. 
compact in size, electronic programmability and near-instantaneous beam response. The main 
concept of stationary tomosynthesis is to replace the single X-ray tube in the original digital 
tomosynthesis with an array of multiple X-ray sources aligned along the moving track over the 
angular coverage. Therefore projections are captured sequentially by individual sources in the 
stationary fashion which completely eliminates the use of a rotating gantry and the subsequent 
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focal spot blur. Besides, the rapid beam response with convenient electronic control largely 
reduces the overall scan time and thus limits the patient motion during the exposure.  
So far, several prototypes of stationary digital tomosynthesis dedicated for different 
diagnostic purposes have been developed in our lab, including the stationary digital breast 
tomosynthesis (s-DBT) system [61-64], the stationary digital chest tomosynthesis (s-DCT) 
system [65, 66], and the recently demonstrated stationary intra-oral digital tomosynthesis (s-IOT) 
unit [67].  
 
   
Figure 2.6 Left: the original Hologic Selenia Dimensions DBT system with a rotating gantry; middle: the prototype s-DBT 
system with a linear CNT source array retro-fitted into the Hologic Selenia Dimensions scanner; right: a photo of the s-DBT 
prototype installed at North Carolina Cancer Hospital (Chapel Hill, NC) for clinical trial [68].  
 
Stationary digital breast tomosynthesis system 
Digital breast tomosynthesis serves as a new imaging modality for breast cancer detection, 
and has shown to improve the detection capability over 2-D digital mammography by reducing 
the blur and obstruction from overlapping anatomical noise [60]. So far, there are three main 
commercial tomosynthesis systems made by GE, Siemens, and Hologic, respectively. The 
Hologic Selenia Dimensions system is the only one that has received FDA approval. 
Collaborating with Hologic, our group has successfully constructed an s-DBT system by retro-
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fitting a linear array of CNT field emission cathodes into a Hologic Selenia Dimensions system 
with a rotating gantry (Hologic Corp., MA) (Figure 2.6 left and middle). The linear source array 
contains 31 CNT cathodes, and the focal spots span a distance of 370 mm from end to end with 
equal angular spacing of 1° with a maximum angular range of 30° [62]. The X-ray source array 
is mounted 700 mm above the detector surface with 1 mm aluminum X-ray window. The tube 
can operate at up to 45 kV anode voltage with a typical operation range from 26 to 36 kV. One 
prototype s-DBT system (Figure 2.6 right) has been installed at North Carolina Cancer Hospital 
for clinical trial [68], setting a milestone for CNT x-ray source array technology for medical uses.  
The s-DBT system demonstrated a significantly higher spatial resolution than continuous 
motion DBT systems. an significant improved detections sensitivity on lesions compared to 
digital mammography [69]. The comparison studies by Tucker, et al. of imaging 
microcalcifications in lumpectomy specimens have shown that s-DBT produces better MC 
sharpness and reduced tissue overlap compared to continuous motion DBT systems [70], as 
illustrated in Figure 2.7. 
 
Figure 2.7 Comparison of the reconstructed images from s-DBT and DBT in human specimen study. Photos adapted from Tucker 
et al. Proc. of SPIE Vol. 9033, 903316 Medical Imaging 2014 [70] 
 
 
44 
 
Stationary digital chest tomosynthesis system 
 
 
Figure 2.8 The s-DCT prototype installed at the Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center, at UNC 
Marsico Lung Institute for clinical trials  
 
Another stationary digital tomosynthesis (s-DCT) prototype dedicated for chest imaging 
has also been developed using the CNT field emission source array, with the capability to 
improve the detection sensitivity for small lung nodules compared to conventional 2D chest 
radiography [66]. A prototype s-DCT system (Figure 2.8) has been installed at the Marsico Lung 
Institute at the University of North Carolina at Chapel Hill for clinical trials [71]. System 
characterization and evaluation can be found in studies by Shan, et al. [66] and is not detailed 
here.  
Stationary intraoral digital tomosynthesis system 
The feasibility of using CNT field emission source array for stationary digital 
tomosynthesis for intraoral imaging has recently been demonstrated as well [67]. High resolution 
images were successfully generated with detailed 3D information of the dental and alveolar 
anatomy, at the patient dose comparable to a standard 2D intraoral radiography [67]. The studies 
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also showed improved detection sensitivity of caries, root fractures and defects. Further 
investigations are to be carried out to evaluate the overall diagnostic efficacy of this new 
intraoral imaging modality.  
 Radiotherapy systems for preclinical studies 2.3.4.2
The capability of CNT field emission cathodes for generating high current and current 
density makes them suitable sources for another medical application, i.e. radiotherapy systems.  
Cellular irradiator and multi-pixel micro-radiotherapy system 
Early efforts of using carbon nanotube field emission cathodes for high dose radiobiology 
and oncology studies include feasibility studies of developing a high-resolution electron beam 
irradiator for microscopic cellular region irradiation [72, 73], and a multi-pixel micro-
radiotherapy (micro-RT) prototype for small animal irradiation and cancer research [53, 74-76]. 
The prototype single cell electron beam irradiator has demonstrated its ability of achieving a high 
spatial resolution of ~25 µm (electron beam full-width-at-half-maximum or FWHM) with 
variable dose rates of 1-100 Gy/s, using a single CNT field emission cathode about 1 mm in 
diameter. The multi-pixel small animal micro-irradiator was proposed by fabricating a 2D array 
of CNT cathodes and incorporating a transmissive-type anode and a beam collimator. Desired 
irradiation field in various shapes can be formed by activating individual cathodes at different 
coordinates in the array, without having to move the animal, the source or the collimator.  
Image-guided microbeam radiation therapy system 
 The carbon nanotube field emission source array technology enables modification of the 
focal spot shape from a small isotropic point to an elongated focal line. This increases the total 
interaction area on the anode surface, which results in a significant improvement in the total 
power of the X-ray production and the efficiency of heat dissipation. The CNT field emission 
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based line focus X-ray tubes are beneficial for certain applications where high power X-ray is 
required. In particular, it is an attractive alternative and practical solution for generating the 
specific radiation beam pattern, and it promises yet another RT modality namely microbeam 
radiation therapy or MRT. The feasibility of developing a CNT field emission source array based 
compact MRT system has been pursued and ongoing research on the system optimizing, 
characterization, and validation is discussed in the following chapters. 
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 DEVELPING A COMPACT MICROBEAM IRRADIATOR USING THE CHAPTER 3:
CARBON NANOTUBE FIELD EMISSION SOURCE ARRAY 
 
 Overview 3.1
As discussed in the previous chapter, the carbon nanotube field emission source array 
technology affords great flexibility in the source design in terms of the dimension, number of 
sources, geometric configuration of the individual source, and the mode of operation. This opens 
up new possibilities in X-ray tube design and novel applications that are not easily achievable 
using the conventional thermionic cathodes. Particularly, the CNT distributed source array 
allows for high flux microbeam production by customizing the shape and dimension of the 
electron beam focal spot on the anode, and therefore enables the development of a compact MRT 
delivery system [1].  
 
Figure 3.1 Schematic drawing illustrating the difference of point focus and line-focusing X-ray sources, the microbeam 
collimator needed for each source, and the resultant dose profiles.   
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The mechanism to produce high dose rate microbeam using CNT source arrays compared 
to conventional X-ray sources is illustrated in Figure 3.1. An elongated line focus with a large 
aspect ratio (length/width) can be generated by aligning an array of CNT cathodes in customized 
shape and applying optimized focusing voltages. It therefore greatly increases the anode area that 
receives the electron beams which results in a significant increase in the X-ray photon output. 
Anode melting can be avoided since the total energy is spread into a larger surface area instead 
of a single focal spot as in conventional high power X-ray tube. Furthermore, as shown in the 
drawing, a majority of the primary photon beam is blocked by the microbeam collimator and 
wasted as heat, in conventional X-ray tubes with isotropic oval-shape focal spots. In contrast, the 
microbeam generating efficiency is significantly improved with the elongated focal track since a 
larger portion of the photons from the primary beam can contribute to the microbeam production. 
This is in essence equivalent to assembling a large number of microfocus x-ray tubes and 
powering them simultaneously, but without the constraint of space, power consumption and 
beam alignment. Radiation generated from the elongated focal line provides a more uniform dose 
distribution along the microbeam direction while preserving the spatial resolution (steep dose 
gradient with a small beam penumbra) in the other direction across the microbeam.  
The feasibility of  high dose rate microbeams from the CNT source array was confirmed 
by Monte Carlo simulations and phantom-based pilot experiments, prior to the pursuit of 
construction of a prototype system. These efforts were previously reported in detail by Schreiber 
and Chang [2], and by Hadsell, et al. [3, 4] respectively.  
The originally proposed concept of design of a CNT-based compact MRT system is 
illustrated in Figure 3.2, where multiple arrays of microbeams are delivered from different angles 
and directed toward the treatment target simultaneously. Each array contains several microbeams 
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that are generated from individually addressable cathode segments. The number of arrays to be 
used and their distributions can be customized according to different treatment plans. Hence, the 
week penetration of orthovoltage radiation and the poor dose uptake in deep-seated target can be 
mitigated by spatial conformality from multi-directional microbeam arrays that overlap or 
interlace in the target volume, while the microbeam effects are being preserved from the spatial 
modulation in each array.   
 
      
Figure 3.2 Schematic drawings of the design concept of compact high-flux microbeam delivery systems with multiple arrays of 
CNT generated microbeams arranged in a ring (left) or a square (right) configuration around the target to achieve dose 
conformality physically. Customized MRT treatment can be delivered by electronically programming the on-and-off status of 
individual cathode segments.  
 
Considering the complexities and difficulties from engineering perspective involved in 
building a ring-shaped system, as well as other time and financial constraints, a simplified 
version was later proposed for preclinical studies with most of the main features resembling the 
original ring-shaped configuration. Instead of being a full circle, the modified system design 
contains four banks of vacuum chambers, with each consisting of a linear CNT source array.  
After significant amount of simulations and instrumental testing conducted using a 
testing chamber on the performance of major components [4], the design and assembling of a 
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first-generation CNT-MRT system was commissioned. This prototype device employed one 
linear source array in the initial version.  
 
Figure 3.3 A photograph of the CNT-MRT first prototype constructed on an optical table inside a shielded enclosure in our lab at 
UNC Chapel Hill. Some of the main external components are indicated. Secondary shielding panels are also installed 
surrounding the MRT tube on the optical table during operation.  As can be seen, a CNT-based micro-CT scanner is built on the 
same optical table to provide image guidance.  
 
 The First-generation Prototype 3.2
Thermal behavior in the X-ray chamber were simulated by finite element analysis 
software ANSYS
TM 
prior to the assembling of the system to determine the technical details of the 
mechanical design as well as the projected power/specifications in standard operation [5]. 
Guided by the results from the feasibility studies as well as simulations of the performances of 
key components, a first-generation CNT source array based compact microbeam irradiator was 
designed and constructed in our lab in the Department of Physics and Astronomy at the 
University of North Carolina at Chapel Hill. This first-generation system has been under 
continuous development, systematic characterization, optimization, and validation for preclinical 
studies, which is the main subject of this thesis. A photograph of this irradiator is shown in 
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Figure 3.3, and the main components in the system design and system specifications are 
described in the following sections.   
 Main components  3.2.1
 
 
Figure 3.4 Illustration of the main components of the CNT-MRT system including the photon production structures enclosed in 
the vacuum chamber, and the microbeam collimator underneath the X-ray window.  
 
The main components of the irradiator for photon production consist of the cathodes 
array, the anode, the gate mesh and two focusing electrodes, all of which are enclosed in a 
vacuum chamber with an X-ray window embedded for photon exit. The configuration is 
illustrated in Figure 3.4. Besides, a motorized collimation and alignment system was designed to 
generate microbeam from the original broad beam. It’s a detachable assembly installed outside 
the vacuum chamber. Other parts include vacuum accessories, high voltage feedthrough, control 
electronics, a temperature monitoring device, and external heat exchange coils. All major 
components are assembled together and supported with aluminum chamber stands that affix onto 
an optical table. A sample positioning and translation stage is also installed on the optical table, 
which serves between the imaging device and the irradiator. Details of the sample stage will be 
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described in chapter 4. The standalone irradiator is enclosed in a secondary shielding housing 
made of 6 mm thick lead panels.  
Cathode assembly 
The linear source array consists of five individual CNT field emission cathodes. Each 
cathode is around 2.5 mm × 30 mm in size (effective emitting area), fabricated by depositing 
CNT emitters on to the molybdenum substrate using the EPD method as described in the 
previous chapter. Five cathodes are aligned into an array and fastened onto a glass plate from the 
bottom of the molybdenum substrates. The glass plate is clamped against the bottom of the gate 
frame with setscrews. The gate mesh is fabricated by etching a row of curved slits out of a flat 
sheet of stainless steel. Electrons are extracted from the CNT cathodes when a negative voltage 
is applied to the cathode while the gate mesh is grounded. On the other side of the gate mesh is 
an Einzel lens structure consisting of two focusing electrodes layered one on top of the other. 
Simulations on the focusing performance of the Einzel lens was performed using a commercial 
software package (Opera 3D Vector Fields Software, Cobham Plc, Dorset, UK) previously [6]. A 
photograph and SolidWorks drawing of the cathode assembly are shown in Figure 3.5. 
Anode assembly and X-ray window 
The reflection anode is 222 mm × 25 mm × 17 mm in size, with the bulk of it made of 
molybdenum. The front surface (the side facing the cathode assembly, measuring 222 mm × 25 
mm) is uniformly coated with 200 µm thick layer of tungsten-rhenium alloy and is mirror 
finished for uniform photon production and to prevent arcing events. The anode is held in place 
by an L-shaped bracket (via two setscrews) which bridges the anode to a cylinder that extends to 
the bottom of the high voltage feedthrough. The X-ray window is 9 mm × 226 mm × 200 µm 
(length × width × thickness) in size made of stainless steel. It is embedded into a frame that is 38 
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mm × 256 mm and welded into the bottom of the X-ray vacuum chamber, as the primary photon 
beam escaping port as well as a built-in filter.  
 
            
 
Figure 3.5 Top left: a photograph of the CNT cathode. The area in black is the deposited layer of CNT emitters. Top right: 
SolidWorks drawings (trimetric view) of the cathode assembly. Bottom: cross-sectional view. Main structures are labeled, 
including the cathode (CNT emitters deposited on molybdenum substrate), gate mesh, and two focusing electrodes.   
 
The front surface of the anode is positioned parallel to the cathode assembly, in contrast 
to most X-ray tube designs where the anode is placed at a tilt towards the X-ray window. The 
main reason for this design is to avoid the anode thermal expansion-induced change in the 
vertical location of the focal line with respect to the X-ray window. Since both the focal line and 
the microbeam collimator slit are extremely narrow (which will be discussed below), a small 
change in the vertical location of the focal line or its shape would significantly affect the 
alignment of the collimator, and the resultant microbeam profile and dose rate. There are some 
remaining issues, though, with the current design of the anode assembly which will be discussed 
later in this chapter. 
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Vacuum accessories 
The above components are enclosed inside a flange-sealed vacuum chamber, with a turbo 
pump and an ion pump (Agilent Technologies, Santa Clara, CA) incorporated from the rear and 
the side of the chamber respectively. A Residual Gas Analyzer (RGA) (Stanford Research 
Systems Inc., Sunnyvale, CA) with a vacuum gauge are also attached to the other side of the 
chamber for monitoring the total and partial pressures of the gases present in the chamber as well 
as for diagnosis purposes.  
Microbeam collimation and alignment assembly 
A motorized microbeam collimation and alignment assembly is attached to the bottom of 
the vacuum chamber right underneath the X-ray window. It is an add-on to the X-ray chamber 
and can be removed during conditioning or different mode of operation. A SolidWorks drawing 
of the collimator assembly is shown in Figure 3.6. This single slit collimator composed of two 
tungsten carbide blocks (manufactured by KC Precision, India) each measuring 150 mm × 17 
mm × 9 mm (length × width × thickness). They are clamped against two glass spacers at both 
ends of the tungsten carbide blocks to form a uniform slit. The width of the slit is therefore 
defined by the thickness of the glass spacers, which is 175 µm in the current system, and can be 
varied by replacing the glass spacers. The design and dimensions of the collimator directly 
determine the profile of the microbeam coming out of the primary broadbeam, and were 
simulated and validated using a testing prototype previously [4]. Under standard MRT operation 
mode, the microbeam collimation assembly is installed at the bottom of the X-ray chamber 
beneath the X-ray window, with the collimating plane (primary beam entrance surface) 
positioned at 8°angle with respect to the X-ray window and ~ 65.2 mm away vertically from 
the anode focal line.  
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The alignment of the collimator slit to the anode focal line is achieved by three linear translation 
stages and one rotation stage (Newport Corp., CA) that drive the pair of tungsten blocks with two 
degrees of freedom. The actuators that motorize the translation and rotation stages are rated with 
precision of within 2 µm. The collimator alignment procedure will be described in section 3.4. 
 
 
 
Figure 3.6 SolidWorks drawings of the microbeam collimator assembly. 
 
 Source characteristics  3.2.2
During the course of the work discussed in this thesis, the system has gone through 
several iterations of regular maintenance, as well as modifications regarding several detailed 
features. Mainly, the original five cathodes used since the completion of system construction in 
2010 had degraded after 3 years and were replaced in later 2013. The fresh new cathode set as 
well as the rest of the main components inside the vacuum chamber have been fully conditioned 
following the established procedures by the source manufacturer (Xinray Systems Inc., RTP, 
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NC). The source characteristics and performance described here mainly refer to the system with 
the new cathodes since 2013.  
 Tube specifications in standard mode of operation (full power) 3.2.2.1
Table 3.1 Selected parameters for full power operation of the first CNT-MRT prototype 
 
 
The operational protocols and system specifications have been determined after detailed 
simulations and extensive testing, as shown in Table 3.1. To generate stable and high flux 
microbeam radiation, the system operates at 160 kV constant anode voltage and 30 mA total tube 
current from all five cathodes simultaneously. The biased extraction field is created by applying 
a negative electrical voltage to the cathodes while grounding the gate mesh. Emission from 
individual cathode can be adjusted by tuning the resistance that is connected to each cathode. 
The transmission rate (TR), namely the ratio of the anode current and the emission current from 
the corresponding cathode, is determined for each cathode. Current from each of the five 
cathodes is configured such that a uniformly distributed focal line is achieved on the anode. The 
electron emission is triggered in the pulsed-mode, with 225 µm pulse width at 8% duty cycle to 
achieve the optimal cathode degradation protection and fast heat dissipation from the anode. 
Since there is no built-in heat exchange coils through the anode in the first prototype, external 
cooling coils with running chilled water are placed around the anode HV feedthrough where a 
significant amount of heat transfer takes place during full power operation. Additionally, external 
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fans and heat sinks are also available during extensive use of the system to further facilitate the 
heat dissipation.  
 Photon energy spectrum 3.2.2.2
The photon energy spectrum at 160 kVp was also measured experimentally using the 
Amptek XR-100T- CdTe X-ray detector with a PX4 multi-channel analyzer (Amptek Inc., 
Bredford, MA), and a 1 mm pin-hole collimator. The setup was placed directly underneath the 
bottom of the microbeam collimator plate with the pin-hole collimator positioned at 8° angle, 
corresponding to the tilt from the microbeam collimator. The electronics from the detector was 
shielded for protection. Alignment and calibration was first carried out using lower anode 
energies, as well as the characteristic peaks from the iodine solution. The actual measurement 
was taken at 160 kVp with a long exposure (~1 hour). Only dark current was used due to the 
sensitivity and saturation of the detector. The measured photon spectrum and the simulated one 
from SpekCalc are shown in Figure 3.7. The closely located k edges of tungsten and rhenium 
(coated layer on the front surface of the anode) are clearly identified from the spectrum in both 
spectra.  
 Focal line size 3.2.2.3
The characterization of the focal line in the prototype irradiator has been carried out 
following the European Standard EN12543-5 the edge method for mini or microfocus X-ray 
tubes. The original EN12543-5 protocol employs a phantom made of two crossed tungsten wires 
with a diameter between 0.9 – 1.2 mm, to determine the effective focal spot sizes in both 
horizontal and vertical directions across the front surface on the anode. Since the focal track in 
our irradiator has an extremely large aspect ratio (length/width), with the width of the focal line 
being relevant in most of our studies, our modified protocol uses a single tungsten wire with 1 
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mm diameter. The geometry of the measurement setup has been described in detailed by Hadsell 
[4] and is not repeated here. The effective focal line width was measured to be 131 µm, and 175 
µm for the original and the new cathodes sets, respectively.   
 
  
Figure 3.7 The measured photon energy spectrum measured using AmpTek XR-100T-CeTd X-ray detector (top), and the 
simulated spectrum using SpekCalc (bottom). 
 
 Dosimetric Characteristics 3.3
Several reasons make experimental dosimetry in MRT extremely challenging. The 
photon energy spectrum used in MRT spans over a large range (50-250 keV for synchrotron 
MRT, 10~160 keV for our first-generation CNT-MRT system). The spatial modulation means 
that the radiation dose delivered in the peaks can vary by hundreds of grays from that deposited 
in the valleys. These require the dosimeters to have sensitive and non-energy-dependent response 
over a large dose range. Besides, ultrahigh spatial resolution is required for the applicable 
dosimeter due to the submillimeter scale beam size as well as the extremely sharp dose fall-off 
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between the peaks and the valleys. So far there is no commercially-available dosimeter that 
meets all the requirements mentioned above. Specially designed high-resolution dosimeters have 
since then been under development or evaluation for dosimetric measurement in MRT [7, 8]. 
There are several potential candidates including Gafchromic films (Ashland Advanced Materials, 
Covington, KY), fluorescence nuclear track detectors (FNTDs) (Landauer Inc. Stillwater, OK), 
and two-dimensional thermoluminescence dosimetry system [9, 10]. Developing of a silicon-
strip detector with the potential to achieve online dose monitoring during treatment is also one of 
the major focuses in experimental dosimetry in MRT with substantial progress made in the last 
decade.  
Considering the energy and dose range that are relevant to our first-generation system, we 
have established dedicated dosimetry protocols using Gafchromic EBT2 or EBT3 films to 
characterize the microbeams. Several other new dosimeters including the nanoparticle-
terminated fiber-optic dosimeter have also been investigated for dosimetry characterization of 
this microbeam irradiator [11].  
 Film dosimetry with Gafchromic EBT2/EBT3 films 3.3.1
Gafchromic EBT2/EBT3 films are radiochromic films that respond to ionizing radiation 
with color changes without requiring latent post processing such as chemical, optical or thermal 
development of amplification. The near-instantaneous color changing is due to the irradiation-
induced polymerization process of the active film layer, and stabilizes over a short period of time. 
The darkness of the film after postexposure changes (or self-development) correlates to the 
amount of absorbed dose, and therefore is used for quantitative dose determination in the clinic 
[12]. The dynamic dose range for EBT2 or EBT3 films is1cGy to over 40Gy with no or a weak 
energy-dependence from 100keV to 18 MeV[13]. EBT2 and EBT3 films can resolve patterns 
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down to 25 μm and therefore are particularly useful for high spatial resolution dose measurement. 
They are nearly soft tissue equivalent, water resistant, can be handled in room light. The active 
layer composition and thickness, as well as the dose response are the same for EBT2 and EBT3 
films. For both types of film, a yellow marker dye is incorporated in the active layer that enables 
non-uniformity correction with multi-channel dosimetry and also decreases UV/visible light 
sensitivity. As the relatively new generation, EBT3 films have several improvements compared 
to its predecessor, EBT2 films. The active layer is laminated between two identical polyester 
layers in EBT3 films in contrast to the asymmetric layer configuration in EBT2 films. This will 
eliminate the potential errors in the scanning process due to side orientation dependence that 
could result in false measurements of optical density as reported for EBT2 films [14]. The 
polyester film substrate with silica treatment in EBT3 can effectively avoid Newton’s Rings 
formation. The layer structures for both EBT2 and EBT3 films are illustrated in Figure 3.8. With 
all the aforementioned features, Gafchromic EBT2 or EBT3 films are suitable dosimeters for 
relative dosimetry of the first-generation CNT-MRT system in the relatively low dose range.  
 
 
Figure 3.8 Illustration of the different layer configurations of Gafchromic EBT2 (left) and EBT3 (right) films [13].   
 
Initial system dosimetry was carried out with Gafchromic EBT2 films as reported 
previously [4]. These procedures were followed and optimized in the characterization conducted 
in December 2013 with Gafchromic EBT3 films (lot number 07221303), and the results 
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presented later. The system was operating at full power with 160kV anode voltage, 30mA total 
tube current (anode current), 8% duty cycle with 500 μm pulse width during all dosimetric 
characterization procedures. No other external beam filter was applied other than the 200 μm 
thick stainless steel X-ray window. EBT3 films as relative dosimeters were first cross calibrated 
to an ion chamber in the broad field (without microbeam collimator) to establish the dose 
response curve, i.e. the mathematical correspondence between radiation exposure versus the 
pixel value of digitized films. This calibration procedure needs to be carried out with the film 
and the ion chamber positioned and irradiated in identical conditions, so that the corresponding 
radiation exposure that the EBT3 film received can be read directly from the ion chamber, as 
shown in Figure 3.9. The ion chamber used in the experiment was a pre-calibrated farmer-type 
ion chamber (RadCal 10×6 – 6, from UNC Department of Environment, Health and Safety) 
together with an electrometer (MDH – 1015 5C). The EBT3 film sheets were cut into rectangular 
pieces that measured 3 inch × 4 inch in size, and each piece was handled separately. Film 
orientation was labeled properly before irradiation exposure. Extra care was taken since the 
EBT3 films were found to be prone to edge damage from the cutting process. Split edges should 
be avoided in dose measurement or analysis. For each measurement, a single piece of EBT3 film 
was placed between two plastic layers that was each 1.09 mm thick. This setup would simulate 
the environment that the air in the sensitive air cavity of the ion chamber would experience, i.e 
beam attenuation from the top chamber wall and slight photon backscattering from the chamber 
wall on the bottom. The effective point of measurement in a cylindrical ion chamber is the 
geometric center of its sensitive air cavity for kilovoltage measurements [15]. Therefore the film 
with the plastic supporting layers were placed close to the side of the ion chamber with the 
height of the film aligned with the central line of the ion chamber, as shown in Figure 3.9. Both 
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the sandwiched film and the ion chamber were held in air, roughly in the center of the radiation 
field at a distance of 157 mm downstream from the X-ray window.  
 
Figure 3.9 Top: Illustration of the side-by-side setup of EBT3 film and an ion chamber in the cross-calibration process. A piece 
of EBT3 film was placed between two thin layers of plastic, with the plane of EBT3 film aligned with the central plane of the ion 
chamber. Bottom: Illustration of the sectional view of an ion chamber, with sensitive air cavity and collecting electrode indicated. 
A total of thirteen pieces of EBT3 films were irradiated in the setup described above with 
the tube operating at full power, with the exposure read and recorded from the ion chamber and 
the exposure time recorded with a timer as well. The measured radiation exposure levels ranged 
from 0 – 1.0 × 104 Roentgen (exposure time ranged from 0 to 100.0 min). A constant exposure 
rate of 100 R/min was confirmed from the first five exposure levels (consistent in repeated 
experiments), and was thereafter used for longer exposures that were beyond the readout limit of 
the electrometer which was 1000.0 Roentgen. The ion chamber was found to have a constant 
background reading of 10.2 mR/min and was subsequently subtracted from each exposure point.  
The selected measurements had a denser distribution in the lower exposure level ranges 
(7 measurements in 0 – 1000.0 R range, 6 measurements from 1000.0 – 10000.0 R). The 
EBT2/EBT3 calibration curves showed a greater gradient in the lower dose range, and tended to 
flatten out over high dose range, as reported by the manufacturer and our previous experiments. 
Therefore an abundance of measurements in the high gradient region would be beneficial for 
curve fitting afterwards to yield an accurate valley dose definition in our experiments.  
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The exposed EBT3 films were stored in the dark for at least 24 hrs before digitized. The 
film scanning process was carried out using an EPSON V700 scanner following the precedures 
recommended by the manufacture. All three color channels (RGB) were employed and analyzed 
separately to generate three dose response curves at thirteen exposure levels. When analyzing 
each film in ImageJ (developed by NIH, public domain), a region selection box of 1 × 1 inch size 
was placed in the center of the exposed region where the dose distribution is uniform, and the 
averaged pixel value from the selected region was recorded for all three color channels. After 
converting the exposure to dose using the conversion factor of exposure to absorbed dose in dry 
air (air kerma) which is 0.0087, the dose response curves for each channel were plotted and 
shown in Figure 3.10.   
 
Figure 3.10 Dose responding curves of EBT3 film (lot number 07221303) in three color channels obtained through cross 
calibration to ion chamber. The system was operating in standard mode at full power, i.e. 160 kVp, 30mA tube current, 500 µm 
pulse width at 8% duty cycle. Spline-fitted are shown only to guide the eyes. 
 
The discrete points were fitted into continuous curves with polynomial regression for 
each color channel. This curve fitting method was shown to match closely with rational fit in the 
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dose range used in our experiments (unpublished data). The data point at 27Gy was determined 
to be an outlier, and was excluded in the curve fitting and following analysis. Based on the fitted 
calibration curves, a dose calculation program was developed with MATLAB (MathWorks Inc., 
Natick, MA), which employed multi-channel analysis as recommended by the manufacturer. The 
red channel was used for low dose reading up till 10 Gy due to its highest sensitivity, while green 
channel was used for measurements of high dose beyond 10 Gy. This program has been used for 
the analysis of EBT3 films (lot number 07221303) thereafter.  
The microbeam collimation assembly was installed after broad field film calibration. The 
system dosimetric parameters including half value layer, distance correction curve, dose rate, 
percentage depth dose, tissue maximum ratio were subsequently quantified following the 
protocols described by Hadsell [4]. A different procedure was used here compared to those 
reported by Hadsell in 2013. All measurements were performed with Gafchromic EBT3 films 
and a custom MATLAB program with multi-channel analysis, and the same set of parameters of 
beam quality were evaluated using Gafchromic EBT2 films and analyzed with FilmQaPro 
software developed by Ashland Advanced Materials (Covington, KY).  
 Half value layer (HVL)  3.3.2
Half value layer, or HVL, is the parameter that is often used to characterize the spectrum 
or hardness of a radiation beam. It refers to the thickness of material that attenuates the intensity 
of radiation entering it by one half. HVL is usually specified in millimeter of aluminum low 
energy X-ray beams and measured in narrow beam geometry to avoid large amount of scatters 
generated in aluminum. The first HVL of our CNT-MRT system was measured in microbeam 
mode where the beam was estimated to be around 300 µm wide, and therefore the narrow filed 
requirement was met. An aluminum step phantom was made for this measurement, with the 
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dimensions shown in Figure 3.11. There were a total of 10 identical steps on the aluminum 
phantom, and the difference in height is 2.54 mm between the adjacent steps. A piece of EBT3 
film was sandwiched between two 3 mm thick acrylic layers and placed underneath the 
aluminum phantom with 3 mm air gap between the bottom of the step phantom and the top layer 
of acrylic. The air gap prevented an interface effect between the aluminum and the film. The 
entire setup was placed on top of the translation stage and the measurements were performed in a 
step-and-shoot mode, with each microbeam irradiating through one of the ten steps on the 
phantom. The distance between the focal line to the film was 122.10 mm. In calculating the HVL 
one must recall that the microbeam traveled through the phantom material at 8° degree angle. 
The results were summarized in Figure 3.12, and the first half value layer was determined to be 
7.62 mm in aluminum with the CNT-MRT system operating at 160 kVp, 30 mA tube current.  
  
Figure 3.11 A photograph (left) and drawing (right) of the aluminum step phantom for half value layer measurement. The 
phantom has a total of ten identical steps, with each being 2.54 mm in height and 7.56 mm in width. The direction of microbeam 
penetrating through the step is indicated. The measurement EBT3 film sandwiched between two thin layers of acrylic was placed 
underneath the phantom. The dimensions are not drawn to scale.  
 
According to AAPM TG-61 protocol for kilovoltage X-ray beam dosimetry table IV, for 
first HVL of 7.62 mm aluminum the corresponding factor to convert air kerma to water kerma is 
1.043 after linear interpolation [15]. The f-factor is the conversion factor from exposure in air to 
absorbed dose in tissue or water as defined in equation:  
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𝐷 = 𝑓 · 𝑋 
where D is the tissue absorbed dose in rads, X is the air exposure in Roentgens. Combining the 
air kerma to water kerma conversion factor together with the conversion of exposure to absorbed 
dose in dry air (air kerma), the f-factor was thus calculated to be 0.915 rad/R. 
 
Figure 3.12 Results of HVL determination. Measurements were carried out in step-and-shoot mode with ten microbeam 
exposures onto each step of the aluminum phantom. The absorbed doses from ten exposures were recorded by a single piece of 
EBT3 film placed underneath the phantom. The successive exposures were separated horizontally far enough to avoid the effect 
or scatter from the previous or subsequent exposures.  
 
 Dose rate  3.3.3
The average microbeam entrance dose rate (DR) at certain sample heights and the 
consistency were evaluated. The EBT3 film was sandwiched between acrylic layers in the same 
way as in the experiments described above, and placed on top of a lab jack, which was 36.99 mm 
away from the bottom of the collimator. This yielded to a source to axis distance (SAD, focal 
line to center of the film) of 122.10 mm. Four microbeam exposures were delivered successively 
with exposure time ranging from 5min to 20min, and the results were shown in Figure 3.13. The 
average microbeam entrance dose rate was thus determined to be 1.01 ± 0.14 Gy/min at this 
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sample height, with the system operating at 160 kVp at 30 mA tube current. Radiation was 
triggered in pulsed-mode at 8% duty cycle and 500 µs pulse width. The peak microbeam DR 
corresponds to the in-pulse dose rate. The variation in the dose rate measurements could come 
from the small fluctuation of cathode current during beam-on time, the variation of film response 
at different locations due to inhomogeneity, and the uncertainties in the dose/DR response of the 
EBT3 film. The calculated DR in this measurement only corresponded to the entrance dose rate 
at this particular sample height. Entrance dose rate at different sample heights or tissue depths 
shall be calculated with the distance correction, PDD, and TMR results that are described in the 
following sections.  
 
Figure 3.13 Results from the average dose rate measurements that were performed with the system operating at 160 kVp, 30 mA 
anode current, 8% duty cycle, and 500 µs pulse width. The film was placed at 122.10 mm down from the focal line.  
 
 Distance correction 3.3.4
Due to the uniqueness of our radiation generation mechanism as well as the focal spot 
geometry in our CNT-MRT system, in-air primary beam flux falloff behavior over certain 
source-to-surface distance is expected to differ from those in clinical LINAC or conventional 
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orthovoltage X-ray tubes. In order to characterize such relation properly, a distance correction 
curve was obtained by taking multiple dose measurements at different distances from the focal 
line along the microbeam path. A piece of EBT3 film sandwiched in the acrylic layers was 
placed on top of a specially designed sample stage which was capable of high-precision 
translation along both vertical and horizontal directions. The system was operating at full power 
as described above, and eleven irradiations were carried out in the step-and-shoot mode, with the 
exposure time for each irradiation being identical. The measurements covered the SSD range 
from 114.48 mm to 139.88 mm, which was the distance window for conducting animal studies 
discussed in the following chapters.  The results were analyzed and summarized in Figure 3.14. 
As shown on the curve, the microbeam output falloff doesn’t follow the inverse square law at 
such short SSD. As the SSD increases the focal line becomes essentially a finite focal point from 
the point of measurement, therefore one can expect the flux to drop following more closely to the 
inverse square relation. Also noticed during the analysis of the film was the slightly increased 
beamwidth (by about 70 µm) over the distance range in this experiment, which was expected 
mostly due to the divergence nature of radiation beam generated in this system.  The beam 
profiles acquired with EBT3 films were shown in Figure 3.15. 
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Figure 3.14 The distance correction curve obtained using EBT3 films, for SSD between 114 to 140 mm, with the system 
operating at 160 kVp, 30 mA tube current, 8% duty cycle, and 500 µs pulse width.  
 
 
Figure 3.15 Beam profiles (bottom) at different distances recorded by the EBT3 film (top) during the measurement of distance 
correction curve. The beam center-to-center distance shown in this figure does not correspond to the vertical distance translation, 
but the horizontal translation distance between two successive exposures on the film 
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 Percentage depth dose (PDD) 3.3.5
The quantification of beam attenuation as it travels in a medium is one of the major steps 
in reference beam dosimetry. The percentage depth dose (PDD) is one of the quantities that are 
defined for characterizing the depth dose distribution in tissue along the beam axis. It refers to 
the relative absorbed dose at a certain depth along the axis of the beam compared to that at the 
reference depth, as expressed in the following equation:  
𝑃𝐷𝐷 =  
𝐷𝑑
𝐷𝑑0
× 100 
where d0 is usually the depth with maximum deposited dose dmax, and Dd is the absorbed dose at 
depth d.  For orthovoltage and low-energy X-rays, dmax is at the surface of the phantom, i.e.: 
𝑑0 = 𝑑𝑚𝑎𝑥 = 0 (𝑠𝑢𝑟𝑓𝑎𝑐𝑒) 
 
 
Figure 3.16 Illustration of the acrylic phantom for PDD measurement. Each slab was 2.8 mm thick. Seven pieces of EBT3 films 
were inserted between adjacent layers. One microbeam irradiation was carried which exposed all seven films simultaneously at 8° 
angle, as shown in the side view of the phantom on right. The figure is not drawn to scale. 
 
The PDD curve is usually established through numerous measurements in a water 
equivalent phantom at varying depths along the beam axis with a constant source-to-surface 
distance (SSD). 
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Figure 3.17 Percentage depth dose (PDD) curve taken with EBT3 films and the acrylic phantom placed at 22.19 mm down from 
the bottom of the collimator.  
 
A PDD phantom was constructed from a stack of six acrylic slabs of same dimensions 
with a piece EBT3 film placed between two adjacent slabs, as shown in Figure 3.16. The phantom 
was placed on the lab jack, with the top surface being 20.19 mm downstream from the bottom of 
the collimator, and a single microbeam exposure of 15 min at full power was delivered. As 
shown in Figure 3.17, the depth dose distribution obtained through this method presents a near-
linear falloff in the acrylic phantom. Another factor to be noted is that, acrylic shows an 
attenuation coefficient that is a bit higher than water for the beam energy used in our system. 
Therefore, the actual percentage doses at corresponding depths were underestimated with this 
method.  
 Tissue maximum ratio (TMR) 3.3.6
Tissue maximum ratio, or TMR, is another parameter defined to characterize the depth 
dose distribution in tissue for dose calculation. The main distinction between TMR and PDD is 
that, the SAD remains constant in the measurement of TMR with the point of interest at varying 
depth along the beam axis in the phantom, whereas SSD is constant during PDD quantification. 
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The definition of TMR relates to another depth dose quantification parameter called tissue 
phantom ratio (TPR) which refers to the dose at a given point in phantom to the dose at the same 
point at a fixed reference depth. TMR is simply a special case of TPR where the reference depth 
is the depth of maximum dose, dmax, as defined in equation: 
𝑇𝑀𝑅(𝑑, 𝑟𝑑) =  
𝐷𝑑
𝐷𝑑𝑚𝑎𝑥
 
where rd is the lateral distance from the central axis of the beam, Dd is the dose deposited at 
depth d, and Ddmax is the maximum dose along the central axis. The primary beam attenuation is 
then represented by: 
𝑇𝑀𝑅(𝑑, 0) =  
𝐷𝑑
𝐷𝑑𝑚𝑎𝑥
 
where dmax is again at the surface of phantom for the kilovoltage X-ray beams.  
    
Figure 3.18 Photographs of the acrylic step phantom for the measurement of TMR.  
 
Based on such definition, a step phantom for TMR quantification (as shown in Figure 
3.18) was made with acrylic with the same shape and dimensions as HVL aluminum step 
phantom. A single piece of EBT3 film was placed right beneath the bottom surface of the acrylic 
phantom with no air gap in between, different from the setup in HVL measurement. Two layers 
of acrylic were put underneath the EBT3 film and taped tightly to the body of the acrylic step 
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phantom to secure the entire setup and avoid any air gap or relative displacement. The phantom 
was positioned on the lab jack with the top surface at a distance of 36.99 mm down from the 
bottom of the microbeam collimator, which equaled to 122.10 mm from the focal line. Eleven 
radiation exposures were delivered in the step-and-shoot mode with the system operating at full 
power. The beam-on time was kept the same for each exposure. The results were analyzed and 
plotted in Figure 3.19. The curve was fitted with second degree polynomial regression. However, 
both linear regression and semilogarithm regression could achieve close fit but slightly off from 
the polynomial regression. The results presented here differed from those reported by Hadsell in 
the system dosimetry characterization with EBT2 and FilmQaPro in 2012. Suspected sources of 
uncertainties include the tube current fluctuation especially during longer exposures, slightly 
unstable tube performance at high temperature after long beam-on time, geometric 
inconsistencies in the film, and limited number of measurements. The distance range covered in 
this characterization process was considered sufficient for the purpose of dose calculation in 
animal studies in the prototype system. However, further work is still desired for a more 
thorough and consistent dosimetric characterization, including increasing the measurement 
sample size (reducing the depth step size), for a water or tissue equivalent phantom, and 
improving the current stability during exposure.  
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Figure 3.19 The tissue attenuation of the microbeam in acrylic. Data were obtained using EBT3 film placed at 122.10 mm 
downstream from the focal line.  
 
 Challenges and Remedies 3.4
 Microbeam collimator alignment 3.4.1
Microbeam radiation is generated by a multi-slit collimator on the relatively wide and 
quasi-parallel photon beam at a synchrotron beamline. Other than the collimator slit orientation 
with respect to the polarization of the beam, alignment of the collimator exactly at certain 
coordinates is usually not an issue and has little effect on the resultant microbeam profiles. 
Similarly, no particular orientation in the collimator position of a conventional thermionic tube 
with a large isotropic focal spot was used for microbeam generation. However, due to the unique 
geometry of the focal track on the anode as well as the extremely narrow widths of the focal line 
and collimator slit (both within 200 μm in width), it is a critical and challenging task to align the 
extremely narrow collimator slit exactly with the thin focal track in order to achieve the highest 
microbeam flux and the smallest microbeam width. This is also essential to obtain a uniform 
dose distribution along the microbeam long axis. An efficient and accurate alignment method has 
been developed which takes advantage of the geometry of linearly aligned cathodes array. There 
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are five cathodes that contribute to the total tube current and photon flux, and the focal tracks 
created from each of them overlap on the anode. Every cathode geometrically dominates a 
portion of the focal line and therefore the photon flux in the resultant microbeam. This was 
confirmed by capturing the beam profiles from each of the five cathodes individually using a flat 
panel detector and radiochromic film placed downside from the microbeam collimator. The 
beam profile generated by a single cathode shows a non-uniform dose distribution along the 
beam with a higher flux appearing at the location corresponding to the geometric location of the 
emitting cathode in the cathode array. For instance, the microbeam profile along the beam 
showed a higher dose deposition in the middle than that on the rest on the film when only the 
third cathode (located at the center of the cathode array) was turned on. In contrast, when the 
first or fifth cathode (located at either end of the cathode array) was emitting, the deposited dose 
on microbeam profile appeared to be the highest on the corresponding end, and gradually 
decreased farther away from the site of the emitting cathode. In the ideal case where the 
collimator slit is accurately aligned with the anode focal line and the collimator plane positioned 
at the 8° projection angle, the obtained microbeam should be the sum of microbeams from five 
cathodes overlapping exactly. In this configuration, the resultant microbeam delivers the 
maximum flux with uniform dose distribution along the beam, and a symmetric dose profile 
across the microbeam with the minimal beamwidth. In any case where there was a misalignment 
between the focal line and the collimator slit, the above microbeam profile would not be 
achieved.  
Based on this fact, a dedicated method for collimator alignment has been developed with 
a flat panel detector (Hamamatsu C7940DK-02), a partition made of highly attenuating material 
(lead or tungsten), and a LabVIEW program for real-time camera readout of the beam profile and 
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photon counts. During the setup, the detector is positioned on the translation stage below the 
microbeam collimator with the slit roughly aligned with the center line of the active area of the 
detector (10 × 10 mm
2
). The lead partition (3 × 5 × 10 mm
3
 in size) is placed on top of the 
detector active area. The standing partition shields against the photons that come at an angle 
from reaching the other side of the lead. In addition, the vertical height of lead (5 mm) on the 
microbeam path is sufficient to block almost all photons from reaching the detector region 
beneath the partition.  
Particular caution needs to be taken when using the sensitive flat panel detector under the 
primary beam path as the high energy and high intensity radiation beam could cause damage to 
the active area. The alignment is performed with the tube operating at 50 kVp, with less than 1 
mA total tube current, and 1% duty cycle. As discussed earlier in this chapter, the collimator has 
two degrees of freedom, rotation and translation controlled by three linear translation stages and 
one rotation stage. The alignment procedure usually starts with tuning the rotation of the slit, and 
proceeds with the translation adjustment afterwards. Firstly, cathodes one and five are turned on 
simultaneously as illustrated in Figure 3.20 on the left. The recorded profile along the microbeam 
on the detector appears segmented, and the beam intensity varies on different regions along the 
beam as shown in Figure 3.20 on the right. The detector area where the lead partition lands is 
almost completely shielded with minimal to no photon counts. On both sides of the shielded area 
are the regions that receive photons mainly from one end of the focal line. The two ends of the 
microbeam receive the highest flux of photons with less influence from the lead partition.  
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Figure 3.20 Left: Illustration of setup and irradiation configuration for microbeam collimator alignment; right: beam profile 
recorded on the detector. Dimensions are not drawn to scale.  
 
If the two segments on the detector appear shifted in the lateral direction of the beam, as 
shown in Figure 3.21 on the left (top), it usually indicates an angular misalignment of the 
collimator slit with respect to the focal line. This is illustrated on the bottom left in Figure 3.21 
when looking towards the anode focal track through the collimator slit from the bottom of the 
tube. The angular offset can be corrected by rotation of the stage.The beam profile is updated in 
real-time to reflect the adjustment, conveniently providing feedback to adjust the direction and 
the step size in the rotation accordingly. Angular alignment is considered achieved when the two 
segments on the beam profile are aligned in center as shown in Figure 3.21 on right. A 
comparison of beam profiles collected using EBT3 film before and after collimator alignment is 
illustrated in Figure 3.22. 
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Figure 3.21 Top row: Screenshots of the detector readout of the beam profile and photon flux during the collimator alignment. 
Two segments appear shifted if the collimator slit is not in parallel position with respect to the focal line on the anode, as shown 
on the left. The one on the right indicates a parallel-aligned slit and focal track. Middle row: images acquired by the detector 
shown in ImageJ. Bottom row: illustrations of the relative locations of the collimator slit and the anode focal line when not-
aligned (left) and aligned (right) corresponding to the beam profiles as shown in the top and middle row. Dimensions are not 
drawn to scale.  
 
Horizontal translation follows when the angular alignment is completed. This is usually 
carried out with all five cathodes on simultaneously but at reduced anode voltage (60 kVp), low 
current and duty cycle to protect the detector. The averaged cross field microbeam profile is 
plotted on the right hand side of the user interface reflecting the photon flux in the peak and the 
shape of the beam. The photon count in the peak changes with the horizontal location of the 
collimator slit, and reaches the maximum once the slit reaches the desired location where the 
alignment is achieved as described earlier. Symmetry in the profile is another indicator of proper 
alignment. 
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Figure 3.22 Comparison of the beam profiles before (right) and after (left) collimator alignment. Notice the change in the beam 
shape and peak dose rate.  
 
 Anode rotation  3.4.2
As described in section 3.2, the first prototype CNT-MRT system employs a stationary 
molybdenum anode that is positioned parallel to the cathode assembly with the front surface 
perpendicular to the X-ray window. The anode is attached to the L-bracket via two M5 setscrews 
that thread into the bracket through the body of anode from the bottom. This design with a non-
tilted anode could largely limit the vertical drift in the relative location of the focal line, which is 
caused by thermal expansion of the anode material with a tilted anode, comparing to the case 
with a tilted anode. However, it turned out that the motion of the anode within the horizontal 
plane was not securely constrained in this design. Any rotation of the anode about the vertical 
axis would affect the location of the focal line significantly and result in the misalignment of the 
collimator, as in the lower left in Figure 3.21. This was observed for the first time when a sudden 
drop of dose rate and a large broadening in the beamwidth was confirmed during an experiment 
in 2013 after the system had been operating steadily with stable output of microbeam radiation 
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for over two years, near the end of the lifetime of the first set of cathodes. Realignment of the 
collimator through rotation was not able to bring the flux back the normal level. The anode was 
later found rotated about its central axis along the vertical connecting cylinder, as shown in 
Figure 3.23 on right. Similar incidents took place a year after the repair, when a gradual 
broadening of the microbeam width and a significant decrease in the dose rate were found during 
routine beam quality examination using EBT3 films. The extent of rotation was measured to be 
around 2 to 3 degrees from the initial location.  
 
     
Figure 3.23 Left: Non-tilted (in both vertical and horizontal directions) anode as originally installed. Right: the rotated 
anode with further end from the plane of the paper drifted towards the cathode assembly, while the closer end moved 
towards the back wall of the chamber.   
 
After examination, two threaded joints of the cylinder on the anode assembly were 
suspected the most probable locations where the rotation might have occurred, as indicated in 
Figure 3.24. Since the cylinder is the main conducting path of heat from the anode to the outside, 
thermal expansion and contraction during heating cycles could have caused sliding at the threads 
and resulted in the rotation of the anode as described above. However, this recipe did not prevent 
the anode motion, which was detected again afterwards. Further investigation pointed to the two 
setscrews that hold the anode against the L-bracket run into the anode through counter-bored 
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clear holes from the bottom, as shown in Figure 3.25. These two did not catch our attention 
during earlier examination since rotation or displacement was relatively unlikely when confined 
by two setscrews compared to those axes of rotations mentioned above.  However, the clearance 
in the counter-bored holes does allow for relative motion at the interface, which could have been 
manifested during the temperature rise caused by the difference in the thermal expansion 
coefficients between stainless steel (16 × 10 
-6
 m/(m·K)) and molybdenum (5× 10 
-6
 m/(m·K)).  
 
   
Figure 3.24 Left: SolidWorks drawing highlighting the cylinder that connects the anode to the HV feedthrough with two threaded 
joints on both ends. Right: two setscrews were added subsequently after the anode rotation was found, to prevent any rotation that 
might have occurred at the joints on the cylinder from the side towards the back wall of the vacuum chamber.  
 
Furthermore, even though a lot of effort has been made to isolate the chamber from 
external motion, high frequency vibration from peripheral components of the system still exists 
which could have been the major cause of the anode rotation at high temperature during 
irradiation. In particular, the built-in turbo pump connects to a roughing pump through a long 
bellows. The roughing pump, though stands on the ground, introduces a significant amount of 
vibration that propagates to the system via the bellows. As the turbo pump hangs off the rear side 
of the vacuum chamber, such vibration would have a direct impact on the vacuum chamber and 
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the components inside. A hypothesis is therefore made which states that during the normal 
operation, a substantial amount of heat was generated while electrons bombarding the anode 
materials, and caused non-uniform thermal expansions in the anode body, the L-bracket, as well 
as the setscrews that are made of different materials. After switched off the electron emission, 
parts started to cool down and gradually contracted, during which small interspace emerged at 
the contacting surface between different parts during the different linear thermal expansion 
coefficients as well as the difference in the heat distribution. As a result, the originally tightened 
setscrews could become loose and therefore give room for anode rotation as induced by the 
vibration mentioned above.  
     
Figure 3.25 SolidWorks drawing and a photograph (bottom view) of the anode assembly highlighting the two setscrews at the 
bottom of the anode.  
 
To prevent the rotation from happening, changes were introduced to the design of the 
anode assembly.  A modified L-bracket, (illustrated in Figure 3.26) was added to contact the 
back of the anode directly. The counter-bored holes were moved from the anode to the base plate 
on the L-bracket. This not only allowed for more convenient and secure installation of the 
setscrews, but also removed the potential adverse effect of gravity on the setscrews. However, 
this design does require tapping the thread hole in molybdenum which is relatively brittle.  
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Figure 3.26 Left: original design of the anode assembly. Right: modified design of the L-bracket to avoid anode rotation.  
 
Nevertheless, additional isolation of vibration and any externally introduced motion, as 
well as more efficient heat dissipation are desirable to ensure stable operation of the system. In 
the second-generation system Apollo II, the anode assembly is equipped with an active oil 
cooling device which could significantly improve the speed of heat transfer from the anode focal 
line. Thus the total output power of the system can be increased. The design of Apollo II has 
been detailed in the dissertation of Pavel Chtcheprov, and will be briefly introduced in Chapter 7.  
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 IMAGE GUIDANCE FOR MICROBEAM RADIATION THERAPY CHAPTER 4:
 
 Motivation 4.1
The outcome of radiation therapy greatly relies on the conformality  and accuracy in 
radiation dose delivery. In addition to the revolutions in conformal dose delivery techniques, 
such as intensity-modulated radiation therapy and stereotactic radiosurgery, advances in image 
guidance have contributed significantly to the evolution of modern radiation therapy. Cutting-
edge imaging techniques or tools can reduce the uncertainties in target definition and patient 
positioning, therefore improve the agreement between treatment planning and actual treatment 
delivery. The precision and accuracy in treatment delivery can be largely optimized, which in 
turn reduces the unnecessary exposure of healthy tissue during radiation therapy [1]. On-board 
image guidance is inevitably essential in preclinical and clinical MRT where extremely high 
radiation dose is delivered by radiation beam that is in the microscopic range in width.  
Previously, image-guided protocols were not implemented in most of synchrotron based MRT 
preclinical experiments. A large area is typically covered (in the order of 10 mm × 10 mm) by 
mechanically scanning the mouse brain through the microbeam arrays, to ensure a complete 
coverage of the tumor target. In this method, the ratio of tumor volume to the irradiated brain 
volume was estimated to be only about 6%, and therefore a very large amount of normal brain 
was unnecessarily enclosed in the irradiation field where the heaviest damage was seen [2]. X-
ray radiography was utilized in several recent studies either to identify the tumor cell injection 
point [3] or to locate specific skull landmarks for homogenous irradiation of brain regions [4].  
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Direct localization of the target was not achieved due to the limited tumor contrast in planar X-
ray imaging without contrast enhancement. Therefore, the normal tissue sparing effect of 
microbeams is to a great extent compromised and a true evaluation of the overall therapeutic 
outcome of MRT cannot be readily obtained.  
Implementation of on-board imager and dedicated protocols for image-guided microbeam 
delivery are critical steps in the development of compact image-guided microbeam delivery 
system, and these must be completed before the system can be fully commissioned for 
preclinical studies on small animal models. A great amount of effort has been made to fulfill this 
goal including physical component design and integration, methodological development, and 
performance validation. These efforts are described in this and the following chapter.  
 
Figure 4.1 SolidWorks design of a compact system for micro-CT guided microbeam radiation therapy.  
 
 Implementing Image Guidance for Microbeam Delivery 4.2
 Construction of the imaging system  4.2.1
Planar X-ray radiography and high-resolution CT are the two most frequently used 
imaging modalities in IGRT in the clinic due to the high accuracy and precision in beam 
positioning, as well as high compatibility with the treatment machine (little or no field 
interference). Our lab has previously demonstrated the technology of developing micro-CT 
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scanner with a CNT field emission source. A plan to integrate a micro-focused CT scanner with 
the microbeam irradiator was therefore made to employ the clinical practice as well as the 
established technology readily available in our lab. The design of concept is illustrated in Figure 
4.1. 
Table 4.1 Characteristics of the three cathodes in the micro-focused tube of the CT scanner 
 
 
The CNT-based micro-CT scanner followed the main features of design with a stationary 
sample,reported previously by Cao et al [5]. The core of the scanner is a micro-focused X-ray 
tube (body dimension 300 mm × 200 mm × 70 mm) based on CNT field emission sources 
(XinRay Systems Inc., NC, USA). Three pairs of CNT cathodes and tungsten targets are 
incorporated in this scanner for producing different focal spot sizes and flux. The tube was 
originally built with a 1 mm thick aluminum window which was later replaced with a 0.2 mm 
thick beryllium window due to vacuum issues. The characteristics of the cathodes are listed in 
Table 4.1. A miniature ion pump was attached to the micro-focused tube from the back via a CF 
flange. The X-ray tube is mounted on a rotary gantry (One-circle goniometer, model 430, 
HUBER, Germany). The image sensor used in the scanner is a CMOS based flat panel detector 
(model C7921CA-02, Hamamatsu Photonics K.K., NJ) with a 5 cm × 5 cm active area and a 
pixel size of 50 µm × 50 µm. The X-ray tube and detector are mounted on opposite sides of the 
goniometer with the detector surface in parallel to the X-ray window. Other parts that are fixed 
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on the gantry include the anode HV power supply, the ion pump controller, and two focusing 
power supplies. These components are mounted so that the weight distribution on the goniometer 
is well balanced. Minor modifications have been made to the original designs mainly in the base 
plates for mounting the X-ray tube and the detector to the goniometer. The gantry is mounted on 
the optical table on the side of the microbeam irradiator, facing the rear side of the turbo pump. 
Other control electronics for the micro-CT are organized on a rack located outside the shielded 
enclosure. Photographs of the micro-CT scanner and the control console are shown in Figure 4.2. 
This cone-beam micro-CT scanner operates at 50 kVp and up to 2 mA tube current. Objects are 
placed on a stationary sample holder that is positioned in the radiation field, and the gantry 
rotates the source-detector pair around the stationary object to collect images in a step-and-shoot 
fashion. High resolution CT images of hearts or lungs in free-breathing animals can be obtained 
through respiratory and cardiac gated imaging, as demonstrated previously [5, 6].  
    
Figure 4.2 Left: A photograph of the micro-CT scanner built on the side of the microbeam irradiator, with key components 
indicated with red arrows. The gantry stands on top of the optical table, facing the back side of the turbo pump on the microbeam 
irradiator. Right: control console for the micro-CT outside the shielded enclosure.  
 
The direct transport of patient (animal/sample) between the imaging system and the 
microbeam irradiator is achieved by a high-precision translation stage (96.5 mm travel range, 76 
µm line accuracy, motor-drive BiSlides, Velmex Inc., NY) that connects both systems. A sample 
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stage has been designed and built to attach on top of the translation stage. Samples holders or 
animal positioning devices are fixed on the sample stage before imaging and treatment.  
 Integration of the IGMRT system 4.2.2
 
 
Figure 4.3 Illustration of the changes made to the turbo pump support (highlighted in blue color) in the microbeam irradiator, and 
the extended tube stand.  Drawing on the left is the original design, while the one on the right demonstrates the modification.  
 
After the construction of the micro-CT scanner was completed, a detailed examination 
and calculation were performed mainly in the designs and dimensions of the microbeam 
irradiator and the micro-CT scanner. The purpose was to identify and remove potential barriers 
or incompatibilities (conflicts) for the two systems to operate and execute collaboratively after 
integration, with additional consideration of the feasibility and simplicity of the workflow. Main 
changes that were made mostly to the designs of two parts in the microbeam irradiator after the 
thorough evaluation. First of all, the tube stands (as indicated in Figure 4.3) were extended in 
length so the entire vacuum chamber and the attached components were elevated by 8 mm. This 
change allowed for more space in animal handling and adjustment in the radiation field 
underneath the collimator. More importantly, it raised the height of irradiation entrance surface 
to be comparable with the imaging field of view (lined up with the axis of rotation in the CT 
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scan). Therefore, no major adjustment in the sample height would be needed between imaging 
and radiation treatment. In order to ensure steady translation of the sample between the imager 
and the irradiator, the turbo pump support in the back of the vacuum chamber was redesigned as 
shown in Figure 4.3. The benefits with the new design are two-fold. Firstly, more clearance has 
been created for the translation of sample stage between the two systems which has been proved 
critical in the animal experiments. Secondly, the newly designed pump support contains two 
parts that are clamped together around the turbo pump, and therefore holds the turbo pump in a 
steadier way. It can reduce the stress imposed on the connection to the vacuum chamber 
substantially, and it can limit the vibration transmitted from the turbo pump to the vacuum 
chamber. 
In addition, the relative position between the imaging system and the irradiator was 
adjusted so that the axis of rotation of the rotary gantry was approximately aligned with the mid-
line of the microbeam. Separation between the two systems was determined mainly to provide 
sufficient space for animal positioning and loading, within the travel of the translation stage.  
 Design of the animal positioning device 4.2.3
Patient immobilization is a key step in image-guided radiation therapy and to a great 
extent determines the accuracy in dose delivery. Proper and secure positioning is even more 
critical and challenging as body motions and displacement of internal organs are more common 
and severe in small animal models such as mice and rats. Dedicated animal positioning devices 
have been developed for different purposes of studies, and for accommodating different types 
and sizes of animals. Shown in Figure 4.4 (left) is the customized mouse holder particularly for 
brain irradiations, designed based on the anatomy of the young adult mice. This device is 
assembled with two separate parts, i.e. the base plate and the nosecone housing. The base plate 
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provides support of the mouse body, and fixation to the head through ear bars. Accommodation 
for the pressure sensor is also included on the base plate, for monitoring the respiration during 
imaging and treatment.  Attached to the top is the housing for anesthesia delivery nosecone as 
shown in Figure 4.4 on right. A looped nylon wire is attached to the front of the nosecone as 
teeth clamp. Isoflurane from the gas vaporizer (outside the shielding enclosure) is fed in from the 
top, while excess gases are removed through the wider tubing that is attached to the rear end of 
the nosecone and absorbed by the gas filter canister (Omnicon F/Air). As illustrated in Figure 4.5, 
the mouse is typically placed in the prone position on the base plate. The ear bars, nosecone and 
the teeth clamp altogether provide 3-point immobilization and stereotactic placement of the 
mouse head. The position of the nosecone is adjustable along both x and y-axis, to ensure a 
steady and conformable positioning of the mouse head. Setscrews are installed after proper 
immobilization is completed.  The pressure sensor is placed underneath the abdomen of the 
mouse. Additional tapes and gauze are used as needed.  
 
     
Figure 4.4 SolidWorks drawing of the home-made mouse holder. The design includes two parts, i.e. the main body of the holder 
and a nosecone holder attached on top. [7]. 
 
The mouse holder assembly including the ear bars and setscrews were fabricated out of 
ABS plastic through 3D printing. The main design has been modified for different imaging and 
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irradiation purposes. Figure 4.6 on the left demonstrates the drawing of the modified holder for 
positioning mouse pups during brain irradiation. The ear bars are replaced with a neck support in 
this design. Two small holes are drilled on both sides of the neck support to feed the rubber band 
that is used for fixing the mouse head in place.  
 
 
Figure 4.5 A photo of a nude mouse positioned on the mouse holder under anesthesia.  
 
    
Figure 4.6 SolidWorks drawings of the modified mouse holder for P12 mouse pups (left); and the double-stage (right). 
 
Animal positioning and immobilization are usually performed on the optical table. 
Afterwards, the mouse holder can be loaded and fixed on the sample stage as mentioned above. 
The sample stage has two vernier micrometers (0 – 25 mm measuring range) installed to allow 
for manual adjustment along both z and y axes. Adjustment along x-axis is made by the 
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motorized BiSlide translation stage. A special double-stage (Figure 4.6) has also been designed 
and constructed later for positioning of two mouse holders side by side in the double-mouse 
image-guided MRT studies, as detailed in chapter 5. 
 Peripheral components 4.2.4
The respiration rate recorded by the pressure sensor is monitored through Biovet (m2m 
Imaging Corp., HO) user interface installed on the control PC of the micro-CT. Another monitor 
has been installed inside the shielded chamber for parallel monitoring during the animal handling 
process. Biovet also allows for ECG monitoring in parallel with the respiration monitoring. 
 A complete setup for animal anesthesia and monitoring are installed including two 
vaporizers (SurgiVet®, Smiths Medical, MA), an induction chamber (SurgiVet®), compressed 
oxygen (medical grade, Airgas National), and bottled isoflurane (Phoenix 
TM
), tubings and 
anesthesia gas filter canister (Omnicon F/Air). Annual calibration of the vaporizers has been 
routinely performed.  
 
Figure 4.7 A photo of the anesthesia setup equipped to the CNT-MRT system for small animal studies.  
A high speed computer workstation is also used for image processing and image 
reconstruction. A MATLAB program based on the Feldkamp algorithm  and a commercial 
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software package COBRA (EXXIM Computing Corp., CA) are used for CT image 
reconstruction [5, 8].  
 System calibration and testing  4.2.5
Complete calibration procedures for the microbeam irradiator were described in the 
previous chapter. The micro-CT scanner was also fully conditioned and characterized. The X-ray 
tube to detector distance was determined based on the dimension of the mouse positioning setup, 
and the imaging geometry was fully calculated and calibrated using a two-ball phantom 
following the procedure outlined by Noo et al [9]. Up till this point, the development of the 
physical components for the compact IGMRT system was completed. The entire setup includes a 
CNT-based micro-CT scanner, a CNT-based microbeam irradiator, dedicated patient (animal) 
positioning and translation system, anesthesia equipment, and respiration monitoring devices. 
Photographs of the IGMRT system built on the optical table and the control units outside the 
shielding chamber are shown in Figure 4.8. 
 
  
Figure 4.8 A photograph of the CNT-based image-guided microbeam radiation therapy system constructed on an optical table in 
our lab at the University of North Carolina at Chapel Hill.  
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 IMAGE-GUIDED MICROBEAM DELIVERY IN SMALL ANIMALS CHAPTER 5:
 
 Motivation 5.1
Upon completion of system construction, planning for small animal studies was initiated 
in order to evaluate the performance of the compact image-guided MRT system as a preclinical 
tool for microbeam radiobiological effect for brain cancer treatment, as well as to investigate the 
feasibility to translate the CNT source array technology for MRT clinical applications. 
Comprehensive methods and protocols that address each critical step including tumor 
identification, animal immobilization, and beam positioning were to be established and validated. 
The accuracy and uncertainties had to be determined, before animal studies could be conducted 
to correlate any radiobiological responses with the treatment parameters.  
The majority of work presented in this part was to establish an efficient and accurate 
method for targeted delivery of microbeam radiation in treating brain tumor bearing mice. 
Considering the size of the animal, the fine structures in its anatomy, and the limited size of the 
brain tumor, it is technically challenging to accurately align the narrow microplanar beams with 
the tumor target. Planar X-ray imaging or CT can quickly capture bone structures but are not 
ideal for brain tumor imaging due to the low soft tissue contrast. A considerable dose of contrast 
agent is often required, which on the other hand causes nephrotoxicity and complicates the 
treatment outcome. Magnetic resonance imaging (MRI) provides excellent tumor contrast non-
invasively, and therefore is often used as the gold standard in brain tumor diagnosis.  Hence the 
feasibility of combined MRI and X-ray imaging for MRT treatment guidance dedicated for brain 
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tumor bearing mice was investigated. Tumor diagnosis and delineation was performed with MRI, 
while skull structures and landmarks were identified with the micro-CT scanner. The radiation 
beam delivery was planned afterwards based on the registered image of these two modalities.  
For the image-guided microbeam irradiator, the feasibility of microbeam irradiation in 
different treatment configurations was evaluated, i.e. delivery of radiation from a unidirectional 
microbeam array to a mouse brain tumor and multi-array microbeam irradiation of a mouse brain 
tumor. Both of these two delivery methods rely on precise target delineation and accurate beam 
positioning with variations in certain procedures including animal re-positioning and additional 
imaging requirement. Dedicated protocols, validated which employed multi-modality image 
registration either in 2D or 3D space, were developed. With 2D registration, planar images of 
MR scan and X-ray radiographs from the same orientation were obtained for target identification 
and beam planning. This method allows for a quick capture of targeted features in unidirectional 
beam delivery, and allow for irradiating two mice simultaneously using a double-mouse setup to 
improve the experimental throughput. In contrast, more detailed target localization with a higher 
accuracy is desired in multi-directional microbeam delivery. This requires at least two-view 
planar X-ray imaging and MRI with 2D registration, or complete scans of 3D MRI and CT and 
3D image registration. Detailed procedures and the evaluation of the accuracy and consistency of 
each method are presented in the following sections.  
Parts of the main results for the 2D image-guided MRT has been published in as “Image-
guided microbeam irradiation to brain tumor bearing mice using a carbon nanotube X-ray source 
array” in Physics in Medicine and Biology [1]. Methods and protocols of image-guided 
microbeam radiation therapy (IGMRT) discussed in this chapter have been used for subsequent 
preclinical studies, including those described in chapter 6.  
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 Delivery of Single Array Microbeams in Mouse Brain with 2D Image Guidance 5.2
As described in Chapter 3, the microbeam radiation field is around 300 µm wide, and 
over 160 mm long without conformal collimation in the long axis. An array of microbeams 
would transverse the entire brain as it passing through the tumor target as illustrated in Figure 5.1. 
Unnecessary dose to the rest of the mouse body should be avoided by delivering the beams from 
the top as the mouse is positioned in prone posture on the mouse holder. In the treatment space 
defined by the Cartesian coordinate system as indicated in Figure 5.1 the relative location of the 
tumor target with respect to the radiation beam needs to be determined prior to beam delivery. 
Since the z coordinate of the tumor location becomes irrelevant in beam targeting using such 
radiation configuration, a single projection in the sagittal view registered from a planar MR 
image and an X-ray radiograph would be sufficient to define the x and y coordinates of the tumor 
target.  
 
Figure 5.1 Illustration of a single array of microbeams irradiating the mouse brain. The relative locations of target, landmarks, 
and radiation field are defined by a Cartesian coordinate system as indicated.  
 
 Methods 5.2.1
The overall workflow is outlined in Table 5.1. Firstly, animals undergo MRI scans (9.4T 
MR scanner, Bruker BioSpin Corp., MA, USA) the day prior to MRT for tumor diagnosis and 
delineation. X-ray imaging is performed prior to treatment to capture the bone structures and 
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landmarks on the mouse bed. Animals are anesthetized and immobilized the same way on a 
customized mouse bed for both MRI and X-ray imaging. MR images and x-ray radiographs are 
registered using a 2D rigid-body method to present the tumor location relative to the skull and 
landmarks. With the landmarks pre-calibrated as a reference to the microbeam location, the 
registered images provide the tumor coordinates in the microbeam treatment space, and enable 
accurate delivery of microbeams to the tumor target. This entire procedure was first evaluated 
using acrylic phantoms. However a more thorough evaluation of the accuracy and consistency of 
the method was still required for brain tumor bearing mice. Therefore a feasibility study of the 
image-guided microbeam delivery to mouse brain tumors was conducted under the approval 
from the Institutional Animal Care and Use Committee at our the University of North Carolina.  
Table 5.1 A flow chart illustrating the procedure of multi-modality image-guided microbeam radiation therapy in brain tumor 
bearing mouse models. 
 
 
 
 Tumor cell and animal preparation  5.2.1.1
Fourteen young adult (4 - 6 weeks old), male, athymic nude mice were used in this study. 
U87MG human glioma tumor cells were kindly provided by Dr. Ryan Miller’s lab at UNC 
Department of Pathology. The tumor cells were cultured in Dulbecco's Modified Eagle's Medium 
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(DMEM) plus 1% Fetal Bovine Serum (FBS) before being collected for injection. Three weeks 
before irradiation, and with stereotactical guidance, 2 × 10
5
 cells in 5 l serum-free medium were 
injected intracranially into the right forebrain — 1mm anterior, 2.5 mm lateral, and 4 mm down 
to the bregma — to induce brain tumor growth in the mouse. The cell preparation and tumor 
inoculation were carried out by the Biomedical Research Imaging Center (BRIC) at UNC.  
 Imaging and beam planning  5.2.1.2
  
          
  Figure 5.2 Top row: on the left is a picture of animal immobilized on the customized mouse holder under anesthesia, while on 
the right is a picture showing the setup of double-mouse imaging. Bottom row: illustrations of two mice imaged by the micro-CT 
scanner one after the other, in the image-and-shift manner. Pictures are reprinted with permission from Zhang et al. Physics in 
Medicine and Biology 59, 1283-1303 (2014) [1]. 
 
                                          
The animals were housed with care for about three weeks after cell injection to allow for 
tumor development until the average tumor size reaches about 1.5 – 3 mm in diameter. Mice 
were transported to the small animal imaging facility at BRIC for MR imaging. This was 
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performed using a 9.4 Tesla MR scanner (Bruker BioSpin, Inc. Billerica, MA). T2-weighted 
images were acquired using a Rapid Acquisition with Refocused Echoes (RARE) sequence with 
an echo spacing-to-recovery time ratio (TE/TR) of 22/3406, 256 × 256 matrix size, 0.5 mm slice 
thickness, and 100 micron sagittal and coronal in-plane resolution. The tumors were delineated 
in T2w images with hyper-intense signal. The MR images used for registration were created 
from the sagittal images. The central three slices near the brain midline were averaged to form a 
sagittal projection image. This projection was later used to align with the sagittal X-ray 
projection of the same mouse. The tumor location was projected to the center slice. For all 
imaging and MRT treatment procedures, the mice were anesthetized with 1% - 2.5% isoflurane 
in medical-grade oxygen at 0.8 or 1 L/min flow rate. 
After MRI, the mice were transported to the MRT lab on the day of irradiation. While 
under anesthesia, the mice were first immobilized in the prone position on the customized 
holders (Figure 5.2). The ear bars, nose cone and the teeth clamping altogether ensured 
immobility of the sedated mice. Two mice were immobilized on two separate mouse beds, which 
were then mounted side by side on the double-stage within the micro-CT imaging field, as shown 
in Figure 5.2. Planar X-ray images of the two mice were taken using the micro-CT scanner at 45 
kVp and 0.024 mAs per projection. Imaging of the mice was performed one at a time in an 
image-and-shift manner, as illustrated on the top row in Figure 5.2. The actuator and micrometer 
attached to the mouse bed positioned the head of the mouse being imaged at the center of the 
detector field of view, while the other mouse was kept outside of the X-ray beam pathway. X-ray 
projections were acquired from the same orientation (sagittal view) as that in the MRI, with the 
animals positioned in the same way as well with the same immobilizing device as described 
earlier in this chapter. Afterwards the mouse imaged first was shifted out from the field of view; 
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the other was moved in, and imaged in the same manner. The projections were corrected with 
dark and blank images using a MATLAB (MathWorks Inc., Natick, Massachusetts, US) program. 
For X-ray imaging, the ear bars on the mouse holder were used as the fiducial landmarks because 
they were easily calibrated to both the microbeam position and the brain structures of the mouse. 
   
Figure 5.3 Left: MR image of the mouse brain with the targeted tumour circled. Middle: X-ray projection of the same animal 
showing the landmark ear bars and skull features. Right: X-ray projection registered with MR image showing the relative 
position of the tumour and ear bars. Pictures are reprinted with permission from Zhang et al. Physics in Medicine and Biology 59, 
1283-1303 (2014) [1]. 
 Image processing and registration 5.2.1.3
Planar X-ray images were firstly processed for background subtraction, and then 
calibrated in size with the MR images before registration could be performed. The sagittal MR 
images and corrected X-ray images were then aligned manually through rigid-body registration 
methods with a commercial image processing software (Photoshop, Adobe Systems Inc., San 
Jose, California U.S.) and ImageJ (Public Domain, Developed by Wayner Rasband, NIH). 
Alignment was performed based on the anatomy of the moue brain [2]. Features including the 
bregma and cerebellum were used as major references for registration. The registration process is 
illustrated in Figure 5.3. Once the images were registered, the coordinates of the tumor with 
respect to the skull and landmarks on the mouse bed can be directly visualized and determined. 
The distance from the tumor center to the ear bars, x1, was measured from the registered images 
in both anterior-posterior and superior-inferior directions, as shown in Figure 5.4. Since the two 
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ear bars may not be concentric in the projection images depending on their location in the image 
and the differences in magnification, the midpoints of two ear bars were averaged and used as 
the ‘center of ear bar’.  
 Microbeam alignment and irradiation 5.2.1.4
Figure 5.4 shows the geometrical parameters that need to be determined in order to 
deliver the microbeam to the tumor accurately. Since the planar microbeams are delivered in the 
y-z plane and no conformal collimation is used in the current setup, only the relative distances in 
the x direction are needed. The beam position, i.e. the microbeam entrance position with respect 
to the ear bars, has to be calibrated on a daily basis. To do this, first x2 was recorded, with 
Gafchromic film placed on top of the mouse holder. A low dose single microbeam was delivered 
to the film for calibration purposes. The distance between the center of the microbeam and x3, 
the center of ear bars, was measured with calipers. With the tumor location relative to the ear 
bars, x1, determined from registration, the distance between the tumor and the microbeam 
entrance point for the mice pair was therefore calculated by the summation of x1, x2, and x3, 
with the signs assigned accordingly.  
 
Figure 5.4 Diagram showing the geometric relations between the targeted tumor, landmark, and microbeam locations. The z-
direction is perpendicular to the paper plane. The microbeam plane is in the y-z plane. Δx1 is the distance from the tumor to the 
ear bars measured in the registered image, Δx2 is the distance of translation from the MRT chamber to the micro-CT, and Δx3 is 
the distance between the center of the ear bar and the alignment microbeam track measured during microbeam alignment. The 
mouse holder with the Gafchromic film was first irradiated for beam alignment, as shown on the left, and then translated to the 
right, followed by mouse positioning and X-ray imaging. Pictures are reprinted with permission from Zhang et al. Physics in 
Medicine and Biology 59, 1283-1303 (2014) [1]. 
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Once plans for microbeam delivery were determined, the mice were translated from the 
imaging location to the irradiation site, ready for treatment. The number of microbeams, beam 
pitch, and the beam delivery locations on the tumor site, were decided based on the registered 
image and tumor size (as illustrated in Figure 5.5 on left). For this targeting study, we chose 
various dose levels and different numbers of microbeams for the animals (as assigned below), 
which was also investigated in another study for cellular responses. The microbeam irradiator 
was running at a constant anode voltage of 160 kV, producing a microbeam of 280 µm full-
width-half-maximum (FWHM) at the animal head entrance plane. The average dose rate at the 
entrance plane was 1.16 Gy/min, determined as noted before. In total, fourteen tumor bearing 
mice were irradiated in seven groups, two mice at a time following the procedures described 
above, as shown in Figure 5.5 on right.  
  
Figure 5.5 Left: illustration of the beam planning procedure based on the size and location of the tumor from the registered image. 
Regions in green color are from the MR layer showing soft tissue contrast, while bony structures and the mouse bed presented in 
the planar X-ray images are overlapped on top. The red lines indicate the microbeams penetrating through the tumor target 
(outlined in darker green). Microbeams project at an 8° angle from collimator tile as described in Chapter 3. Right: a picture of 
the double-mouse setup in the microbeam irradiator, ready for treatment. The pink plane indicates the microbeam entrance plane. 
Also noticeable is the heat lamp placed inside the lead chamber. The heat lamp switch is controlled electronically to maintain a 
proper body temperature in the mice. Pictures are reprinted with permission from Zhang et al. Physics in Medicine and Biology 
59, 1283-1303 (2014) [1].  
The first pair of mice was irradiated by a single microbeam of 138 Gy entrance dose, 
targeted at the center of the tumor. The second pair of mice was irradiated by two parallel 
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microbeams with center-to-center distance of 900 m. A 900 m center-to-center distance was 
chosen to maintain a relatively high PVDR with 280 m beamwidth, and to achieve good 
coverage of the tumor area. The prescribed entrance dose for each microbeam was about 108 Gy. 
Between the two microbeams, the first was targeted at the center of the tumor while the second 
was targeted 900 m away. The remaining 5 pairs of mice were irradiated by three microbeams, 
with a 900 m pitch, delivering 48 Gy at the entrance of each microbeam. 
 Beam verification using immunohistological staining 5.2.1.5
To evaluate the targeting accuracy and the tumor cell response, -H2AX 
immunofluorescence staining was used as a quantitative biomarker of radiation-induced DNA 
double-strand breaks (DSB). This process confirms the delivery of microbeams through the 
tumor tissue sections post irradiation. The mice were euthanized at various time points (1 hr, 4 
hrs, 24 hrs, 48 hrs, and 7 days) post-MRT. Their brains were collected and fixed in formalin. The 
fixed brains were cut in half along the midline and embedded in paraffin. Before tissue 
sectioning, the distance between the center midline to the targeted tumor plane in the sagittal 
view that was used for treatment planning was first measured from both coronal and sagittal MR 
images. This distance was then used in sectioning to determine the tumor location on the 
paraffin-embedded brain hemisphere, taking into account a 20% shrinkage rate from the 
dehydration process [3]. Ten slices of tissue each 5 m thick were collected in the sagittal plane, 
perpendicular to the microbeams, near the target locations. One of the tissue slices was used for 
-H2AX staining. The staining procedures followed the published protocol [4]. Briefly, the tissue 
section was de-paraffinated, rehydrated, antigen-demasked by citrate buffer, and then incubated 
with the primary antibody (Phosphohistone H2AX Rabbit anti-mouse antibody, Cell Signaling 
Technology Inc.) for 60 min. This was followed by incubation with the secondary antibody with 
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Cy5 Tyramide and DAPI counter-staining on the nuclei. The section was then scanned with a 
fluorescence slide scanner system (Scanscope FL scanner, Aperio Inc., Vista, CA) to obtain a 
whole brain slide image.  
 Results 5.2.2
 Dose verification 5.2.2.1
Gafchromic EBT2 films were used throughout this study for qualitative verification of 
dose delivery. Films were placed after imaging and prior to treatment, at the entrance and exit 
planes of mouse head, as well as on the side wall of the ear bar pillars.        
  
Figure 5.6 Pictures of the recovering animal on the mouse holders. As shown here, Gafchromic films were placed at the beam 
entrance, exit, as well as on the side of the mouse bed, to verify the delivered radiation dose and beam patterns. 
 
Figure 5.6 showed the film positions and the recorded beam patterns after the MRT. All 
films were scanned in 48-bit color and at 2400 dpi using the V700 scanner following the 
handling procedures recommended by Ashland, Inc. Number of beams and c-t-c distances were 
confirmed in all films to be consistent with the prescription. The films irradiated by planned 
doses that fell into 0 - 60 Gy dose range were analyzed using triple channel dosimetry in 
FilmQAPro. The films from a tumor mouse treated with three microbeams with dose of 48 
Gy/beam are shown in Figure 5.7. The FWHM of the dose profile was measured to be 280 m at 
the entrance plane, which was consistent with our tube calibration results. The beam width 
113 
 
broadened to 380 m at the exit plane underneath the mouse skull. The measured peak dose of 
each beam was consistent with the prescribed value as well. The PVDR was calculated from the 
following equation:  
PVDR = 
Dpeak
Dvalley
 
 
Dpeak and Dvalley are the average doses measured at the center of peak, and the center of 
valley respectively. The average PVDR was calculated to be 16 ±1 at the entrance plane, and 
reduced to 14 ±1 at the exit plane.    
                          
   
Figure 5.7 Beam patterns recorded by Gafchromic  EBT2 films at the entrance (top left) and exit (top right) planes on the mouse 
head, and corresponding dose profiles (bottom) analyzed by FilmQAPro program (using multi-channel dosimetry). The beam 
width at the entrance plane is about 280 microns, and 380 microns at the exit plane. The PVDRs recorded for this animal were 
roughly 16 at the entrance plane, and 15 at the exit plane. Pictures are reprinted with permission from Zhang et al. Physics in 
Medicine and Biology 59, 1283-1303 (2014) [1].  
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 Immunohistological staining 5.2.2.2
 Figure 5.8 and Figure 5.9 showed the -H2AX stained images of the brain tissues from 
the irradiated animals. The -H2AX foci-positive cells shown as pink strips were clearly visible 
in the stained sections indicating radiation-induced DNA double-strand breaks. These patterns 
corresponded to the microbeam path through the tumor and normal tissues. The geometric 
center-to-center distance between two adjacent tracks was measured to be 800 m, which 
matches with the prescribed beam pitch of 900 m when taking into account the average 20% 
anisotropic shrinkage rate [3] of the paraffin embedded slice. 
   
Figure 5.8 Fluorescence images of -H2AX stained mouse brain tissue slices after microbeam irradiation. The -H2AX foci-
positive cells, shown as pink strips, correspond to the microbeam pattern. Areas circled in yellow are tumour targets. The images 
correspond to animal ID 1087 (left) that was treated with two microbeams with 109 Gy/beam, and 1089 (right) which received a 
single microbeam radiation with 138 Gy entrance dose. In both cases, microbeams were delivered right on target as planned. 
Pictures are reprinted with permission from Zhang et al. Physics in Medicine and Biology 59, 1283-1303 (2014) [1].  
 
The targeting error was first evaluated directly from the stained sagittal sections by 
measuring the horizontal displacement, x, from the center of the microbeam to the center of the 
tumor. Out of the 14 animals in this study, one was excluded due to cutting and staining mistakes. 
The average horizontal displacement x of the remaining 13 mice was approximately 454 m. 
The values measured via this manner are listed in column 2 of  
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Table 5.2. 
  
Figure 5.9 Comparison of the -H2AX stained mouse brain tissue slices from animal ID 1152 and ID 1149 both treated with three 
microbeams with 48 Gy/beam entrance dose. As labeled in the images, three planned microbeams were delivered on target for 
the case on left, while for the one right, two out of the planned three microbeams were delivered off-target. Pictures are reprinted 
with permission from Zhang et al. Physics in Medicine and Biology 59, 1283-1303 (2014) [1].  
 
   
Figure 5.10 -H2AX stained, sagittal image registered with MR projection for the same slice of tissue, from two animals (Left: 
ID 1152 and right: ID 1145) irradiated with three microbeams of 48 Gy/beam. Microbeam tracks are the pink strips through the 
higher contrast tumour region, demarcated by the yellow circle. The targeting error was measured from the microbeam location 
to the targeted tumour center. Pictures are reprinted with permission from Zhang et al. Physics in Medicine and Biology 59, 
1283-1303 (2014) [1]. 
 
Since the MR images were taken the day before MRT and the animals were euthanized at 
different time points post MRT, there might have been anisotropic tumor growth between the 
MRI and euthanization. This created difficulties in identifying the original target center in the 
stained section. The targeting accuracy was also evaluated by manually registering -H2AX 
stained image back to the corresponding pre-treatment MR sagittal images, as shown in Figure 
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5.10. The -H2AX stained image recorded the microbeams’ positions while the MR sagittal 
image showed the original targeted tumor center. This alignment method is similar to the X-
ray/MR image registration mentioned previously in this paper, except that here we used features 
in the brain and cerebellum instead of skull contour for alignment. The targeting errors x 
measured in this way are listed in column 3 of  
Table 5.2. 
Table 5.2 Summary of the uncertainties in beam targeting using the 2D image-guided MRT protocol. Pictures are reprinted with 
permission from Zhang et al. Physics in Medicine and Biology 59, 1283-1303 (2014) [1]. 
 
 
 Discussion 5.2.3
In total, 14 animals were irradiated using the combined X-ray/MRI image-guided MRT 
protocol described above. Due to tissue sectioning and staining errors, one mouse was excluded 
from the analysis. The histology data showed that 11 out of the remaining 13 animals 
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successfully received all of the prescribed number of microbeams on the targeted tumors. The 
other two mice received one out of the three planned microbeams at the primary tumour site 
while the other 2 microbeams were delivered outside the targeted tumour location. One of these 
two mice with misplaced microbeams had a relatively small tumour size (<1.4 mm) along the 
beam array direction, considering the center-to-center spacing used in this study was 900 m. It 
is noticed that one of the two mice (Animal ID 1086), which was irradiated with a single high 
dose microbeam, showed a relatively high error (in both error calculation methods) compared to 
the rest of the mice. The respiratory pattern recorded by the Biovet monitoring program indicated 
that this animal experienced multiple substantial gasps during the irradiation. This could have 
caused body movement or loosening of the ear bars, leading to the reduced targeting accuracy for 
this specific animal. Regardless, the results for these two mice were included in the estimation of 
the targeting error.   
There are several potential sources of error in the present procedure including 
uncertainties in the registration of MR and X-ray images, and consistency in positioning the 
mouse. First of all, since MR and X-ray images were taken at different facilities, there were 
transportation and re-positioning of animal from one facility to another. Even though 
immobilized using the same type of mouse holders and imaged from the same direction, the 
animals were not positioned exactly the same for MR and X-ray imaging. The variations in 
orientation of the mouse eventually led to variations in the images. Secondly, the features used 
for image matching were not perfectly sharp and the images were collected at a finite resolution, 
both of which contributed to the targeting error observed in this study. Besides, the large tissue 
shrinkage and deformation not only made it hard to align the stained tissue section manually to 
the MR image, but it also degraded the accuracy of any measurement on the stained slice.  
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Another source of uncertainty comes from the mouse head immobilization and anesthesia 
during irradiation. In our customized mouse holder design, the teeth clamping wire, nose cone, 
and the ear bars altogether should provide sufficient immobility during irradiation providing that 
the animals were put under anesthesia. However, if the animal experienced substantial gasping 
during RT, such as what has happened to mouse ID 1086, drastic body motion or even loosening 
of the ear bars and teeth clamp could lead to animal dislocation, and hence, the microbeam being 
off-target.  
The microbeam delivery accuracy obtained in the present study is comparable with the 
targeting accuracy reported in the literature for image-guided small animal irradiators [5]. 
Matinfar et al. showed an error of 0.2 mm in beam alignment when irradiating a radio-opaque 
marker in a rigid phantom using an in-house small animal radiation research platform (SARRP) 
[6], and an average displacement in mouse repositioning of 0.8 ± 0.49 mm with this system was 
reported in a separate study [7]. Another commercially available small animal irradiation device, 
X-Rad 225Cx (PXI, North Branford, CT) claimed an image-guidance accuracy of no larger than 
0.5 mm, and the study on this device by Clarkson et al. concluded a consistent accuracy on the 
order of 0.2 mm in targeting the center of a metal BB fixed to radiochromic film [8]. The small 
animal research system adapted from a micro-CT at Stanford University achieved 0.1 mm 
accuracy in each direction using a solid water phantom containing a metal sphere [9]. A 
distinction must be made when comparing the image-guidance performance of our system to 
other small animal IGRT systems is the target objects used in the evaluation. In this study, the 
accuracy level was quantified in vivo – targeting the mouse brain tumour, which usually has no 
well-defined structure and no sharp, clear edges, whereas in other systems it was evaluated with 
rigid phantoms with unambiguous margins. In addition to the higher requirement in image 
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quality for brain tumour visualization, the respiration-induced brain motion in the animal during 
imaging and irradiation posed more challenges for our evaluations compared to rigid phantom 
studies. On the other hand, all other preclinical IGRT systems generally operate at too large of a 
field size with large beam penumbras, making them not suitable for MRT. For example, the 
smallest field size that the SARRP can produce is 500 m, at which the system can only provide 
a dose rate of up to 22 cGy/min at 1 cm depth in water [10]. And even then, the 20-80% 
penumbra is almost 0.2 mm on each side [10]. So far, the system presented in this study is the 
only one capable of generating microbeams of relevantly high dose rate for small animal studies 
[5], with a PVDR well within the range of Synchrotron MRT [11].  
The results reported here demonstrate that targeted delivery of microbeam radiation in 
mouse brain tumors is feasible with a MRI/X-ray combined image guidance procedure. The 2D 
image guidance protocol described in the previous section provides a feasible and efficient way 
to deliver a single exposure of microbeam array to two mice simultaneously. Nevertheless, there 
remains much room for improvement in this protocol, i.e. the microbeam alignment, animal 
fixation, image registration and staining procedures, which would all contribute to a better 
targeting accuracy. An affine registration algorithm for the brain histology section and MR 
image alignment can potentially be implemented to provide more accurate evaluation of the 
targeting errors. Besides, if one mouse is irradiated at a time instead of two, CT images of the 
mouse can be collected with the on-board micro-CT scanner for 3D registration with the MRI to 
improve the registration accuracy, which will be introduced in the following section.  
 Multi-array Microbeam Irradiation in Brain Tumor Bearing Mice 5.3
Multi-directional delivery of microbeams could alleviate skin tissue toxicity caused by 
the high entrance dose in the peak regions, and at the same it could improve tumor volume 
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coverage and dose conformality. Several studies have demonstrated the favorable effect of 
multiple arrays with the potential to improve the tumoricidal effect [12-16]. Radiation beam 
energy and the entrance dose both need to be increased from the currently used values in small 
animal studies when it comes to treatment in larger animals and in human. Skin tolerance to the 
orthovoltage radiation becomes the limiting factor, where multi-port treatment may be the 
ultimate solution in order to deliver the extremely high dose microbeam radiation to deep seated 
tumor targets. Preliminary results from the ESRF pet trials demonstrated severe normal tissue 
damage when a high dose microbeam radiation was delivered in a single array (personal 
communication).  
To investigate the feasibility and efficacy of delivering multi-array MRT from various 
different directions using the compact microbeam irradiator, the exploration started from the 
simple and most straightforward case where two arrays are delivered at a right angle, i.e. cross-
beam configuration as illustrated in Figure 5.11. 
 
Figure 5.11 Illustration of two orthogonal arrays of microbeams traversing through the mouse brain.  
 
 Upgrade in animal positioning device  5.3.1
As the radiation field is fixed in place, the animal positioning setup had to be customized 
in order to vary the beam entrance location on the mouse head A new sample stage for the 
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purpose of cross-beam irradiation has been designed and machined as shown in Figure 5.12. This 
upgraded device included three mounting plates that are engraved with customized hole patterns 
to allow for sample positioning at three different angles, i.e. 0° position (L0) which is normal to 
microbeam entrance line (L), and another two positions at 45° (L1) and -45° (L2) angle relative 
to L0. Position L0 is for imaging, and is the same as in single array MRT setup. Position L1 and 
L2 are dedicated for microbeam irradiation with different beam entrance orientations. During the 
experiment, the animal together with the mouse holder was first mounted on the center plate for 
imaging at position L0. The two are then removed from the center plate after imaging, and 
mounted on one of the two side plates for treatment at L1 position. Re-mounting is required for 
treatment at L2 after the first array is delivered at L1. The design shown in Figure 5.12 employed 
two side plates with mirrored patterns of mounting holes, and two side blocks for alignment 
purposes. This design was to accommodate the long mouse stage within the narrow space 
underneath the microbeam collimator, and also assured that the tumor target fell in the central 
portion of the radiation field where the flux was the maximum and uniformly distributed. 
However, a large positioning error was found using this crossbeam stage and the long mouse 
holder. Modifications were made to both the mouse holder and the sample stage as shown in 
Figure 5.13. The new mouse bed (base plate) has a reduced length, and also incorporates a close-
fit pin hole for extra precision in positioning. Two narrow slots were added on either side as film 
holders. The new sample stage is a mounting plate with mounting holes for positioning the 
mouse bed at all three locations (L0, L1 and L2).   
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Figure 5.12 Photographs of the setup for delivery two perpendicular arrays of microbeams in the cross-beam configuration. A 
mouse phantom is placed on the mouse holder, and the green lines demonstrate the microbeam entrance location on the mouse 
head.  
Ideally, switching between mounting positions can be realized by rotation of the mouse 
holder about a single pin on the sample stage if a wider radiation field in z direction is used. In 
that case, errors involved in sample repositioning procedures can be largely reduced.  
  
 
Figure 5.13 SolidWorks drawings of the modified sample stage and mouse holder. The three mounting positions are indicated 
with dash lines (top right), and illustrated on the bottom row.  
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 Image guidance protocols  5.3.2
In order to deliver multi-directional microbeam arrays to mouse brain tumors, a high 
accuracy is required in the target identification and beam targeting to avoid false delivery of ‘hot 
spots’, i.e. regions with augmented doses where the beams overlap, outside the target volume. As 
opposed to the axially deliver single array MRT where the tumor depth in z direction is not 
required for beam planning, three-dimensional coordinates of the target need to be fully 
determined in order to calculate the beam entrance locations for beam arrays from different 
directions. Therefore image guidance procedures had to be optimized accordingly in order to 
obtain the stereotactic localization of tumor in the treatment space. The first attempt was made to 
upgrade the current single planar image guidance method with two-view projections. Afterwards, 
MRI/CT guidance with 3D registration aided by a clinical treatment planning software was 
evaluated.   
 Two-view planar image guidance with 2D image registration  5.3.2.1
This method mostly followed the procedures described in section 1.2 for single array 
microbeam delivery, except that two projects were collected from coronal view and sagittal view 
for both MRI and X-ray imaging and that only one animal was imaged and treated at a time. 
U87MG human glioma bearing nude mouse underwent MRI on Day one for tumor delineation at 
BRIC small animal imaging facility. The MR imaging protocol used was the same as described 
earlier in section 1.2.1 with the 9.4 Tesla Bruker BioSpin MR scanner. T2-weighted images were 
acquired using a Rapid Acquisition with Refocused Echoes (RARE) sequence with an echo 
spacing-to-recovery time ratio (TE/TR) of 22/3406, 256 × 256 matrix size, 0.5 mm slice 
thickness, and 100 micron sagittal and coronal in-plane resolution. Tumor contours were 
delineated with hyper-intense signal on each slice. Slices with the largest tumor cross-section 
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(through the center of the tumor volume) in both coronal and sagittal views were used for 
registration with X-ray projections taken in the corresponding plane. The Animal was then 
transported to our facility on the next day. Two X-ray projections in coronal view and sagittal 
view were acquired while the animal was immobilized on the mouse holder under anesthesia (the 
same protocol as for MR imaging). X-ray projections were taken at 50 kV anode voltage and 0.4 
mA anode current with 100 ms pulse width per projection. Afterwards, the MR images and 
contrast corrected X-ray radiographs were registered in coronal view and sagittal view 
respectively, as shown in Figure 5.14. Tumor location with respect to the ear bar center (the 
landmark) in the treatment coordinate system (along x, y and z axis) was determined from the 
registered images. Since microbeam location with respect to the ear bar center was recorded 
beforehand, the relative distance between the microbeam entrance and the center of the tumor 
target can be thus calculated.  Instead of direct translation as in unidirectional MRT, rotation of 
the sample stage was involved after imaging and in between subsequent radiation deliveries. 
Therefore angular offset as well as the 8° beam tilt needed to be included in the beam targeting 
calculation for the arrays at both L1 and L2 position as illustrated in Figure 5.12. 
           
Figure 5.14 Registered MR/X-ray projections in sagittal view (left) and coronal view (right) for the same animal. The tumor 
target was circled out in green line. The tumor measured 1.5 × 2 mm2 in the sagittal plane, and 2 × 2 mm2 in the coronal plane.  
125 
 
Two arrays of microbeams were delivered in two fractions to tumor target at position L1 
and L2. Within each array four microbeams were delivered in the step-and-shoot manner at 900 
µm beam separation (center-to-center distance), with the center of each beam array targeting at 
the center of the tumor volume. For beam targeting verification purpose, only five minutes short 
exposure was delivered per microbeam. Animal with the mouse holder was repositioned for the 
second fraction immediately after the irradiation for the first array was completed. Gafchromic 
EBT3 films were used for dose verification at the beam entrance, exit locations as well as on the 
side walls of the mouse holder, as shown in Figure 5.15 on left. The animal was afterwards 
transferred back to the animal facility and euthanized 4 hours after the radiation as completed. 
Brain tissue was collected and fixed in formalin. A number of 5 µm thick tissue slices were 
collected in the coronal plane across the tumor location as determined from the MRI.  Tissue 
slices were sent for γ-H2AX staining at the UNC Translational Pathology Laboratories using the 
same protocol as described in section 1.2.1.   
   
Figure 5.15 Left: A photograph of the U87MG human glioma bearing mouse after treatment of two orthogonal arrays of 
microbeams. As shown in the Gafchromic EBT3 films, each array consisted four 300 µm wide microbeams at equal spacing (900 
µm c-t-c distance). Right: an image of γ-H2AX stained mouse brain tissue (sliced in coronal plane) from the same animal, 
capturing the microbeam patterns (pink lines) and the covered tumor target (~2 mm in diameter). Animal euthanization was 
performed 4 hours after radiation was completed for tissue collection and fixation.   
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A fluorescence image from the tissue slide at the tumor center is shown in Figure 5.15 on 
right. The histology image is presented with the tissue slice positioned in correspondence to the 
brain position shown on left. The strong γ-H2AX positive signals, shown as pink strips, indicated 
the DNA double strand breaks caused by microbeam irradiation. The tumor target, shown as a 
hyper contrast region compared to surrounding normal tissue, is outlined in yellow line. As can 
be visualized directly from the histology, beam array 2 was delivered precisely on target as 
originally planned (center of the array aligned with the center of the tumor region), whereas 
beam array 1 was delivered slightly off-center by 900 µm.  The main sources of error probably 
were the sample stage repositioning, small motion of the mouse head, as well as from the 2D 
image registration that’s subject to the operator’s judgment. Besides, the hardware has intrinsic 
tolerance which could also contribute to the systematic uncertainties in the beam targeting.  
 MRI/CT guidance with 3D image registration 5.3.2.2
Eventually, the feasibility 3D image-guided microbeam delivery with 3D MRI/CT 
registration was evaluated through the in-house radiation treatment planning software PLUNC 
(or PLanUNC) developed at UNC Department of Radiation Oncology. 3D reconstructed images 
from CT scan provides better in-plane resolution compared to the 2D projection images due to 
the removal of overlapping tissue/bone structures. Besides, accurate scale calibration is 
challenging in planar X-ray images due to the difference in source-to-object distances and 
viewing angles of different features overlapped in the projection, which results in errors in image 
registration to MR slice. Such errors can be therefore eliminated with CT images instead. 
PLUNC is an adaptable and extensible software system for external beam radiation 
treatment planning (photon and electron) [17]. It incorporates various features including 
graphical tools for contouring anatomical structures, virtual simulation, dose calculation and 
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analysis, and IMRT planning etc. It also allows for manual rigid-body based registration of two 
sets of 3D images from the same or different imaging modalities. Given the main purpose of the 
study and operating platform, a special edition of PLUNC was prepared with the aid of the 
PLUNC developing team and installed on the imaging control desktop computer in our lab.  
 
 
Figure 5.16 Top: screenshot of the user interface of PLUNC, clinical treatment planning software developed at UNC Department 
of Radiation Oncology. A special edition was installed on the desktop computer for micro-CT operation. Bottom: a screenshot 
showing 3D registration (sagittal view) of a MR scan and CT scan of a mouse in PLUNC. Soft tissue contrast in MR image 
(shown in red) and the contrast in bony structures presented in CT (shown in green) can be adjusted individually. Translation and 
rotation are performed in three anatomical planes (coronal, sagittal, and axial).  
 
MR imaging protocol remains the same as previous studies. However, instead of 
selecting a certain image slice, the full stack of DICOM images from the MR scan (2D coronal 
acquisition), which contained the 3D information of the entire mouse brain, was used for 
registration afterwards.  A small metal ball bearing (made of aluminum, 0.79 mm in diameter) 
was glued on top of one ear bar pillar as the landmark for image registration as well as for 
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treatment beam location calibration. CT imaging was performed using the micro-CT scanner at 
50 kVp with 1.2 mA anode current. A total of 400 projections were collected at 0.5° angular step. 
Exposure time was 40 ms for each projection. After corrections with blank and dark images, the 
projection images were reconstructed at 76 µm isotropic voxel size with COBRA.  
 
 
    
Figure 5.17 Image registration in three anatomical planes using PLUNC. Tumor target is shown with hyper-intense signal from 
MR images (in green) with the center of volume indicated with a cross mark.  
 
During image registration, the DICOM images from both MRI and CT were first 
converted to the designated format with Command Prompt before launching PLUNC. The 
graphical user interface of PLUNC is illustrated in Figure 5.16. Image registration was 
performed manually in the Dose window. CT and MR images were assigned with different 
colors. The contrast and intensity window were adjusted respectively for each image set. In 
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‘Register Images’ mode, the relative location of the CT and MR images were adjusted with one 
image fixed while the other was translated and rotated into alignment. Adjustment was 
incremental, and usually started in one of the three anatomical planes and was repeated in the 
other two orientations to minimize the matching errors. The alignment of the two images was 
verified in all slices from each orientation. Once the alignment was accomplished in all three 
orientations, the relative location of the two image sets was fixed, and the 3D coordinates of any 
feature in the registered image space could be calculated for any point of interest.  
Figure 5.17 shows the registered MR and CT of a brain tumor bearing mouse from 
sagittal (top), coronal (bottom left) and axial (bottom right) view in PLUNC. The tumor volume 
can be clearly delineated. A cross mark (p1) was placed at the center of the tumor volume 
(confirmed in three orientations). The metal BB (landmark) on the mouse holder was also 
identified in the registered images (not shown here) and its center was marked with p2. The 
aligned images were saved, and the 3D coordinates of p1 and p2 were calculated and recorded. 
Translation required for beam arrays were calculated based on the calibration of the microbeam 
entrance location to the center of the landmark (p2).  
 
Figure 5.18 Photographs of the new mouse holder designed for crossbeam MRT. A metal bb (Aluminum, 0.79 mm in diameter) 
is embedded on the ear bar pillar as indicated. The picture on left is from a phantom study to test the reposition consistency of the 
sample stage, and the picture on right is from U87 bearing mouse irradiated with crossbeam MRT.  
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The feasibility of this method to guide the delivery of cross-beam MRT was evaluated in 
five U87MG human glioma bearing mice (average tumor size 1~ 1.5 mm in diameter). Each 
array contained one to three microbeams depending on the shape and volume of the tumor target. 
Seven minute exposure was delivered per beam with the microbeam irradiator operating at full 
power. Animals were sacrificed 4 hours after radiation treatment, and the brains were collected 
and fixed in formalin for 48 hours. Twelve or fifteen slices of brain tissue were collected around 
the tumor target at different locations/depths based on the MR images. Each slice is 5 µm thick. 
The tissue slices were stained with γ-H2AX following the same protocol as in the previous 
studies. Figure 5.18 on right shows a photo of the animal after crossbeam irradiation. The results 
from the histological staining are summarized in Table 5.3. 
Table 5.3 Summary of the results from the MRI/CT image guided MRT delivered in orthogonal arrays.   
 
 
Figure 5.19 shows the MR image and the stained tissue slices for two mice (ID 1293 and 
ID 1300) treated with 2 × 2 (two arrays, two microbeams/array) crossbeam MRT. For both 
animals, one out of the two arrays (array 1) was delivered accurately on tumor target while the 
other array (array 2) was delivered off target. The targeting errors in array 2 for these two 
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animals were about 350 µm and 900 µm, respectively. A systematic error was suspected to be 
involved in the dose delivery since targeting errors were identified consistently in array 2. In the 
other three animals, the planned microbeam patterns were shown clearly in the stained tissue 
slices as shown in Figure 5.20. However, the tumor targets were not present in these stained 
tissue slices. As mentioned earlier, shrinkage and distortion could be up to 20% during the tissue 
processing, making it challenging to determine the true target location for tissue collection. 
Besides, the average tumor size at the time of treatment was merely about 1.5 mm in diameter. 
Therefore, false slicing depths and insufficient tissue collection resulted in the issues shown in 
Figure 5.20.   
    
    
Figure 5.19 γ-H2AX stained tissue slices and the corresponding MR slices from animal ID 1293 (top row) and 1300 (bottom 
row). Tumor targets are indicated with yellow arrows in the histology slices. For both animals, one out of the two microbeam 
arrays was delivered accurately on tumor target. Beam array 2 was delivered off-center by about 350 µm for animal ID 1293, and 
900 µm for animal ID 1300.   
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Figure 5.20 γ-H2AX stained tissue slices and the corresponding MR images for the other three animals with ID 1294, 1295 and 
1298.  
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Rigid-body based registration relies largely on animal positioning in both imaging 
modalities. Since the registration is based on the skull structures where the brain tumor is secured 
inside, the variation in positioning is expected to have relatively little effect on the alignment. 
Two main limiting factors of the targeting accuracy in the current method are MR image 
resolution and the size of the labeling cross mark in PLUNC. In the above feasibility studies, MR 
images were acquired using a rapid acquisition protocol with 100 µm in-plane resolution and 500 
µm slice thickness. The relatively large voxel size in MR dicom would degrade the capability to 
resolve fine structures for registration, especially in the direction perpendicular to the image 
plane. A full 3D MR scan of the mouse brain would be desired for an improved image resolution, 
although the procedure would be rather time consuming. On the other hand, the smallest cross 
mark available in PLUNC is 0.2 mm in diameter which would be more than enough for clinical 
applications. However, considering the fine anatomical features and the extremely narrow beam 
sizes (~280 – 300 µm), such large reference points would not provide sufficient precision for 
determining the exact location of the target with respect to the treatment landmark. Optimization 
in the PLUNC program would be desired to allow for ultra-fine reference points placement in 
future experiments.  
Although the beam targeting accuracy and consistency remains to be evaluated with 
further experiments and considerable statistics, the 3D image-guidance offers the potential with 
enhanced dose delivery accuracy.   
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 PRECLINICAL EVALUATION OF MRT THERAPEUTIC EFFICACY CHAPTER 6:
USING THE COMPACT IRRADIATOR 
 
 Introduction 6.1
The development of the compact microbeam radiation therapy system is a long-term 
continuing effort with iterative system optimization, which requires comprehensive 
characterization in source and radiation beam quality, dosimetric parameters, as well as extensive 
preclinical and clinical validation. Preclinical study on small animal models not only stands as a 
critical step in the therapeutic efficacy evaluation of a new RT modality, but also provides 
valuable feedback of the system performance. It was finally made possible after the development 
of physical components and methodologies was achieved as described in previous chapters in 
this thesis and those completed previously [1]. This chapter presents the initial effort of 
biological assessment carried out using the prototype image-guided MRT system over the course 
of three years. These preliminary results from animal studies not only validated the treatment 
efficacy of the unique dosimetric characteristics generated by the prototype microbeam irradiator, 
but also demonstrated the potential of the compact system as an efficient and effective tool for 
MRT radiobiological studies both preclinically and clinically.  
The majority of this work was conducted as an effort of collaboration with Dr. Hong 
Yuan at UNC Biomedical Research Imaging Center. The method of image-guided delivery of 
single array microbeams was introduced in Chapter 5, and the detailed procedures were 
published in Zhang et al. in Physics in Medicine and Biology [2]. The main biological results 
from the single array MRT experiments were published in “Treating brain tumor with 
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microbeam radiation generated by a compact carbon-nanotube-based irradiator: initial radiation 
efficacy study” by Yuan et al. in Radiation Research 184, 322 – 333 (2015) [3]. Part of the 
preliminary results from the crossbeam microbeam irradiation was published in “Nanotube x-ray 
for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment” by 
Zhang et al. in Expert Review of Anticancer Therapy 14 (12), 1411 – 1418 (2014) [4].  
 Methods and Materials 6.2
Biological effects of microbeam radiation therapy were evaluated in terms of tumor local 
control, and cellular responses in both tumor and normal tissues. A total number of 76 human 
brain tumor bearing mice and six normal mice were included in the investigation.  Animals were 
grouped for different treatments as summarized in Table 6.1.  
Table 6.1 Summary of the biological studies carried out with the CNT-MRT system 
 
 
 Brain tumor bearing mouse model 6.2.1
All animal handling and experimental procedures in the study were approved by the 
Institutional Animal Care and Use Committee at University of North Carolina. Male athymic 
nude mice (4 – 6 weeks old) were used for brain tumor inoculation. U87MG human glioblastoma 
tumor cells were obtained from Dr. Ryan Miller’s lab at UNC Department of Pathology and 
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maintained in the laboratory at BRIC. About 23,105 cells in 5 µl culture media mixed with 5% 
methylcellulose were injected into the forebrain of mice using the stereotaxic technique at 1 mm 
anterior, 2 mm lateral to the bregma and 4 mm deep from the surface to form the orthotopic 
xenograft glioblastoma mouse model. Three weeks after tumor cell injection, the mice were 
brought to the Imaging Core Facility for MRI and subsequent radiation treatment.  
 Image guidance 6.2.2
 Unidirectional microbeam array 6.2.2.1
Single view X-ray/MR image guidance, described in Chapter 5.1.2 was employed for 
delivering a single array microbeams in the survival and immunohistological studies [2]. Briefly, 
mice were first imaged at BRIC small animal imaging core facility for tumor delineation, and 
then transported to our lab at the Department of Physics and Astronomy the next day for X-ray 
imaging, beam planning, and MRT. Animals were transferred back to BRIC for euthanization, or 
housed at UNC Division of Laboratory Animal Medicine for further investigation. During all 
imaging and radiation procedures, the animals were anesthetized with isoflurane (1.5%) mixed 
with 100% oxygen. The respiration signals were monitored with a pressure sensor that’s placed 
underneath the abdomen and presented via Biovet user interface.  
Mice were initially imaged at 3 weeks after tumor cell inoculation for tumor localization 
and volume measurement. MRIs were performed on a small animal 9.4 Tesla MRI system 
(Bruker Inc., Billerica, MA). T2-weighted images were acquired in  rapid acquisition with 
refocused echoes (RARE) sequence with the following parameters: TE/TR = 22/3,400 ms, 256 × 
256 matrix size, 0.5 mm slice thickness and 100 µm in-plane resolutions. Tumor volume was 
measured manually on each MRI slice with ImageJ.  
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X-ray projections were taken at 50 kV anode voltage and 0.4 mA anode current with 100 
ms pulse width. Projection images were then corrected with blank and dark images, and were 
registered manually to MR images in photoshop. Thereby the tumor location (center) with 
respect to the ear bar center (the landmark) in the treatment coordinate system (along x and y 
axis) was determined from the registered images. Animals were translated to the microbeam 
irradiator accordingly and irradiated with a single array of microbeams.     
 Crossbeam MRT 6.2.2.2
The orthogonal array MRT was delivered following the two-view planar MR/X-ray 
image guidance protocol with 2D image registration as described in chapter 5 section 1.3.2. The 
detailed procedure is not repeated here for the purpose of simplicity.  
 Radiation treatment  6.2.3
 Microbeam radiation therapy 6.2.3.1
Fifty-nine tumor-bearing mice and six normal mice were treated with MRT for survival 
and immunostaining studies. In the survival study, 42 tumor bearing mice were distributed into 
three groups, and the average tumor size of each group was not statistically different from the 
other groups before treatment. The three groups included a non-irradiated control group 
(isoflurane only, no irradiation, n = 19), a low-dose MRT group (48 Gy/microbeam, n = 19) and 
a high-dose MRT group (72 Gy/microbeam, n = 4). Two U87 bearing mice with relatively large 
tumor volume received crossbeam MRT (50 Gy/microbeam, 2 arrays) in two days. Another 
batch of U87 tumor-bearing mice (n = 15) and normal mice (n = 6) were used for 
immunostaining studies.  
The source-to-surface distance (focal line to mouse head) during the microbeam 
irradiation was kept at ~124 mm. The average dose rate at the entrance plane was measured to be 
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1.2 Gy/min. Peak dose of 48 or 72 Gy was used for the low- or high-dose MRT group, 
respectively. Each microbeam was 280 µm wide and 160 mm long, spaced at 900 µm center-to-
center distance. Three microbeams of radiation were delivered unidirectionally across the mouse 
brain in the low-dose MRT group, while two microbeams were delivered in the high-dose MRT 
group, so that the total integrated doses remained the same in the two MRT groups.  
For the crossbeam MRT group, two arrays of microbeams were delivered successively in 
two days with the crossing regions targeted to the tumor volume. Each array has four 
microbeams with 50 Gy/beam peak entrance dose. Beam separation was 900 µm to maintain a 
valley dose at no more than 3 Gy. Microbeam profiles were verified by Gafchromic films placed 
at the entrance and exit plane of the mouse head.  
 
  
Figure 6.1 Illustration of the configuration of a mouse being irradiated in the head using the microbeam generated by the CNT-
based microbeam radiation therapy system. The source-to-surface distance was kept at 124 mm for all treated animals.   
 
 Broad-beam radiation treatment 6.2.3.2
A separate group of U87MG tumor-bearing mice (n = 17) was treated with conventional 
broad-beam radiation (BRT) as a comparison group. Mice were anesthetized with isoflurane 
inhalation method and immobilized with the same mouse holder. Conventional radiation of 10 
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Gy was delivered to the mouse brain from a clinical linear accelerator (Siemens Primus, 6 MV 
photon beam). The radiation field is 1 cm × 1 cm centered on the mouse brain covering the 
tumor target. The treatment dose was computed with in-house clinical treatment planning 
software PLUNC. After irradiation, one group of mice (n = 9) was used for survival time 
investigation. The remaining eight animals were used for histological analysis. Brain tissue 
samples were collected at 24 h (n = 4) and 48 h (n = 4) after irradiation. 
 Survival & statistical analysis 6.2.4
After irradiation, mice were imaged with MRI (same protocol as for image guidance) 
weekly for two weeks after MRT to monitor changes in tumor volume. The monitoring period 
terminated when the last animal was euthanized due to tumor progression. The survival time (in 
days) individual animal was recorded, and the survival curves for each group were generated 
using Kaplan-Meier method (GraphPad Prism software; GraphPad Software Inc., LaJolla, CA). 
The median survival time (MST) and the percentage of extended life span were reported. The 
extended life span is defined as the ratio of the MST extension of the treated group to the MST 
of the control group (sham group). Survival curves were compared using the logrank test 
between each group. Data on expression level of γ-H2AX, caspase-3 and Ki-67 were presented 
as mean ± standard error of the mean (SEM). Differences between expression level on tumor and 
normal tissue at different time points after MRT were compared using t test. P < 0.05 was 
considered statistically significant. 
 Immunohistological analysis 6.2.5
Tumor-bearing mice were euthanized at 1, 4, 24, 48 h and day 7 after low-dose MRT or 
at 24 and 48 h after BRT. Brains were collected and fixed in formalin for 48 h. The fixed brains 
were then dehydrated, embedded in paraffin and cut into 5 µm brain sections in sagittal plane 
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perpendicular to the microbeam direction near tumor location. The cutting location was 
determined from MR images. Three consecutive brain sections were stained with antibodies to 
phosphorylated histone γ-H2AX (rabbit anti-mouse γ-H2AX antibody; Cell Signaling 
Technology®, Danvers, MA), cleaved caspase-3 (Biocare Medical Inc., Concord, CA) and Ki-67 
protein (BD Pharmingen, San Diego, CA) to assess DNA double strand breaks, apoptosis and 
cell proliferation, which have been well documented in the literature [5, 6]. All immunostaining 
procedures were conducted in the Tissue Pathology Core Facility (UNC Lineberger 
Comprehensive Cancer Center) with standardized staining protocol for all the tissue slides and 
positive/negative slides. For staining, tissue sections were deparaffinized followed by antigen 
retrieval with citrate buffer, and incubated with primary antibodies to one of the three proteins 
following the protocols: γ-H2AX, 1:1,000 dilution, 8 h incubation; cleaved caspase-3, 1:400 
dilution, 4 h incubation; and Ki-67, 1:500 dilution, 4 h incubation. The sections were then 
incubated with an appropriate secondary antibody followed with tyramide Cy5 amplification 
(PerkinElmert Inc., Boston, MA). To stain nuclei and preserve the fluorescent signals, ProLong® 
Gold antifade reagent containing 4, 6-diamidino-2-phenylindole (DAPI) was used (Molecular 
Probes®, Eugene, OR) on stained sections. The section was then scanned in the DAPI and Cy5 
channels using a high-resolution (20 × objectives) fluorescence slide scanner system (ScanScope 
FL scanner, Aperio®, Vista, CA). Immunostaining of γ-H2AX, caspase-3 and F4/80 (microglia 
and macrophage marker) was conducted on normal mouse brain tissues at 24 h and at day 30 
after irradiation to assess both acute and chronic damage on normal tissue from microbeam 
radiation. 
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 Characterize DNA damage with γ-H2AX staining 6.2.5.1
 The γ-H2AX quantification method was based on a previously published study [7] where 
the positively stained γ-H2AX fluorescence signal in nuclei was confirmed to be correlated with 
the expressed γ-H2AX protein level measured by Western blot. To quantify the γ-H2AX signal, 
cell nucleus region was first extracted from the DAPI nuclei counterstaining channel and masked 
to the γ-H2AX Cy5 fluorescence channel. Since γ-H2AX foci were present solely in cell nuclei, 
only signals inside the cell nuclei were measured. This method prevented the possibility of bias 
caused by different cell density in tumor and normal brain tissue. Five regions were defined 
based on the γ-H2AX staining images: radiation beam passing regions on the tumor tissue (tumor 
peak region) and on the contralateral normal brain tissue (normal peak region), beam valley 
regions on the tumor tissue (tumor valley region) and normal brain tissue (normal valley region) 
and regions away from the MRT field as normal tissue background (normal tissue region). 
Average fluorescence signal on the masked nuclei area was measured as mean γ-H2AX signal 
for the five regions.  
 Characterize cell apoptosis using cleaved caspase-3 6.2.5.2
Apoptosis was detected using cleaved caspase-3 staining. The caspase-3 images were 
first aligned with the γ-H2AX images from the neighboring section with ImageJ, and the five 
tissue regions defined in the γ-H2AX images were mapped to the caspase-3 images. Numbers of 
positively stained cells in peak and valley regions were counted in tumor and normal tissue. The 
number of positively caspase-3 stained cells per mm
2
 was calculated as a quantitative measure of 
the apoptosis level after irradiation. 
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 Characterize cell proliferation using Ki-67 immunofluorescence staining  6.2.5.3
Cell proliferation in irradiated brain tissue was quantified using Ki-67 
immunofluorescence staining. One tumor section from a sham-irradiated mouse was always 
included as a positive control. Area fraction of positive Ki-67 staining on the nuclei area was 
measured in the tumor peak and tumor valley regions. The ratio between irradiated tumor tissue 
and non-irradiated positive control was reported as the proliferation ratio. In the contralateral 
normal brain tissue, the number of positively stained cells on the irradiated region in the middle 
of striatum of MRT mice and the same sized region of BRT mice was measured as the parameter 
to quantify normal tissue proliferation. 
 Results 6.3
 Verification of dose delivery 6.3.1
The radiation delivery was verified using Gafchromic EBT2 films placed at the entrance 
and exit planes of the mouse head. Films in this study were analyzed with FilmQaPro. The 
beamwidth (FWHM) was measured to be 280 µm at the entrance plane on the top of the mouse 
brain and 380 µm at the exit plane at the bottom of the head. The PVDR was 16 at the entrance 
plane and decreased to 14 at the exit plane as shown in Figure 6.2 top row. The positive 
expression of γ-H2AX, shown as pink strips, correspond to the tracks of microbeam radiation 
dose deposition which induced DNA double strand breaks in both normal and tumor cells 
(Figure 6.2 middle and bottom row). The center-to-center distance between two adjacent tracks 
in the γ-H2AX image was measured to be 782.2 µm on average, close to the prescribed 900 µm 
beam separation when taking the 20% tissue shrinkage during histology processing into 
consideration [8].The FWHM of the beam track was 343.4 µm measured from the γ-H2AX 
staining images, slightly wider than the radiation beamwidth at the exit plane after taking the 
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tissue shrinkage into consideration. This was possibly due to the nonlinear response between 
radiation dose and γ-H2AX expression at doses above 10 Gy [9]. 
 
     
 
Figure 6.2 Top row: microbeam profiles recorded by Gafchromic EBT2 films placed at the radiation entrance (left) and exit (right) 
planes on the mouse head. Middle row: images of γ-H2AX stained brain tissue from a normal mouse (left) and a brain tumor 
bearing mouse (right). The positive expression of γ-H2AX, shown as pink strips, correspond to the tracks of microbeam radiation 
dose deposition, which induced DNA double strand breaks in both normal and tumor cells.  Bottom row: the beam profiles drawn 
from the histology slices. Reprinted with permission from Yuan et al. Radiation Research 184, 322-333 (2015) [3]. 
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 Microbeam effects on the mean survival time 6.3.2
The survival curves of four experimental groups are summarized in Figure 6.3.The 
median survival time for the non-irradiated control group was 35 days after tumor inoculation 
[95% Confidence Interval = (34.4, 35.6)]. The MST for animals treated with low-dose MRT, 
high-dose MRT and BRT was 46 (43.2, 48.8) days, 52 (40.8, 63.2) days and 52 (50.9, 53.1) days 
(values shown in parentheses are 95% confidence interval) respectively. The life spans of 
animals treated with high- and low-dose MRT were significantly extended by 31.4 and 48.5% (P 
< 0.001,) respectively, compared to the control group. The extended life span for the BRT group 
was 48.5%. There was no significant difference among the BRT group and the two MRT groups 
in terms of median survival time (P > 0.05,). 
 
Figure 6.3 Survival curves of U87MG bearing mice with different treatments. Animals in the sham group were anesthetized with 
isoflurane without any radiation treatment. BRT group was treated with 10 Gy conventional radiation with a 1 cm × 1 cm field 
size, using a clinical linear accelerator. Radiation doses were 48 Gy/microbeam and 72 Gy/microbeam for low-dose MRT and 
high-dose MRT groups, respectively. Reprinted with permission from Yuan et al. Radiation Research 184, 322-333 (2015) [3]. 
 
 Microbeam effects on tumor local control 6.3.3
Tumor volumes in all animals were monitored with MRI scans before and after radiation 
treatment. Figure 6.4A shows typical T2 weighted MR images from each group at different time 
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points. Absolute tumor volume measurement for each group is shown in Figure 6.4B. The 
relative volume change is defined in the following equation: 
𝑉𝑡 − V0
𝑉0
 
Where Vt is the volume at time t, and V0 represents the initial tumor volume at the day before 
treatment. Such relative tumor volume change was calculated for individual animals and plotted 
in Figure 6.4C. At one week after MRT, the control group had 10.0 ± 2.1 fold of increase in 
tumor volume, while the low-dose and high-dose MRT groups had only 4.1 ± 1.1 fold and 1.5 ± 
0.8 fold of volume increase, respectively, demonstrating significant inhibition of tumor growth 
after MRT (P < 0.01 for both MRT groups and the control group). At day 14 after MRT, tumor 
volume was 51.7 ± 16.0, 37.0 ± 9.4 and 14.3 ± 4.1 fold of increase in the sham-irradiated, low-
dose and high-dose MRT groups, respectively. Tumor growth was continuously suppressed (>10 
times) by the high-dose MRT at a significant level (P = 0.04), while only a trend of inhibition 
was observed with low-dose MRT (P = 0.21). 
 
Figure 6.4 A: T2 weighted MR images of the mouse brains before and after different treatment. Tumor targets were contoured 
with white dash lines. B and C: absolute and relative tumor volumes growth calculated from the MR images. Reprinted with 
permission from Yuan et al. Radiation Research 184, 322-333 (2015) [3]. 
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 Microbeam radiation induced DNA damage and its dynamics 6.3.4
Expression of γ-H2AX was measured at 1, 4, 24, 48 h and day 7 after MRT. Figure 6.5 
shows γ-H2AX staining on both tumor and normal tissue in the contralateral hemisphere. Strong 
expression was observed as early as 1 h post-irradiation on both tumor and normal tissue on the 
radiation beam passing regions, indicating radiation-induced DNA DSBs. The expression 
reduced over time from 1 h to day 7 after irradiation on both tumor and normal tissue, which 
suggests ongoing repair process in response to DNA damage. Seven days after irradiation, the γ-
H2AX signal in the normal valley region dropped to background level, which was not the case in 
the tumor tissue. Average γ-H2AX signal in nuclei was quantified in the five regions, as defined 
in the Materials and Methods section. In the irradiated region, there was a trend of higher γ-
H2AX level in tumor (tumor peak) compared to that in the normal brain tissue (normal peak) at 
all time points, but it was not statistically significant, possibly due to high variation. In the 
radiation valley region, the γ-H2AX signal was initially similar between the tumor valley and 
normal valley regions, but showed significantly higher in tumor valley region starting at 24 h 
post-irradiation. The signal in the tumor valley was 1.38-, 1.61- and 1.92-fold higher than that in 
the normal valley region at 24 and 48 h and day 7 after irradiation (P = 0.045, 0.038 and P < 
0.001, respectively). More interestingly, the γ-H2AX signal differences between peak and valley 
regions in tumor reduced dramatically at 48 h and almost diminished (ceased?) at day 7. The 
signal ratio between peak and valley regions in tumor changed from 5.2 at 1 h after MRT to 2.3 
at 48 h and 1.1 at day 7 after MRT. Figure 6.5A shows that the γ-H2AX foci were more 
dispersed from the beam tracks to the overall tumor region at 48 h and day 7 after irradiation. In 
contrast, there were still clear separations between peak and valley regions at 48 h and day 7 
after MRT in normal tissue, although the signal was quite weak at the 7-day time point. The 
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spreading of γ-H2AX signal in the tumor might be caused by tumor cell migration and possible 
bystander effect. 
 
Figure 6.5 γ-H2AX stained normal mouse brain tissue and brain tumor tissue after microbeam treatment. A: changes of γ-H2AX 
positive signal at different times post-irradiation. Microbeam paths were clearly distinguishable from the background in both 
tumor region and normal tissue at 1h and 24h post-irradiation. The beam tracks blurred out in tumor at 48h and 7 days after 
radiation, which was not observed in normal tissue in contrast. B and C: quantification of the γ-H2AX expression. The expression 
decreased over time after treatment, indicating the cell repair process. Reprinted with permission from Yuan et al. Radiation 
Research 184, 322-333 (2015) [3]. 
 
 Microbeam effects on apoptosis and cell proliferation 6.3.5
Figure 6.6 shows the results of caspase-3 staining on tumor and normal brain tissue. In 
the tumor tissue, positive cleaved caspase-3 signal was initially low, but increased over time in 
both the tumor peak and tumor valley regions Figure 6.6 (A-C). Interestingly, the difference in 
apoptosis level between the peak and valley regions in the tumor decreased significantly at 48 h 
and at day 7 after irradiation. The ratio of apoptotic cells in the peak to that in the valley region 
was 2.3 at 4 h, dropping to 1.1 at day 7 after MRT Figure 6.6C.  The number of apoptotic cells 
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was (59 ± 12)/mm
2
 in the peak region and (55 ± 14)/mm
2
 in the valley region at day 7 in the 
tumor tissue.  
 
Figure 6.6 Immunofluorescence staining of cleaved caspase-3 as cell apoptosis assay. Cleaved caspase-3 signal is shown in red, 
while DAPI counterstaining of the nuclei is shown in blue. A and B: Levels of apoptosis in tumor at 1h and 7d after MRT. 
Reprinted with permission from Yuan et al. Radiation Research 184, 322-333 (2015). 
 
The number of apoptotic cells in contralateral normal brain tissue within the microbeam 
radiation field was quantified after the low-dose MRT (Figure 6.6 D). Compared to the tumor 
tissue, there was a much lower level of apoptosis in the normal brain tissue after MRT. Apoptotic 
cells were mainly in the microbeam peak region with little to no apoptotic cells in the valley 
region, as shown in Figure 6.8. The number of apoptotic cells peaked at 24 h after MRT (0.66 ± 
0.12/mm
2
) and reduced thereafter in the normal brain tissue. Apoptosis level was also assessed in 
normal brain tissue at 24 and 48 h after BRT and was significantly higher (0.65 ± 0.11/mm
2
) 
compared with that in the MRT group (0.35 ± 0.09 /mm
2
) at 48 h after irradiation.  
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Figure 6.7 Immunofluorescence staining of Ki-67 on tumor as biomarker for cell proliferation 1h (A) and 48h (B) after MRT. Ki-
67 positive cells are shown in red,, while DAPI counterstaining of the nuclei are shown in blue. White arrows indicate the 
microbeam radiation paths on the tumor. Ratios of proliferation staining to non-irradiated control are plotted (C) over time for 
both the peak and valley regions. Proliferation rate continuously decreased from 1h to 48 h, but bounced back at day 7 after MRT. 
Reprinted with permission from Yuan et al. Radiation Research 184, 322-333 (2015). 
 
  
Figure 6.8 Apoptosis in normal mouse brain tissue after MRT. Reprinted with permission from Yuan et al. Radiation Research 
184, 322-333 (2015). 
 
Proliferation measurement with Ki-67 staining showed that tumor proliferation was 
significantly reduced in the radiation beam passing region at 1 h after irradiation (average of 15% 
drop from the non-irradiated control level), and continued to drop at 4, 24 and 48 h after 
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irradiation (average of 27, 50 and 70% drop, respectively), as shown in Figure 6.7. Tumor cells 
in the valley dose region had a lower reduction on proliferation compared to the irradiated region 
(3, 9, 28 and 43% drop at 1, 4, 24, and 48 h after MRT, respectively). However, at day 7, tumor 
proliferation recovered to the level similar to that at 4 h post-irradiation. The irradiated region 
and radiation valley region at day 7 had averages of 77 and 83% proliferation levels compared to 
the non-irradiated tumor tissue, suggesting tumor regrowth after MRT.  
 
 
Figure 6.9 Quantification of cell proliferation using Ki-67 immunohistological staining on the contralateral normal mouse brain 
tissue after MRT and BRT. A significantly higher number of proliferation cells were found in the MRT treated mice, but not in 
the BRT treated mice at 24h or 48h post-irradiation (* P <0.05, compared to BRT). Reprinted with permission from Yuan et al. 
Radiation Research 184, 322-333 (2015). 
 
In the contralateral normal tissue, there was an increase of cell proliferation after MRT 
that peaked at 48 h, as shown in Figure 6.9 (top row). The proliferation cells were found mainly 
in the valley region in the MRT field, as shown in Figure 6.9 (bottom two images). Compared to 
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the normal brain tissue after BRT, there was a dramatically higher level of cell proliferation in 
the MRT-treated normal tissue (7.43 ± 2.09/ mm
2
 and 10.64 ± 3.41/mm
2
 for 24 and 48 h, 
respectively, for the MRT vs. 0.51 ± 0.11/mm
2
 and 0.50 ± 0.11/mm
2
 for 24 and 48 h, 
respectively, for the BRT), which was more than 20 times higher at 48 h after irradiation. The 
higher proliferation level after MRT suggests a rapid tissue regeneration process in the normal 
brain tissue after MRT.  
 
Figure 6.10 F4/80 immunostaining on normal mouse bran tissue at 24 hours and 30 days after MRT. No positively stained 
macrophages or microglia cells were found at either time point. No other morphological brain tissue damage was detected. 
Reprinted with permission from Yuan et al. Radiation Research 184, 322-333 (2015). 
 
Normal mice were irradiated with the low-dose MRT protocol in the forebrain region, 
and expressions of γ-H2AX, caspase-3 and F4/80 on normal brain tissue were examined at 24 h 
and day 30 after MRT. Thirty days after MRT, there was no obvious track of γ-H2AX positive 
signals, although low γ-H2AX staining signal was found sporadically in the irradiated region. 
The apoptosis level at 24 h after MRT on normal mouse brain was 0.41 ± 0.07/mm
2
, which was 
much lower than the level at the contralateral normal brain tissue in the tumor mice (0.66 ± 
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0.12/mm
2
) (P = 0.08). Thirty days after MRT, the apoptosis level in the irradiated region 
dropped to its lowest (0.18 ± 0.04/mm
2
) compared to all time points examined.  
Neither microglial activation nor macrophage infiltration was found on normal brain at 
24 h or day 30 after irradiation, as shown in F4/80 staining images (Figure 6.10). There was 
some nonspecific F4/80 staining in the neuron cells, but no positive staining in microglial or 
macrophages compared to a positive control. 
 Preliminary results with MRT delivered in orthogonal arrays 6.3.6
      
Figure 6.11 Tumor progression monitored by MRI following different treatments. Tumor volume was shown as relative to the 
volume one day prior to treatment. Adapted from Zhang et al. in Expert Review of Anticancer Therapy 14 (12), 1411 – 1418 
(2014) [4].  
 
Compared to the BRT group where 10 Gy MV radiation was delivered homogenously to 
the entire tumor volume, more significant suppression of tumor growth was seen in the animals 
treated with crossbeam MRT as expected (Figure 6.11). Assuming both arrays were accurately 
delivered to the tumor target in the crossbeam group, about 50% tumor volume was irradiated by 
high dose radiation whereas the rest of the tumor cells received minimal exposure. No obvious 
radiation-induced normal tissue complications such as skin infections or behavior change were 
detected clinically either in the beam overlapping areas or in microbeam paths with peak doses. 
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No complete tumor ablation was achieved partially due to the relatively large initial tumor size 
by the time of treatment and the insufficient valley doses in the crossbeam MRT group.  
 Discussion  6.4
The work described above was the initial radiobiological studies carried out using the 
CNT-based image-guided MRT system. The preliminary results showed that the life span of 
animals in the two MRT-treated groups was significantly extended compared to the sham group 
even at the relatively low-dose level. Although more than half of the tumor volume was in the 
valley dose regions, which received lower dose radiation (less than 5 Gy, calculated with the 
average PVDR of 15), the MST in MRT group was shown similar to that of the 10 Gy BRT 
group. In-beam dose (peak dose) was 4 – 8 times higher in the MRT than in BRT. No apparent 
skin complications were found in the treatment area including the peak dose region. Tumor 
growth was greatly suppressed in the high-dose MRT group over the two-week monitoring 
period after irradiation, although it did not result in a significant extension of survival compared 
to the low-dose MRT and BRT group. Animals treated with low-dose MRT had initial tumor 
suppression, with tumor regrowth at a later phase, which was consistent with the Ki-67 staining 
of tumor proliferation. Immunostaining of γ-H2AX and cleaved caspase-3 showed higher DNA 
damage and more apoptosis in tumor tissue compared to normal brain tissue. MRT on normal 
brain tissue caused low apoptosis and little macrophage infiltration at 30 days after exposure, 
indicating that normal brain tissue tolerates the prescribed MRT.  
The results from the discussed survival study was similar to the synchrotron-based MRT 
study by Prezado et al [10]. They reported an increased life span of about 42% on 9L glioma rats 
treated with unidirectional MRT (as used in this study) with 100 Gy peak dose, 0.64 mm 
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beamwidth and 1.12 mm center-to-center distance. In their study, the life span was further 
increased to 100% when an interlaced microbeam pattern was applied.  
Histologically, low level of normal tissue damage was detected in normal mouse brain 
after MRT with either 48 Gy or 72 Gy. At 48 h post-irradiation, the number of apoptotic cells 
was significantly fewer in MRT treated animals compared to those received 10 Gy BRT. A low 
level of apoptosis and no F4/80
+
 macrophages were observed at 24 h or day 30 after MRT in 
normal mouse brain, indicating a good tolerance to the prescribed dose in MRT. So far, only 
DNA damage and apoptosis were quantified regarding to the evaluation of normal tissue 
complications. More physiological and functional assays including blood-brain-barrier and 
inflammation measurement remain to be investigated for a comprehensive assessment of normal 
tissue responses. 
Although there is yet no conclusive theories to fully explain the preferential effects 
demonstrated in MRT preclinical studies, the main hypothesis pointed to the fast repair of 
normal microvessels and the radiation-induced bystander effects (RIBE) [11, 12]. Dilmanian et 
al. also proposed beneficial bystander effects through the release of growth factors after MRT, 
promoting proliferation, migration and differentiation of the progenitor glial cells to produce new 
functional glial cells [13]. However, the exact pathway, dynamics and essential molecular 
elements of bystander effects still require extensive investigation. The results presented here 
showed over 20 times higher cell proliferation in the MRT treated normal brain compared to 
those treated with BRT. Crosbie et al. reported that normal skin tissue showed increased 
proliferation starting from 48 h after MRT as one of the tissue-repairing processes [14]. In our 
study, increased number of Ki-67-positive cells was observed beginning at 24 h and continuing 
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48 h after MRT of the brain, indicating rapid tissue regeneration and repair from MRT. The 
mechanisms of normal tissue repair and regeneration warrant further investigation. 
One interesting finding from the tissue immunohistological staining is the spreading of 
the γ-H2AX expression from the radiation peak region to the valley region at 48 h and day 7 
after irradiation. A similar situation was also observed in the cleaved caspase-3 stained tissue for 
apoptosis. Although the ratio of apoptosis in general is relatively low compared to other cell lines 
after radiation treatment [15], the distribution of the apoptotic cells can be clearly observed. Two 
mechanisms that might be attributed to this phenomenon are cell migration or bystander effect. 
Crosbie et al. reported on the different responses between tumor cells and normal tissue, with 
results showing that the irradiated peak and valley zones were indistinguishable in tumors 
because of extensive cell migration between the zones [14]. Sprung et al. also reported that γ-
H2AX foci at later time points did not directly correspond with the targeted regions, which 
suggests cell movement or bystander effects as a potential mechanism for MRT effectiveness. 
Kashino et al. showed that the induction  of DNA DSBs and cell migration in glioma cells 
exposed to MRT in vitro were mediated by bystander effects [16]. Our results are consistent with 
those studies in terms of indistinguishable damage in tumor tissue. However, extensive 
mechanistic studies are needed in the future.  
The survival time and normal tissue damage from the MRT treated animals were 
compared with BRT treated animals. The dose level of 10 Gy was chosen for BRT in the study 
mainly because it has been widely used in small animal studies with single-fraction conventional 
radiation [12, 17, 18]. However, it is quite a challenge to establish the true biological equivalence 
in dose between MRT and BR due to the complex dosimetry in MRT. Priyadarshika et al. 
suggested that the integrated dose of MRT, which is the microbeam dose averaged over the 
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entire radiation volume, might be more relevant than the peak or valley dose when compared to 
broad-beam radiation [19]. Recently, Ibahim et al. conducted serial cell irradiation studies to 
evaluate the equivalence between synchrotron MRT and conventional BRT, and reported that 
BRT doses of 3.4 ± 0.1 Gy were radiobiologically equivalent to a peak microbeam dose of 112 
Gy (25 µm wide spaced, 175 µm on center) in clonogenic assays on EMT6.5ch cells [17], which 
is much lower than the integrated MRT dose. On the other hand, the in vitro cell radiation study 
could not truly represent in vivo irradiation where possible bystander effects and vascular 
network factors might greatly influence the final efficacy. It is still debatable which dose level of 
broad-beam radiation can be used for a comparison with the MRT study. Our study showed that 
10 Gy of BRT led to a survival extension similar to MRT. However, the histological results 
shown in this study indicated that BRT might cause more normal brain tissue damage than MRT. 
Apoptosis doubled at 48 h in normal brain tissue after BRT compared to MRT, although 
apoptosis levels in both BRT and MRT groups were very low (0.65 ± 0.11/mm
2
 vs. 0.35 ± 0.09 
/mm
2
, respectively). In addition, Ki-67 staining revealed the number of proliferating cells to be 
20 × higher in the normal tissue after MRT than after BRT, which indicates much more rapid 
tissue repair and recovery after MRT, and thus low damage to normal tissue functionality. Future 
studies to compare MRT to the clinical standard of care for glioblastoma, i.e., the combination of 
fractionation radiation and temozolomide [20] will be needed for a more clinically relevant 
comparison in terms of therapeutic efficacy.  
Despite the lack of large statistical sampling, the preliminary results demonstrated that 
increasing the total integral dose and tumor coverage by spatially distributing the microbeam 
peak doses into two multi-directional arrays can  increase the efficiency in tumor growth delay 
without serious normal tissue damage. Further investigation is still to be carried out to compare 
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the therapeutic efficacy to that from the same total dose delivered in a single array. As the true 
evaluation relies on the accurate dose delivery, implementing MRI/CT with 3D image 
registration is also desired in future experiments.  
The preclinical results discussed above validated the treatment efficacy of the unique 
dosimetric characteristics generated by the prototype microbeam irradiator. For the current 
prototype system, two major differences in the beam dosimetric parameters compared to 
synchrotron-based MRT preclinical experiments are the beamwidth and dose rate. As described 
earlier, the intrinsically divergent beam is about 300 µm thick at the skin entrance, versus 25 – 
75 µm as in classical MRT studies at ESRF beamline ID17. However, increasing evidence has 
shown that normal tissue sparing effect can be preserved even with a beamwidth of up to several 
hundred microns, as long as the valley doses were kept under the threshold. MRT with thicker 
beams (up to 0.68 mm) is usually termed as minibeam radiation therapy, or MBRT, as proposed 
by Dilmanian et al [10, 21-23]. Admittedly, a higher dose rate would largely limit the motion-
induced beam blurring and errors in beam delivery. However this is no convincing evidence so 
far to demonstrate the therapeutic advantage of the extremely high dose rate as produced with 
synchrotron beamline. The beam blurring originated from the respiration or cardiac pulsation can 
be eliminated with the physiological gating technique for radiation beam delivery [24].  
The dose rate produced by the current prototype microbeam irradiator is comparable with 
a clinically used radiotherapy system, or any commercially available small animal radiotherapy 
devices [25]. However, since the microbeam peak doses delivered within a single fraction can be 
as high as two orders of magnitude higher than the conventional RT, a higher microbeam dose is 
still desirable in order to deliver the total prescribed dose within the time window allowable for 
animal anesthesia, and for patient immobilization. A second-generation CNT-based microbeam 
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irradiator has been constructed and is currently under testing which will potentially provide a 
more than 20 times higher microbeam dose rate (see chapter 7).  
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 CONCLUSIONS AND PROSPECTS CHAPTER 7:
 
 Summary of This Work 7.1
Microbeam radiation therapy is a radical experimental RT modality for cancer treatment, 
with remarkable preferential tumoricidal effects that have been demonstrated in preclinical 
studies. It differs dramatically from conventional RT modalities with a highly confined radiation 
field with orders of magnitude higher flux delivered within one fraction. The unique dosimetric 
characteristics yield an unprecedented therapeutic outcome, but also pose a great challenge in 
microbeam radiation production using conventional methods. Other than the national 
synchrotron facilities that are currently employed as the sole source of microbeam radiation, 
compact and economically viable technologies for microbeam generation is largely desired to 
translate the promising RT modality from preclinical investigation to clinical application.  
The novel CNT x-ray source array technology overcomes the limitations of conventional 
orthovoltage tubes and makes it possible to develop a first of its kind compact laboratory-scale 
MRT systems for cancer research and provides a potential pathway for clinical translation. 
Compared to the current synchrotron-based MRT facilities, CNT-based MRT also has several 
intrinsic advantages, including orders of magnitude lower in dimensions and cost. The 
electronically controlled and near-instantaneous beam response ensures a great reliability and 
safety in radiation dose delivery as desired in clinical uses. Additionally, the programmable 
source control allows for physiologically gated radiation delivery where radiation exposure is 
synchronized with the respiratory or cardiac signals, to minimize motion-induced microbeam 
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blur during treatment [1]. Work from this dissertation presented the development, 
characterization, and preclinical evaluation of the first prototype CNT-based image-guided 
microbeam radiation therapy system. The effort mainly focused on two specific aspects, i.e. 
development and optimization of system characterization, dosimetry calibration, implementation 
of image guidance for microbeam delivery, and preliminary radiobiological studies. The first part 
detailed the effort in improving the system performance in terms of stability and heat 
management. Modifications have been made to the anode assembly in order to alleviate the 
vibration induced anode rotation. While further effort is still needed in the complete motion 
isolation with alternative in the design of the anode assembly, heat related anode deformation 
should be reduced in the next-generation prototype where an active oil cooling system is 
employed. Radiation source and beam dosimetric characterization with Gafchromic EBT3 films 
was described in detail. While EBT3 film offers great sensitivity and accuracy of dosimetry in 
the lower dose range, other films with a larger dynamic dose range such as Gafchromic HD-810 
might be desirable as the prescribed dose levels increase in future studies.   
On-board image guidance is implemented, for the first time, in microbeam radiation 
delivery. A CNT-based micro-CT was constructed and integrated with microbeam irradiator in 
the same chamber. Dedicated multi-modality imaging and registration methods have been 
developed to facilitate the delivery of microbeams radiation in small animal models. The 
evaluation using brain tumor bearing mice yielded a high consistency and accuracy in beam 
targeting. Orthogonally crossed multi-array microbeam radiation therapy was demonstrated 
feasible with the aid of 3D MRI/CT guided targeting method. The image-guidance protocols 
established in this work bring the system development a step further towards preclinical 
evaluations.   
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The first MRT biological assessments using the compact MRT system were conducted 
and the key findings were presented in detail in Chapter 6.  Effective tumor control and lifespan 
extension without clinical normal tissue complications were demonstrated in U87MG human 
glioma bearing mice treated with the prototype system. Further investigation in cellular 
responses with histopathological staining revealed elevated levels of DNA damages and 
apoptosis in tumor versus normal tissue after microbeam irradiation. Less damage was also 
confirmed in low-dose MRT treated normal tissue compared to that irradiated with conventional 
broad beams. Rapid repair in normal tissue was identified histologically in microbeam irradiated 
normal tissue.  
 High-power Compact MRT System 7.2
 The second-generation prototype 7.2.1
Although the feasibility of the CNT source array technology for microbeam radiation 
therapy has been demonstrated with the first prototype irradiator, the full potential of this 
technology for higher flux production remains to be explored. The maximum dose rate 
achievable using the first prototype is around 1.2 Gy/min at the entrance plane. This dose rate is 
considered sufficient as a preclinical and a clinical RT system, but it is not ideal to achieve the 
extremely high peak dose typically utilized in MRT. Besides, a higher dose rate is needed when 
physiologically gated radiation delivery is employed, which generally requires substantially 
longer treatment time compared to non-gated dose delivery. The achievable radiation flux is 
currently limited by the relatively low efficiency in the anode heat dissipation in the first 
prototype system. Higher power output can be potentially achieved by introducing active anode 
cooling device, or by implementing a rotating cylindrical anode.  
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A second-generation CNT-MRT system has been constructed and is currently under 
conditioning and calibration, as illustrated in Figure 7.1. An active oil cooled device is 
incorporated into this upgraded system to increase anode heat capacity and radiation output. 
Three cathode arrays generate 3 parallel microplanar beams simultaneously, with an anticipated 
20 times higher dose rate and a higher mean photon beam energy compared to the first prototype 
device (Table 7.1). This will allow for high dose (200 – 700 Gy) delivery within 1 hour for small 
animal irradiation.  
 
 
Figure 7.1Top row: design of concept of the second-generation compact MRT system with three CNT cathodes arrays. A 
specially designed oil cooling system is incorporated in this upgraded system to increase anode heat capacity and radiation output. 
Three microbeams with adjustable width can be generated simultaneously. Bottom row: a photograph of the three-line cathode 
assembly is shown on left; on right shows a photograph of the vacuum chamber of the second-generation system. 
 
 Design for human MRT with multiple beam arrays 7.2.2
Perhaps the only way for MRT to benefit brain cancer treatment is through spatial 
distribution of beam arrays. With this distribution, the physical dose conformality from spatial 
modulation of radiation beam, and the biological tissue specificity from MRT can be combined 
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to widen the therapeutic window and to improve treatment outcomes. Particularly, the CNT 
distributed source arrays with simultaneous dose delivery from different ports/directions, has the 
advantages of a single fraction MRT treatment less patient motion, short hospitalization time, 
and reduced amounts of anesthesia for patients. Figure 7.2 illustrates the design of concept of a 
CNT-based human MRT system with microbeam array spatially distributed in a circular 
configuration. Radiation from each direction is individually collimated with both microbeam 
collimator and conformal collimator. Each microbeam is generated by a cathode array and can be 
thus electronically controlled individually. This design would reduce the toxicity to skin and 
subcutaneous tissue caused by high dose orthovoltage radiation and improve the radiation dose 
delivery to deep-seated and invasive tumor targets.  
Table 7.1 Comparison of the system specifications of the first and second generation CNT-based MRT prototypes  
 
 
 Future Directions  7.3
Microbeam radiation therapy is attractive and promising in many ways. As a novel RT 
modality, its potential impact on the clinical practice of cancer management as well as 
168 
 
fundamental radiobiological research in oncology is revolutionary and cannot be overestimated. 
In recent years MRT research has attracted worldwide attention from various research groups 
within the synchrotron communities and beyond. A lot of progress has been made towards a 
better understanding of the underlying therapeutic mechanism, which is beneficial not only the 
development of MRT as a single treatment modality, but also inspiring as for cancer therapy in 
general. Other than the potential as a single RT modality, a few additional aspects of MRT 
remain to be explored including dose enhancement with radiosensitizers, the feasibility as a 
combined treatment with chemotherapy, potential utilization in whole-body RT for 
immunotherapy, etc.  Ideally, microbeam radiation therapy would contribute to the eventual 
realization of and effective cure for brain malignancies in the foreseeable future. 
 
  
Figure 7.2 Schematic illustration of the CNT-based human MRT system in a circular design. Microbeam are generated from 
distributed CNT source arrays from multiple directions and directed towards the treatment target simultaneously. Each beam 
array contains multiple microbeams for which the beamwidth and lengths can be adjusted individually. Figures were not drawn to 
scale. Picture on the left is adapted from Zhang et al. Expert Review of Anticancer Therapy 14(12), 1411-1418 (2014) [2] 
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